前往化源商城

910232-84-7 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: SERCaMPGLuc-p1-antagonist
Protocol: PROTOCOL TABLES
SEQUENCE No. (1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Reagent; 5 uL; 1000 SH-SY5Y cells per wells
2; Time; 5 hour; 37C, 5% CO2
3; Compound; 23 nL; Control inhibitor / compound library
4; Time; 16 hour; 37C, 5% CO2
5; Reagent; 100 nM; Thapsigargin
6; Time; 4 hour; 37C, 5% CO2
7; Reagent; 1 uL; 0.5x coelenterazine
8; Detection; Luminescence; ViewLux imaging system

NOTES (numbers refer to sequence above)
1; SH-SY5Y human neuroblastoma cells stably expressing GLuc-SERCaMP (SH-SY5Y-GLuc-ASARTDL) cells were seeded in 1,536 well white tissue culture treated plates (Corning, Cat# 7464) in DMEM-high glucose-sodium pyruvate (ThermoFisher Scientific, Cat #10569) supplemented with 10% bovine growth serum (Hyclone), 10 U/ml penicillin (Gibco), 10 ug/ml streptomycin (Gibco), and 20 mM HEPES.
2; Assay plates were incubated for 5 hour at 37C in a humidified incubator containing 5% CO2.
3; qHTS libraries (23 nl, final concentrations of 1.53 uM, 7.67 uM, 38.3 uM) or controls (neutral control: DMSO, positive control: dantrolene) were added using a Kalypsis pin-tool Robotic System equipped with 1536 pinheads.
4; Cells were then incubated for 16 hours at 37C, 5% CO2.
5; Thapsigargin was added at 100 nM to deplete ER calcium stores.
6; Cells were incubated for 4 hour (37oC, 5% CO2)
7; Gaussia luciferase in the medium was measured by adding 1 ul of 0.5x coelenterazine (final concentration 0.07x) prepared in Gaussia Luciferase Glow Assay Buffer (Pierce), without addition of the Cell Lysis Buffer Reagent.
8; Luminescence was measured using a ViewLux high-432 throughput CCD imaging system (Perkin Elmer) equipped with clear filters. Compounds exhibiting inhibitory activity (defined as curve class -1.1, -1.2, -1.3, -1.4, -2.1, -2.2, -2.3, -2.4, -3) were identified by normalizing plate-wise to corresponding intra-plate controls (neutral control = Tg only; positive control (100% inhibition) = DMSO vehicle) with percent activity derived using in-house software (https://tripod.nih.gov/curvefit). The same controls were also used for the calculation of the Z' factor, a measure of assay quality control, as previously described (Zhang et al., 1999). For the initial validation of activity in the SERCaMP assays, hits from the primary screen were assayed again at 11-concentrations (1.3 nM - 76.6 uM). SH-SY5Y-GLuc-SERCaMP cells were assayed for ER Ca2+ depletion as outlined above.

Reference:
1. Zhang, J.H., Chung, T.D., and Oldenburg, K.R. (1999). A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4, 67-73.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000259387 uMActivity at 0.0000710850 uMActivity at 0.0001271514 uMActivity at 0.0003024044 uMActivity at 0.0005030064 uMActivity at 0.0006524306 uMActivity at 0.00193 uMActivity at 0.00341 uMActivity at 0.00584 uMActivity at 0.010 uMActivity at 0.018 uMActivity at 0.052 uMActivity at 0.078 uMActivity at 0.156 uMActivity at 0.276 uMActivity at 0.478 uMActivity at 0.883 uMActivity at 1.507 uMActivity at 3.884 uMActivity at 7.354 uMActivity at 12.96 uMActivity at 21.63 uMActivity at 38.41 uMActivity at 76.33 uMActivity at 137.0 uMActivity at 204.0 uMCompound QC
Inhibitor1104.966488Complete curve; high efficacy-63.51170.6658-104.96640-1.10 0 0-97.13-85.6484-112.8671-97.13QC'd by Tocris
Inhibitor0.316259.327888Complete curve; high efficacy-6.50.81-84.7193-25.3915-1.10 0 0-83.9327-75.7429-81.922-83.9327QC'd by BIOMOL
Inhibitor3.162320.498785Complete curve; high efficacy-5.54.95490.4756-107.8212-87.3224-1.10 0 0-101.1849-96.9354-114.4343-101.1849QC'd by SIGMA
Inhibitor0.749266.151166Complete curve; partial efficacy-6.125410.8229-74.6135-8.4624-1.20 0 0 0 0 0 0 0 0 0 0-67.099-7.8787-22.7216-1.4525-29.6562-23.5194-8.332-25.0891-62.4832-68.6466-63.9027-67.099QC'd by Microsource
Inhibitor121.684566Complete curve; partial efficacy-64.95490.9699-77.7873-56.1028-1.20 0 0-76.43-65.0857-78.9894-76.43QC'd by BIOMOL
Inhibitor1.12259.675865Complete curve; partial efficacy-5.951.210.9999-66.8495-7.1736-1.20 0 0-66.096-42.6313-61.4055-66.096QC'd by Vitas
Inhibitor1.995334.026364Complete curve; partial efficacy-5.74.95490.9891-73.9118-39.8855-1.20 0 0-72.1972-47.1162-75.3813-72.1972QC'd by SigmaAldrich
Inhibitor12.589337.266562Complete curve; partial efficacy-4.911-78.1117-40.8452-1.20 0 0-68.8431-44.9463-54.9089-68.8431QC'd by Tocris
Inhibitor14.125432.429762Complete curve; partial efficacy-4.851.22160.9999-88.7022-56.2725-1.20 0 0-81.3177-58.1227-66.7029-81.3177QC'd by Enzo
Inhibitor1029.898362Complete curve; partial efficacy-53.29750.9999-76.1051-46.2067-1.20 0 0-75.9694-46.234-54.866-75.9694QC'd by Microsource
Inhibitor11.220226.849761Complete curve; partial efficacy-4.954.0950.9996-65.1082-38.2585-1.20 0 0-65.0072-38.2023-43.2866-65.0072QC'd by SigmaAldrich
Inhibitor25.118945.784461Complete curve; partial efficacy-4.61.53861-101.459-55.6745-1.20 0 0-85.8367-56.2934-62.0903-85.8367QC'd by SigmaAldrich
Inhibitor31.622832.29860Complete curve; partial efficacy-4.52.18760.9999-141.8428-109.5448-1.20 0 0-129.0357-109.6207-111.066-129.0357QC'd by Microsource
Inhibitor31.622835.977260Complete curve; partial efficacy-4.51.10.9999-99.0432-63.0659-1.20 0 0-82.9526-64.2216-69.1965-82.9526QC'd by Microsource
Inhibitor35.481337.624260Complete curve; partial efficacy-4.454.95490.9762-81.2779-43.6537-1.20 0 0-66.0936-45.7944-41.8015-66.0936QC'd by Tocris
Inhibitor35.481350.188560Complete curve; partial efficacy-4.454.44950.9982-87.6877-37.4992-1.20 0 0-66.8089-38.2236-36.8414-66.8089QC'd by Pharmacopeia
Inhibitor35.481347.340560Complete curve; partial efficacy-4.454.95490.9906-107.1544-59.8139-1.20 0 0-87.9757-61.3159-58.1701-87.9757QC'd by Prestwick Chemical; Inc.
Inhibitor5.9508124.625145Partial curve; high efficacy-5.22542.72020.864-126.7319-2.1068-2.10 0 0 0 0 0 0 0 0 0 1000-13.748-1.3723-25.9483-11.282526.65188.4521-36.83-113.80310QC'd by ChemAxon
Inhibitor11.873489.544142Partial curve; partial efficacy-4.92541.24750.9863-91.1278-1.5837-2.20 0 0 0 0 1 0 0 0 0 0-74.7046000-4.6868-8.0974-38.15161.1319-8.2196-21.8072-47.3218-74.7046QC'd by Cayman
Inhibitor25.1189267.383841Partial curve; partial efficacy-4.64.95490.8835-100.7065166.6773-2.20 0 0-71.9482116.4983215.4265-71.9482QC'd by Tocris
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:U2OS
External ID: CHEMBL5724698
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL615023
ChEMBL Target Name: U2OS
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: EUbOPEN Chemogenomic Library
Standard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
ER-phagy suppression=-5.515%
ER-phagy suppression=11.49%
ER-phagy suppression=-63.24%Suppressor
ER-phagy suppression=-37.11%Suppressor
ER-phagy suppression=6.149%Suppressor
ER-phagy suppression=46.79%Suppressor
ER-phagy suppression=-2.879%
ER-phagy suppression=2.788%
ER-phagy suppression=9.958%
ER-phagy suppression=17.86%
ER-phagy suppression=4.664%
ER-phagy suppression=-2.854%
ER-phagy suppression=-6.061%
ER-phagy suppression=-17.19%
ER-phagy suppression=-21.85%
ER-phagy suppression=-36.6%
ER-phagy suppression=-35.46%
ER-phagy suppression=-31.72%
ER-phagy suppression=-0.3871%
ER-phagy suppression=-17.27%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: IP6K1-p1
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.

1. Reagent, 3 uL of 1.3 mM ATP and 130 uM IP6 mixture in assay buffer was dispensed to a white, 1536-well assay plate.
2. Compound, 23 nL of compounds of the top two doses (57.5 uM and 19.1 uM final concentration) of the libraries were dispensed into the mixture using the Kalypsis pintool.
3. Reagent, 1 uL of 2.4 uM IP6K1 was dispensed to the assay plates.
4. Incubation, 2 hr incubation at room temperature.
5. Reagent, 2 uL of ADP-Glo reagent was added to the wells.
6. Incubation, 1 hr incubation at room temperature.
7. Reagent, 4 uL or ADP-Glo substate was added to the wells.
8. Incubation, 45 min incubation at room temperature.
9. Detection, luminescence signal was detected using the ViewLux microplate imager (PerkinElmer).
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Majority of the compounds were tested at 58uM and 11uM. Percent inhibition at 58uM (Max_Response) was obtained and used for compound ranking.
2. For all inactive compounds, with Max_Response >= -25.00, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds (Max_Response < -25.00, more than 25% inhibition) a score range was given between 25 and 100. The activity score is based on the absolute value of the Max_Response.
PhenotypeAnalysis CommentActivity_ScoreMax_ResponseActivity at 0.029 uMActivity at 0.115 uMActivity at 0.144 uMActivity at 0.230 uMActivity at 0.575 uMActivity at 1.257 uMActivity at 2.059 uMActivity at 2.870 uMActivity at 3.790 uMActivity at 5.750 uMActivity at 7.911 uMActivity at 11.54 uMActivity at 17.22 uMActivity at 25.95 uMActivity at 38.35 uMActivity at 57.50 uMActivity at 85.10 uMActivity at 115.2 uMActivity at 153.0 uMActivity at 245.0 uMActivity at 288.0 uMCompound QC
Inactive0-0.963.5361-0.96QC'd by Chemdiv
Inactive0-0.9559-3.6852-0.9559QC'd by Chemdiv
Inactive0-0.9553-5.7534-0.9553QC'd by Chemdiv
Inactive0-0.9545-5.6084-0.9545QC'd by ChemRoutes
Inactive0-0.953-2.3216-0.953QC'd by Sytravon
Inactive0-0.94922.2186-0.9492QC'd by Edelris
Inactive0-0.9486-1.2758-0.9486QC'd by Chemdiv
Inactive0-0.94674.4666-0.9467QC'd by ChemRoutes
Inactive0-0.9436-8.9932-0.9436QC'd by Chemdiv
Inactive0-0.9422-1.7826-0.9422QC'd by Analyticon
Inactive0-0.9415.2115-0.941QC'd by Chemdiv
Inactive0-0.93984.3972-0.9398QC'd by Sytravon
Inactive0-0.93624.3836-0.9362QC'd by Chemdiv
Inactive0-0.92992.8643-0.9299QC'd by Sytravon
Inactive0-0.92934.8772-0.9293QC'd by Chemdiv
Inactive0-0.9286-10.0521-0.9286QC'd by Chemdiv
Inactive0-0.9253-2.1742-0.9253QC'd by Sytravon
Inactive0-0.92040.4163-0.9204QC'd by Edelris
Inactive0-0.9193-0.0183-0.9193QC'd by Analyticon
Inactive0-0.9182-0.8109-0.9182QC'd by Analyticon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Cyclin-dependent kinase 2
External ID: CHEMBL5062802
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL301
ChEMBL Target Name: Cyclin-dependent kinase 2
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned

Data Source: EUbOPEN Chemogenomic Library
Standard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
Delta TM=0.1409CThermal Shift Assay
Delta TM=-0.01457CThermal Shift Assay
Delta TM=-0.19C
Delta TM=1.16CThermal Shift Assay
Delta TM=1.921CThermal Shift Assay
Delta TM=-0.3406CThermal Shift Assay
Delta TM=0.6CThermal Shift Assay
Delta TM=-0.1127CThermal Shift Assay
Delta TM=-1.169CThermal Shift Assay
Delta TM=0.82C
Delta TM=0.31CThermal Shift Assay
Delta TM=-0.02CThermal Shift Assay
Delta TM=0.46CThermal Shift Assay
Delta TM=-1.475CThermal Shift Assay
Delta TM=-0.6313CThermal Shift Assay
Delta TM=0CThermal Shift Assay
Delta TM=-0.6762CThermal Shift Assay
Delta TM=1.46CThermal Shift Assay
Delta TM=0.98CThermal Shift Assay
Delta TM=0.83CThermal Shift Assay
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: SNCA-p-activity-luciferase
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION

1; Cells; 4 uL; Dispense 1500 HEK-293-SNCA-luc cells/well into Greiner 1536-well white / solid bottom tissue culture treated plate. The plate was covered with metal lids with gas-exchange holes.
2; Incubate; 24 hours; Incubate at 37C, 5% CO2, 95% RH.
3; Compounds; 23 nL; Compounds and controls were transferred via a Kalypsys Pin Tool (Wako USA) equipped with a 1536-slotted pin array. The plate was covered with metal lids with gas-exchange holes.
4; Incubate; 24 hours; Incubate at 37C, 5% CO2, 95% RH.
5; Dispense; 1 uL; Dispense Gly-Phe-7-amino-4-trifluoromethylcoumarin (GF-AFC, prepared at 125 uM in PBS) was added. The plate was covered with metal lids with gas-exchange holes.
6; Incubate; 30 min; Incubate at 37C, 5% CO2.
7; Detector; Fluorescence; Measure fluorescence with ViewLux microplate reader (PerkinElmer) equipped with 405/10 excitation and 540/25 emission filters.
8; Dispense; 3 uL; Dispense ONE-Glo (PerkinElmer) lucifase detection reagent was added to each well. Plates were covered with metal lids with gas-exchange holes.
9; Incubate; 15 min; Incubate at room temperature.
10; Detector; Luminescence; Measure luminescence with ViewLux microplate reader (PerkinElmer) equipped with clear filters.

NOTES (numbers refer to sequence above)
1; HEK-293-SNCA-luc were cultured and suspended in phenol-red free DMEM (4.5 g/L glucose, 25 mM HEPES, cat #21063 (Thermo)).
3; Compounds were added to the assay plate in an 11-point intra plate dose response, 1:3 titration in DMSO with a final concentration range of xxx - yyy uM. Vehicle-only plates, with DMSO being pin-transferred to every well, were inserted at the beginning of screening runs to confirm expected assay performance. Activity was normalized to wells containing medium only (-100% activity, full inhibition) and SNCA-luc cells treated with DMSO vehicle control (0% activity), contained on the same plate as test samples.
10; Signals were analyzed, and dose-response curves were fit using the Hill equation. Compounds in curve classes -1.1, -1.2, -2.1, -2.2 in the SNCA-luc assay were considered active. Compounds were eliminated from further consideration if also active (curve class -1.1, -1.2, -1.3, -1.4, -2.1, -2.2, -2.3, -2.4) in the GF-AFC cytotoxicity assay.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000386857 uMActivity at 0.0001060182 uMActivity at 0.0001896372 uMActivity at 0.0004510146 uMActivity at 0.0007501981 uMActivity at 0.0009728036 uMActivity at 0.00288 uMActivity at 0.00508 uMActivity at 0.00871 uMActivity at 0.015 uMActivity at 0.026 uMActivity at 0.053 uMActivity at 0.079 uMActivity at 0.232 uMActivity at 0.457 uMActivity at 0.692 uMActivity at 1.068 uMActivity at 2.292 uMActivity at 3.859 uMActivity at 11.39 uMActivity at 17.02 uMActivity at 25.62 uMActivity at 57.25 uMActivity at 87.55 uMActivity at 183.4 uMActivity at 286.0 uMCompound QC
Inactive0-6.754.95490.97270.090117.540 0 0 18.940815.9527-1.59161.49698.9408QC'd by Sytravon
Inactive0-5.34.0950.99965.5-7.782340 0 0 1-11.1081-7.5736-7.73535.034-11.1081QC'd by Sytravon
Inactive0-5.154.95490.907-15.92079.540 0 0 117.87255.287413.9021-13.683917.8725QC'd by Sytravon
Activator35.481346.40950Single point of activity-4.452.5884145.9404-0.469131 0 0 035.59340.1678-0.39091.93335.593QC'd by Sytravon
Activator39.810772.26460Single point of activity-4.44.95490.951568.1912-4.073330 0 0 058.01175.8738-9.2278-8.522458.0117QC'd by Sytravon
Activator14.125445.33190Partial curve; partial efficacy; poor fit-4.852.40640.998240.7728-4.55912.41 0 0 040.0933-24.9557-3.884511.525440.0933QC'd by Sytravon
Inactive0-5.754.95490.9291-20.608633.154541 0 0 0-12.846445.456928.2161-28.42-12.8464QC'd by Sytravon
Inactive0-4.354.95490.855-24.2184-0.540 0 0 0-18.932-3.6477-2.4094.988-18.932QC'd by Sytravon
Inactive0-4.73.62720.862515-8.552340 0 0 014.477-2.951-13.7936-5.964614.477QC'd by Sytravon
Inactive0-6.74.95490.66373-16.86440 0 0 08.8169-15.726.3794-6.35998.8169QC'd by Sytravon
Inactive0-4.752.40640.999921.5-2.410141 0 0 020.218433.3778-2.42513.577120.2184QC'd by Sytravon
Inactive0-4.44.95490.81172.5-8.34540 0 0 01.096-8.966-5.5054-11.12091.096QC'd by Sytravon
Activator39.810738.79450Single point of activity-4.44.95490.624141.75572.961230 0 0 036.203921.355-6.3904-4.532536.2039QC'd by Sytravon
Inactive0-6.054.0950.9994-6.05182040 0 0 120.515619.73771.4122-6.293220.5156QC'd by Sytravon
Inactive0-5.24.095110.5-10.168341 0 0 1-15.988436.1362-10.14028.7939-15.9884QC'd by Sytravon
Inactive0-6.51.39050.9999-24.2410.274540 0 0 1-5.5981-4.3546-20.7587-23.9509-5.5981QC'd by Sytravon
Inactive0-6.84.95490.711-2.44592140 0 0 0-3.345317.3219-9.95495.5495-3.3453QC'd by Sytravon
Activator39.810747.8090Partial curve; partial efficacy; poor fit-4.44.95490.521250.23992.43092.40 0 0 043.472230.2363-10.9855-11.514343.4722QC'd by Sytravon
Activator22.387275.50810Partial curve; high efficacy; poor fit-4.651.96730.982996.532421.02432.30 0 0 086.498526.093216.336536.261386.4985QC'd by Sytravon
Inactive0-6.84.95490.7429-1-13.073840 0 0 01.8063-11.31150.8702-5.17571.8063QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Colon organoid
External ID: CHEMBL5724804
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL5739550
ChEMBL Target Name: Colon organoid
ChEMBL Target Type: 3D CELL CULTURE - Target is a 3D cell culture model such as an organoid, sphereoid or tumoroid that mimics tissues or organs
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: EUbOPEN Chemogenomic Library
Standard TypeStandard RelationStandard ValueActivity Comment
Cell Viability Ratio=1.077Pronounced Effect In Normal Organoids
Cell Viability Ratio=1.735Strong Effect In Tumor Organoids
Cell Viability Ratio=0.9777Pronounced Effect In Normal Organoids
Cell Viability Ratio=0.9298Pronounced Effect In Normal Organoids
Cell Viability Ratio=0.673Pronounced Effect In Normal Organoids
Cell Viability Ratio=0.9902Pronounced Effect In Normal Organoids
Cell Viability Ratio=1.062Pronounced Effect In Normal Organoids
Cell Viability Ratio=0.9407Pronounced Effect In Normal Organoids
Cell Viability Ratio=0.9821Pronounced Effect In Normal Organoids
Cell Viability Ratio=1.055Pronounced Effect In Normal Organoids
Cell Viability Ratio=3.874Strong Effect In Tumor Organoids
Cell Viability Ratio=0.3535Pronounced Effect In Normal Organoids
Cell Viability Ratio=1.431Strong Effect In Tumor Organoids
Cell Viability Ratio=0.957Pronounced Effect In Normal Organoids
Cell Viability Ratio=1.247Pronounced Effect In Normal Organoids
Cell Viability Ratio=0.903Pronounced Effect In Normal Organoids
Cell Viability Ratio=1.309Strong Effect In Tumor Organoids
Cell Viability Ratio=0.6872Pronounced Effect In Normal Organoids
Cell Viability Ratio=0.9253Pronounced Effect In Normal Organoids
Cell Viability Ratio=1.056Pronounced Effect In Normal Organoids
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: huntington-HTTAS8-p1-FF-overN
Protocol: PROTOCOL TABLES
SEQUENCE No. (1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Reagent; 4 uL; 2,500 Hek293 luciferase reporter cells per wells
2; Time; 24 hour; 37C, 5% CO2
3; Compound; 23 nL; Control inhibitor / compound library
4; Time; 24 hour; 37C, 5% CO2
5; Reagent; 2.5 uL; Firefly Luc reagent; Dual-Glo Luciferase Reporter Assay System (Promega)
6; Time; 10 min; room temperature incubation
7; Detection; Luminescence; FLuc

NOTES (numbers refer to sequence above)
1; High-throughput screening, measuring luminescence from a Hek293 luciferase reporter, was performed in 1,536 well white-walled tissue-culture treated plates. 2,500 cells were plated in 4 muL of Opti-MEM per well using a Multidrop Combi Reagent Dispenser (ThermoFisher).
2; Assay plates were cultured for 24 hours.
3; Control inhibitor (PTC124; final concentration of 50 uM) and compound library (at final concentrations of 460 nM - 57.5 uM) were added to the assay plate using the Kalypsis Pintool Robotic System equipped with 1536 pinheads.
4; Cells were then incubated for 24 hours at 37 degrees C prior to luminescence measurements.
5; In all cases, luminescence was measured using the Dual-Glo Luciferase Reporter Assay System (Promega) following the manufacturer's instructions.
6; Room temperature incubation.
7; Luminescence signal was obtained using the PerkinElmer ViewLux plate reader. Results were normalized to vehicle control (0% activity) and zero RLU (-100% activity).
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = 1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 || ratio.curve_class == 2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds also have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentFF-overN-Activity_ScoreFF-overN-Curve_DescriptionFF-overN-Fit_LogAC50FF-overN-Fit_HillSlopeFF-overN-Fit_R2FF-overN-Fit_InfiniteActivityFF-overN-Fit_ZeroActivityFF-overN-Fit_CurveClassFF-overN-Excluded_PointsFF-overN-Max_ResponseFF-overN-Activity at 0.0000389080 uMFF-overN-Activity at 0.0001066275 uMFF-overN-Activity at 0.0001907270 uMFF-overN-Activity at 0.0004536066 uMFF-overN-Activity at 0.0007545096 uMFF-overN-Activity at 0.0009786459 uMFF-overN-Activity at 0.00290 uMFF-overN-Activity at 0.00503 uMFF-overN-Activity at 0.00876 uMFF-overN-Activity at 0.015 uMFF-overN-Activity at 0.026 uMFF-overN-Activity at 0.052 uMFF-overN-Activity at 0.080 uMFF-overN-Activity at 0.235 uMFF-overN-Activity at 0.459 uMFF-overN-Activity at 0.740 uMFF-overN-Activity at 1.165 uMFF-overN-Activity at 2.228 uMFF-overN-Activity at 5.999 uMFF-overN-Activity at 11.47 uMFF-overN-Activity at 19.13 uMFF-overN-Activity at 25.10 uMFF-overN-Activity at 57.49 uMFF-overN-Activity at 115.7 uMFF-overN-Activity at 221.8 uMFF-overN-Activity at 288.0 uMCompound QC
Inactive0004-8.5233-2.8988-12.5908-2.7412-8.5233QC'd by Sytravon
Inactive0-5.34.95490.5242-0.0894-10.926540 0 0 0-0.0745-3.5393-17.8554-0.1186-0.0745QC'd by Sytravon
Inactive0004-2.5515-1.0417-4.89670.166-2.5515QC'd by Sytravon
Inactive0-5.252.63840.99936-4.427940 0 0 05.847-4.5232-4.1214.75475.847QC'd by Sytravon
Inactive00040.20430.5279-0.6989-3.01060.2043QC'd by Sytravon
Inactive0004-20.4584-16.0227-10.542-12.7-20.4584QC'd by Sytravon
Inactive00040.38111.93282.01373.54250.3811QC'd by Sytravon
Inactive0-4.61.86170.9679-30.78-11.312340 0 0 0-27.3167-13.1248-9.8436-15.1075-27.3167QC'd by Sytravon
Inactive0-4.651.88510.9245-20.4108-4.652640 0 0 0-18.259-6.997-2.6272-8.4549-18.259QC'd by Sytravon
Inactive00047.074912.07649.436310.99557.0749QC'd by Sytravon
Inactive0-4.652.33320.9933-31.579-4.453840 0 0 0-28.8158-5.5887-3.2948-9.4116-28.8158QC'd by Sytravon
Inactive00042.86354.45163.82067.19372.8635QC'd by Sytravon
Inactive0-5.651.75290.99993.5-15.00740 0 0 1-13.3605-15.0059-10.57742.4893-13.3605QC'd by Sytravon
Inactive0-4.71.96730.9934-42.2319-13.804440 0 0 0-38.812-14.9413-12.7536-21.2969-38.812QC'd by Sytravon
Inactive0-4.93.1320.6223-3.5849-13.726140 0 0 0-3.8208-9.1712-18.1051-9.386-3.8208QC'd by Sytravon
Inactive0-5.450.40.82621.069-18.834640 0 0 0-2.4425-15.6955-9.0343-9.4911-2.4425QC'd by Sytravon
Inactive0-4.953.1320.77051.5-12.370740 0 0 01.5975-7.9378-16.9756-5.17381.5975QC'd by Sytravon
Inactive0-6.84.50450.3905-9.2851-1.574640 0 0 0-7.9625-2.9788-14.4042-5.0533-7.9625QC'd by Sytravon
Inactive0-4.44.95490.8608-22.7116-5.668440 0 0 0-20.1763-4.2865-9.9046-3.4737-20.1763QC'd by Sytravon
Inactive0-5.154.95490.56371-8.347840 0 0 1-11.1241-3.9652-12.78990.2253-11.1241QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CYP3A4437
Protocol: Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). Test compounds dissolved in DMSO and positive control (ketoconazole) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature, the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000073560 uM-Replicate_1Activity at 0.0000367800 uM-Replicate_1Activity at 0.0000735600 uM-Replicate_1Activity at 0.0001677464 uM-Replicate_1Activity at 0.0003678000 uM-Replicate_1Activity at 0.0007362988 uM-Replicate_1Activity at 0.00153 uM-Replicate_1Activity at 0.00368 uM-Replicate_1Activity at 0.00723 uM-Replicate_1Activity at 0.00914 uM-Replicate_1Activity at 0.018 uM-Replicate_1Activity at 0.039 uM-Replicate_1Activity at 0.092 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.460 uM-Replicate_1Activity at 0.910 uM-Replicate_1Activity at 1.182 uM-Replicate_1Activity at 2.302 uM-Replicate_1Activity at 4.834 uM-Replicate_1Activity at 11.49 uM-Replicate_1Activity at 23.94 uM-Replicate_1Activity at 57.45 uM-Replicate_1Activity at 115.4 uM-Replicate_1Activity at 193.5 uM-Replicate_1Activity at 288.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive0-8.32134.95490.64234-4.834640 0 0 0 0 0 1-4.4443-2.77887.36895.36932.33973.33831.6715-4.4443QC'd by Sytravon0
Inhibitor2.391969.704984Complete curve; high efficacy-5.62130.90.993-69.49290.212-1.10 0 0 0 0 0 0-66.6604-0.25131.2197-5.3806-9.9311-37.162-53.3921-66.6604QC'd by Sytravon0
Inhibitor9.522176.407442Partial curve; high efficacy-5.02131.1110.9951-75.90940.498-2.10 0 0 0 0 0 0-66.59123.4283-1.6815-1.5622-0.1199-13.7121-41.7015-66.5912QC'd by Sytravon0
Inactive0-4.52131.75290.9212-24.98775.540 0 0 0 0 0 0-17.48977.36232.46169.84163.36053.96510.8896-17.4897QC'd by Sytravon0
Inhibitor1.5092115.26487Complete curve; high efficacy-5.82131.46410.9934-109.85685.4073-1.10 0 0 0 0 0 0-110.2979-0.81499.86343.518-7.3368-73.6123-100.848-110.2979QC'd by Sytravon0
Inhibitor1.6933117.978187Complete curve; high efficacy-5.77134.50450.9912-112.735.2481-1.10 0 0 0 0 0 0-115.265815.93722.4103-1.24092.2518-88.9575-109.7932-115.2658QC'd by Sytravon0
Inhibitor4.772481.295643Partial curve; high efficacy-5.321310.9946-78.60572.6899-2.10 0 0 0 0 0 0-71.671-0.64476.43020.1885-3.4582-24.3313-55.7062-71.671QC'd by Sytravon0
Inhibitor7.563794.395183Complete curve; high efficacy-5.12134.95490.9967-94.6258-0.2307-1.10 0 0 0 0 0 0-93.87483.4317-2.5012-1.7201-2.44552.6182-85.3984-93.8748QC'd by Sytravon0
Inhibitor2.683765.029784Complete curve; high efficacy-5.57134.0950.989-65.3833-0.3537-1.10 0 0 0 0 0 0-70.4739-2.312-0.8042-1.22813.0628-22.6396-60.696-70.4739QC'd by Sytravon0
Inhibitor7.563757.206142Partial curve; partial efficacy-5.12131.62590.9942-54.13193.0742-2.20 0 0 0 0 0 0-52.30876.2072.82521.47620.0987-3.9796-35.0702-52.3087QC'd by Sytravon0
Inhibitor1.198874.619785Complete curve; high efficacy-5.92131.13410.9933-70.92043.6993-1.10 0 0 0 0 0 0-71.49064.2219-0.18864.5237-17.1469-46.9199-63.4145-71.4906QC'd by Sytravon0
Inhibitor2.1317118.451686Complete curve; high efficacy-5.67132.72020.993-110.08868.3631-1.10 0 0 0 0 0 0-116.12727.57825.10285.881412.5352-56.6231-102.2879-116.1272QC'd by Sytravon0
Inhibitor2.1317122.703187Complete curve; high efficacy-5.67132.40640.9787-115.72726.9759-1.10 0 0 0 0 0 0-122.07513.858917.443-6.083311.7009-62.2871-106.7609-122.0751QC'd by Sytravon0
Inhibitor6.7412121.082984Complete curve; high efficacy-5.17134.0950.9954-126.4671-5.3842-1.10 0 0 0 0 0 0-126.975-0.8069-3.4445-2.4548-11.8834-10.2564-113.7668-126.975QC'd by Sytravon0
Inhibitor4.772486.82744Partial curve; high efficacy-5.321310.9941-85.3831.444-2.10 0 0 0 0 0 0-78.6992-2.43161.8612-0.004-1.8987-28.5107-58.6303-78.6992QC'd by Sytravon0
Inhibitor7.5637125.15484Complete curve; high efficacy-5.12133.92950.9979-122.58722.5668-1.10 0 0 0 0 0 0-123.07953.09863.12671.8871-2.10935.2605-101.0355-123.0795QC'd by Sytravon0
Inhibitor0.6741119.919989Complete curve; high efficacy-6.17131.37230.9986-109.745410.1745-1.10 0 0 0 0 0 0-110.8548.84597.74156.7576-35.5397-88.9969-106.7803-110.854QC'd by Sytravon0
Inhibitor6.7412115.981384Complete curve; high efficacy-5.17132.30310.9963-113.59672.3846-1.10 0 0 0 0 0 0-113.37-1.2322-1.59845.85995.7708-6.0722-86.9448-113.37QC'd by Sytravon0
Inhibitor1.5092114.050988Complete curve; high efficacy-5.82131.96730.9946-113.91580.1351-1.10 0 0 0 0 0 0-113.0117-0.8223-4.0553-2.3728-1.6822-81.3904-111.2484-113.0117QC'd by Sytravon0
Inhibitor8.486660.792742Partial curve; partial efficacy-5.07132.40640.9868-57.96392.8287-2.20 0 0 0 0 0 0-56.54736.87814.87661.3348-2.20081.3516-39.1581-56.5473QC'd by Sytravon0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CYP2D6395
Protocol: Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). Test compounds dissolved in DMSO and positive control (quinidine) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature, the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000073560 uM-Replicate_1Activity at 0.0000367800 uM-Replicate_1Activity at 0.0000735600 uM-Replicate_1Activity at 0.0001677464 uM-Replicate_1Activity at 0.0003678000 uM-Replicate_1Activity at 0.0007362988 uM-Replicate_1Activity at 0.00153 uM-Replicate_1Activity at 0.00368 uM-Replicate_1Activity at 0.00723 uM-Replicate_1Activity at 0.00914 uM-Replicate_1Activity at 0.018 uM-Replicate_1Activity at 0.039 uM-Replicate_1Activity at 0.092 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.460 uM-Replicate_1Activity at 0.910 uM-Replicate_1Activity at 1.182 uM-Replicate_1Activity at 2.302 uM-Replicate_1Activity at 4.834 uM-Replicate_1Activity at 11.49 uM-Replicate_1Activity at 23.94 uM-Replicate_1Activity at 57.45 uM-Replicate_1Activity at 115.4 uM-Replicate_1Activity at 193.5 uM-Replicate_1Activity at 288.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive0-7.260.70.983122040 0 0 0 0 0 0 018.72430.75090.74030.16150.22082.57129.062412.490518.7243QC'd by Labotest0
Inactive00043.08132.90954.18193.06831.54751.9993-1.48293.82823.0813QC'd by Labotest0
Inhibitor10.96462.697110Partial curve; high efficacy; poor fit-4.964.95490.998-66.9977-4.3007-2.31 0 0 0 0 0 0 0-65.7875-42.8846-3.6636-4.8429-3.3836-3.8623-4.4736-41.4229-65.7875QC'd by Microsource0
Inhibitor38.901833.850110Partial curve; partial efficacy; poor fit-4.414.95490.924-33.35010.5-2.40 0 0 0 0 0 0 0-29.0418-1.55510.52060.875-1.2476-0.5605-1.80927.4199-29.0418QC'd by SIGMA0
Inhibitor1.737781.229885Complete curve; high efficacy-5.761.96730.9976-79.95641.2734-1.10 0 0 0 0 0 0 0-78.3324.47950.76060.0181-0.701-3.7995-49.0322-80.0522-78.332QC'd by Tocris0
Inhibitor34.671337.231710Partial curve; partial efficacy; poor fit-4.462.35310.9195-37.23170-2.40 0 0 0 0 0 0 0-28.52643.96925.0423-3.0201-3.1048-1.1738-0.8348-2.4447-28.5264QC'd by Microsource0
Inhibitor15.487171.27341Partial curve; high efficacy-4.811.44870.9928-70.41130.8617-2.10 0 0 0 0 0 0 0-61.76430.28531.9381-1.2811-0.34364.6186-4.2001-27.4432-61.7643QC'd by GVK0
Inhibitor0.218891.972890Complete curve; high efficacy-6.660.80.9894-90.01021.9626-1.10 0 0 0 0 0 0 0-83.87692.77070.8657-14.6874-27.4321-55.0254-79.0233-92.6031-83.8769QC'd by Prestwick Chemical; Inc.0
Inhibitor34.671345.828810Single point of activity-4.462.35310.9938-45.82880-30 0 0 0 0 0 0 0-35.0976-0.4182-0.112-0.91482.1786-0.5211-0.77-3.3082-35.0976QC'd by Vitas0
Inhibitor13.8029116.598142Partial curve; high efficacy-4.860.70.9704-115.4741.1242-2.10 0 0 0 0 0 0 0-87.4803-1.2071.2781-1.1552-1.0641-0.761-34.877-47.6739-87.4803QC'd by Vitas0
Inhibitor19.497171.169541Partial curve; high efficacy-4.712.33320.9649-71.6292-0.4597-2.10 0 0 0 0 0 0 0-66.007-7.5073.5896-6.58233.21022.04942.4442-17.4355-66.007QC'd by Enzo0
Inactive0004-0.33970.68341.1935-3.1601-7.1353-6.692-3.5353-4.6055-0.3397QC'd by Microsource0
Inhibitor38.901899.707710Single point of activity-4.412.90230.9979-103.2475-3.5398-30 0 0 0 0 0 0 0-78.9754-2.6538-1.9475-2.4198-3.036-5.7354-4.4174-6.1242-78.9754QC'd by Labotest0
Inactive00040.55794.29663.86970.9141.57842.77632.2827-0.27460.5579QC'd by Microsource0
Inactive0004-2.28934.50485.93892.79056.12561.13645.75735.7586-2.2893QC'd by Tocris0
Inhibitor12.301842.282721Partial curve; partial efficacy-4.912.33320.9667-45.1528-2.8702-2.20 0 0 0 0 0 0 0-43.5551-8.1379-5.4062-0.92150.1464-0.2747-3.1761-22.7908-43.5551QC'd by Labotest0
Inactive00042.7074-0.37290.3242.07662.64641.1615-0.70884.47812.7074QC'd by Prestwick0
Inactive0004-1.99643.70481.65273.62083.19225.03624.9342-1.7586-1.9964QC'd by Microsource0
Inactive0-6.360.80.89615-7.047740 0 0 0 0 0 0 04.9227-4.8515-7.6164-8.7898-3.26990.29170.34185.50584.9227QC'd by VitasInactive00
Inhibitor3.4671109.162545Partial curve; high efficacy-5.460.90.9982-103.53135.6312-2.10 0 0 0 0 0 0 0-96.39795.98693.1773.47834.7559-9.3266-39.4946-74.1667-96.3979QC'd by Enzo0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CYP2C9536
Protocol: Assay Protocol Summary:

Two ul of enzyme-substrate mix supplemented with 0.4% Bovine Serum Albumin was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). Test compounds dissolved in DMSO and positive control (sulfaphenazole) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at 37C for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature, the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000073560 uM-Replicate_1Activity at 0.0000367800 uM-Replicate_1Activity at 0.0000735600 uM-Replicate_1Activity at 0.0001677464 uM-Replicate_1Activity at 0.0003678000 uM-Replicate_1Activity at 0.0007362988 uM-Replicate_1Activity at 0.00153 uM-Replicate_1Activity at 0.00368 uM-Replicate_1Activity at 0.00723 uM-Replicate_1Activity at 0.00914 uM-Replicate_1Activity at 0.018 uM-Replicate_1Activity at 0.039 uM-Replicate_1Activity at 0.092 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.460 uM-Replicate_1Activity at 0.910 uM-Replicate_1Activity at 1.182 uM-Replicate_1Activity at 2.302 uM-Replicate_1Activity at 4.834 uM-Replicate_1Activity at 11.49 uM-Replicate_1Activity at 23.94 uM-Replicate_1Activity at 57.45 uM-Replicate_1Activity at 115.4 uM-Replicate_1Activity at 193.5 uM-Replicate_1Activity at 288.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inhibitor21.317485.520741Partial curve; high efficacy-4.67133.19250.957-74.520711-2.10 0 0 0 0 0 0-71.26736.65818.66165.03429.029624.68310.5948-71.2673QC'd by Microsource0
Inactive00040.31867.0625.1975.69257.23591.2670.52010.3186QC'd by Microsource0
Inhibitor7.563793.544743Partial curve; high efficacy-5.12131.92820.9984-89.27954.2653-2.10 0 0 0 0 0 0-87.52897.16565.07882.79792.1575-3.7741-60.4613-87.5289QC'd by Tocris0
Inhibitor26.83748.635610Single point of activity-4.57132.24810.9788-42.84845.7872-30 0 0 0 0 0 0-35.46775.96295.47962.709210.27554.6543-0.1967-35.4677QC'd by NCI0
Inhibitor8.4866130.766843Partial curve; high efficacy-5.071310.9992-119.896710.8701-2.10 0 0 0 0 0 0-102.475811.946611.24277.15545.0781-16.0537-65.0649-102.4758QC'd by BIOMOL0
Inhibitor5.354799.189644Partial curve; high efficacy-5.27130.90.9888-96.57122.6185-2.10 0 0 0 0 0 0-87.001-0.2592-1.6376.8143-4.5159-32.2161-61.4841-87.001QC'd by BIOMOL0
Inactive0-4.67132.33320.6923-15.1448-0.540 0 0 0 0 0 0-13.8707-3.7401-1.27785.1005-4.69041.916-3.5213-13.8707QC'd by InterBioScreen0
Inhibitor25.401256.202240Partial curve; partial efficacy-4.59514.50450.9727-57.7888-1.5865-2.20 0 0 0 0 0 0 0-57.6748-1.4876-4.4957-6.22962.86763.1906-3.7494-18.0858-57.6748QC'd by LightBiologicalsInhibitor40.258241.12110Single point of activity-4.39512.95230.943-42.7254
Inhibitor7.563797.471243Partial curve; high efficacy-5.12131.92820.9955-91.45176.0195-2.10 0 0 0 0 0 0-89.13426.42811.19024.98681.8065-2.3315-62.2028-89.1342QC'd by Tocris0
Inhibitor21.317476.663841Partial curve; partial efficacy-4.67131.24750.9713-70.16386.5-2.20 0 0 0 0 0 0-53.059711.862810.1962-0.30794.2931.9517-17.9254-53.0597QC'd by SigmaAldrich0
Inhibitor26.837101.665640Partial curve; high efficacy-4.57131.59360.9916-96.27045.3952-2.10 0 0 0 0 0 0-73.31095.62388.78586.24482.4666-0.9326-13.5438-73.3109QC'd by Tocris0
Inhibitor3.790887.146544Partial curve; high efficacy-5.42130.80.9942-85.19521.9512-2.10 0 0 0 0 0 0-78.88451.4625-1.87161.6032-10.9203-35.4628-58.552-78.8845QC'd by Tocris0
Inhibitor37.9083129.914810Single point of activity-4.42134.95490.9896-129.29750.6173-30 0 0 0 0 0 0-114.6255-1.4437-2.5082-0.90198.8381-4.54583.1106-114.6255QC'd by SigmaAldrich0
Inhibitor26.837109.062140Partial curve; high efficacy-4.57131.34370.9459-109.3538-0.2917-2.10 0 0 0 0 0 0-82.84382.53255.07320.78280.5149-19.3744-20.4297-82.8438QC'd by Bosche0
Inactive0-4.412.90230.8395-17.3952-0.540 0 0 0 0 0 0 0-13.246-3.84691.9539-0.2562-2.65371.4770.7446-0.9487-13.246QC'd by ACC0
Inactive0-8.363.1320.36283-4.516440 0 0 0 0 0 0 02.109-4.1803-1.83775.2557-1.05048.3001-3.10856.7452.109QC'd by Pharmaron0
Inactive00040.5041-8.57852.70450.1138-10.58420.93582.08840.5041QC'd by Toronto Research0
Inhibitor44.493235.276510Single point of activity-4.35173.67720.8478-34.72730.5492-30 0 0 0 0 0 0 0-32.3137-1.4989-3.7044-1.139-0.492412.1946-1.1884-3.139-32.3137QC'd by RTI0
Inactive00046.63087.63316.0247.39860.22633.18743.42856.6308QC'd by Tocris0
Inactive00045.326112.576410.112211.536311.2627.1953.95915.3261QC'd by NCGCChem0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: TRND-SARS-CoV-2-cytotox-48hr
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1. Cells. Seed 1500 HEK293-ACE2 cells (Expi293F with stable expression of human ACE2) in 2 uL/well media (DMEM, 10% FBS, 1x L-glutamine, 1x Pen/Strep, 1 ug/ml puromycin) in white 1536-well assay plates (Greiner #782073).
2. Incubation. Incubate at 37 C with 5% CO2 overnight (~16 h).
3. Compounds. Dispense 23 nL/well compounds in DMSO via pin transfer.
4. Incubation. Incubate for 1 h at 37C 5% CO2.
5. Reagent. Dispense 2 uL/well of media (DMEM, 10% FBS, 1x L-glutamine, 1x Pen/Strep, 1 ug/ml puromycin).
6. Incubation. Incubate at for 48h at 37C 5% CO2
7. Reagent. Dispense 4 uL/well of ATPLite 1step luminescence assay reagent (PerkinElmer #6016739).
8. Incubation. Incubate for 15 min at room temperature.
9. Detection. Read luminescence signal (Viewlux plate reader, PerkinElmer). Data was normalized with wells containing cells as 100%, and wells without cells (media only control) as 0%.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00457 uMActivity at 0.00705 uMActivity at 0.023 uMActivity at 0.046 uMActivity at 0.070 uMActivity at 0.104 uMActivity at 0.147 uMActivity at 0.228 uMActivity at 0.454 uMActivity at 0.702 uMActivity at 0.990 uMActivity at 1.179 uMActivity at 2.205 uMActivity at 3.547 uMActivity at 5.245 uMActivity at 6.528 uMActivity at 11.35 uMActivity at 18.98 uMActivity at 27.12 uMActivity at 37.89 uMActivity at 57.10 uMActivity at 85.70 uMActivity at 114.4 uMActivity at 171.0 uMCompound QC
Cytotoxic2.511989.96385Complete curve; high efficacy-5.62.40640.9988-81.9638-1.10 0 0 0-81.02564.3424-26.1944-82.8623-81.0256QC'd by MedChem Express
Cytotoxic3.162394.537785Complete curve; high efficacy-5.54.50450.9999-94.32250.2153-1.10 0 0 0-94.7013-0.2373-13.1526-93.6408-94.7013QC'd by SIGMA
Cytotoxic2.818494.81785Complete curve; high efficacy-5.552.04790.9999-95.8221-1.005-1.10 0 0 0-95.0616-6.2542-35.3146-94.5292-95.0616QC'd by APExBIO
Cytotoxic2.818490.520785Complete curve; high efficacy-5.553.06540.9989-88.52072-1.10 0 0 0-86.88350-24.056-89.9601-86.8835QC'd by MedChem Express
Cytotoxic5.623496.974284Complete curve; high efficacy-5.254.0951-95.47421.5-1.10 0 0 0-95.85761.65590-94.7507-95.8576QC'd by SynKinase
Cytotoxic3.981196.100684Complete curve; high efficacy-5.44.50451-95.10061-1.10 0 0 0-94.91080.5692-4.2795-94.8159-94.9108QC'd by Tocris
Cytotoxic2.511977.656384Complete curve; high efficacy-5.62.04790.9997-80.7421-3.0858-1.10 0 0 0-80.0369-5.0715-39.0219-77.613-80.0369QC'd by Microsource
Cytotoxic7.943399.498683Complete curve; high efficacy-5.14.95490.9997-96.99862.5-1.10 0 0 0-96.8051.23063.5418-95.9316-96.805QC'd by MedChem Express
Cytotoxic7.079597.835883Complete curve; high efficacy-5.154.95490.9993-95.83582-1.10 0 0 0-95.644503.4249-95.1788-95.6445QC'd by Tocris
Cytotoxic7.079597.375183Complete curve; high efficacy-5.154.0951-97.37510-1.10 0 0 0-97.18070-0.6843-95.5282-97.1807QC'd by MedChem Express
Cytotoxic7.0795102.439983Complete curve; high efficacy-5.151.69240.9998-100.43992-1.10 0 0 0-96.76290-9.8984-85.0051-96.7629QC'd by MedChem Express
Cytotoxic7.079596.356883Complete curve; high efficacy-5.154.95491-96.35680-1.10 0 0 0-96.164400-95.5939-96.1644QC'd by MedChem Express
Cytotoxic7.079593.612783Complete curve; high efficacy-5.154.95491-93.61270-1.10 0 0 0-93.425800-92.8807-93.4258QC'd by MedChem Express
Cytotoxic8.912597.135783Complete curve; high efficacy-5.054.95491-97.13570-1.10 0 0 0-96.941800-94.9322-96.9418QC'd by APExBIO
Cytotoxic8.9125105.03483Complete curve; high efficacy-5.051.64360.9999-100.0345-1.10 0 0 0-94.72923.0536-3.9173-76.9038-94.7292QC'd by Glixx
Cytotoxic1091.303782Complete curve; high efficacy-52.18761-85.80375.5-1.10 0 0 0-84.12124.86462.5388-67.7158-84.1212QC'd by SIGMA
Cytotoxic1098.125282Complete curve; high efficacy-52.84730.9999-97.62520.5-1.10 0 0 0-96.850400-83.9555-96.8504QC'd by Cayman
Cytotoxic11.220293.877282Complete curve; high efficacy-4.952.40640.9998-92.87721-1.10 0 0 0-91.056100-72.1776-91.0561QC'd by Selleck
Cytotoxic0.891360.234867Complete curve; partial efficacy-6.053.51170.9985-93.1767-32.9418-1.20 0 0 0-93.5509-51.1212-90.8041-91.9137-93.5509QC'd by Selleck
Cytotoxic0.794356.680267Complete curve; partial efficacy-6.13.92950.9999-91.2497-34.5695-1.20 0 0 0-91.0675-40.2642-90.3425-90.8279-91.0675QC'd by MedChem Express
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: TRND-SARS-CoV-2-PP
Protocol: PROTOCOL TABLE (format as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.

1. Cells. Seed 1500 HEK293-ACE2 cells (Expi293F with stable expression of human ACE2) in 2 uL/well media (DMEM, 10% FBS, 1x L-glutamine, 1x Pen/Strep, 1 ug/ml puromycin) in white 1536-well assay plates (Greiner #782073).
2. Incubation. Incubate at 37C with 5% CO2 overnight (~16 h).
3. Compounds. Dispense 23 nL/well compounds in DMSO via pin transfer.
4. Incubation. Incubate for 1 hr at 37C 5% CO2.
5. Reagent. Dispense 2 uL/well of SARS-CoV-2-S pseudotyped particles. [a] PPs are produced with murine leukemia virus pseudotyping. [b] SARS-CoV-2-S is Wuhan-Hu-1 sequence (BEI #NR-52420) with C-terminal 19 amino acid truncation.
6. Centrifuge. Spin-inoculate by centrifugation at 1500 rpm (453 xg) for 45 min at room temperature.
7. Incubation. Incubate at for 48 hr at 37C 5% CO2
8. Centrifuge. Remove supernatant with gentle centrifugation using a Blue Washer (BlueCat Bio).
9. Reagent. Dispense 4 uL/well of Bright-Glo Luciferase detection reagent (Promega #E2620).
10. Incubation. Incubate for 5 min at room temperature.
11. Detection. Read luminescence signal (Viewlux plate reader, PerkinElmer). Data was normalized with wells containing SARS-CoV-2-S PP as 100%, and wells containing bald PP (no fusion protein) as 0%.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00457 uMActivity at 0.00705 uMActivity at 0.023 uMActivity at 0.046 uMActivity at 0.070 uMActivity at 0.104 uMActivity at 0.147 uMActivity at 0.228 uMActivity at 0.454 uMActivity at 0.702 uMActivity at 0.990 uMActivity at 1.179 uMActivity at 2.205 uMActivity at 3.547 uMActivity at 5.245 uMActivity at 6.528 uMActivity at 11.35 uMActivity at 18.98 uMActivity at 27.12 uMActivity at 37.89 uMActivity at 57.10 uMActivity at 85.70 uMActivity at 114.4 uMActivity at 171.0 uMCompound QC
Inhibitor0.707934.828810Complete curve; partial efficacy; poor fit-6.154.95490.7525-34.81130.0174-1.40 0 0 0-43.6793-3.7355-37.8905-22.6342-43.6793QC'd by MedChem Express
Inhibitor35.481336.764810Single point of activity-4.452.40640.8748-40.7648-4-30 0 0 0-31.8873-11.45960-6.0521-31.8873QC'd by Pharmaron
Inhibitor39.810740.392710Single point of activity-4.44.44950.7948-48.5731-8.1804-30 0 0 0-41.7275-5.1127-20.8986-3.4837-41.7275QC'd by FLUKA
Inhibitor39.810736.302110Single point of activity-4.44.44950.9302-39.3021-3-30 0 0 0-33.1684-8.76590-0.1246-33.1684QC'd by Prestwick
Inhibitor1091.825410Partial curve; high efficacy; poor fit-53.92951-91.32540.5-2.31 0 0 0-91.1431-30.0380-57.0259-91.1431QC'd by APExBIO
Inhibitor39.810788.872610Single point of activity-4.44.95490.9981-87.87261-30 0 0 0-75.3105003.3645-75.3105QC'd by Microsource
Inhibitor39.810739.07410Single point of activity-4.44.95490.9982-38.5740.5-30 0 0 0-32.9783001.4313-32.9783QC'd by Carbosynth
Inhibitor17.782845.659310Partial curve; partial efficacy; poor fit-4.751.96730.9887-54.3257-8.6664-2.40 0 0 0-50.2467-11.0836-6.8054-21.6158-50.2467QC'd by TargetMol
Inhibitor39.810774.978610Single point of activity-4.44.44950.9815-77.9786-3-30 0 0 0-65.3989-8.931700-65.3989QC'd by MedChem Express
Inhibitor39.810735.78810Single point of activity-4.44.44950.945-39.8408-4.0529-30 0 0 0-34.034-8.1712-5.8755-0.0441-34.034QC'd by Adooq
Inhibitor19.952698.547510Partial curve; high efficacy; poor fit-4.71.96730.9936-101.5475-3-2.30 0 0 0-90.5058-6.67020-28.4282-90.5058QC'd by MedChem Express
Inhibitor39.810794.209610Partial curve; high efficacy; poor fit-4.44.44950.9731-106.3898-12.1802-2.30 0 0 0-90.4675-6.8168-21.693-10.2877-90.4675QC'd by Axon Medchem
Inhibitor39.810768.339410Single point of activity-4.44.95490.8933-61.33947-30 0 0 0-51.53290021.3412-51.5329QC'd by MedChem Express
Inhibitor11.220245.057510Partial curve; partial efficacy; poor fit-4.951.85790.9996-42.55752.5-2.41 0 0 0-40.794-21.67980-20.0057-40.794QC'd by MedChem Express
Inhibitor22.3872113.332310Partial curve; high efficacy; poor fit-4.651.69241-111.33232-2.31 0 0 0-91.8583-33.87930-25.3979-91.8583QC'd by Microsource
Inhibitor7.079544.4210Single point of activity-5.154.95490.6152-48.42-4-30 0 0 0-44.8333-14.7954-20.3760-44.8333QC'd by SIGMA
Inhibitor39.810732.918510Single point of activity-4.44.95490.6127-36.9185-4-30 0 0 0-32.01542.7163-20.08280-32.0154QC'd by Selleck
Inhibitor39.810751.184410Single point of activity-4.44.44951-51.18440-30 0 0 0-42.6537000-42.6537QC'd by MedChem Express
Inhibitor1058.179910Partial curve; partial efficacy; poor fit-53.51170.9887-59.1799-1-2.40 0 0 0-59.8069-4.87472.0564-35.7833-59.8069QC'd by DC Chemicals
Inhibitor39.810740.290110Single point of activity-4.44.44950.7334-45.6865-5.3964-30 0 0 0-38.9054-16.4277-13.0282-1.1636-38.9054QC'd by Adooq
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-keats_OPM1-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.011890.089787Complete curve; high efficacy-7.92922.47290.96942.5966132.6862-1.10 0 0 0 0 0 0 0 0 0 057.466123.2938140.8388112.24160.901644.089639.767736.478540.20639.176941.461857.466QC'd by ChemAxon
Cytotoxic0.417675.850987Complete curve; high efficacy-6.37921.53860.949872.4265148.2774-1.10 0 0 0 0 0 0 0 0 0 061.5626139.2774158.5971143.0204144.9664147.8567136.015191.815692.950575.674674.676861.5626QC'd by JohnsHopkins
Cytotoxic0.148294.419287Complete curve; high efficacy-6.82921.10.951759.4372153.8564-1.10 0 0 0 0 0 0 0 0 0 055.0456164.8354134.704151.2303143.6834134.761595.648470.062167.305676.105555.692455.0456QC'd by Selleck
Cytotoxic0.166394.102386Complete curve; high efficacy-6.77922.72020.972950.0751144.1775-1.10 0 0 0 0 0 0 0 0 0 056.0568132.0924142.9387160.1371137.1338142.289985.893148.200245.041752.603354.183256.0568QC'd by ACC
Cytotoxic0.0332121.075286Complete curve; high efficacy-7.479210.984142.1192163.1944-1.10 0 0 0 0 0 0 0 0 0 035.7472158.2854158.4708139.505123.340671.574165.258955.071850.086742.178237.195535.7472QC'd by Selleck
Cytotoxic0.742778.671685Complete curve; high efficacy-6.12921.88510.983463.6148142.2865-1.10 0 0 0 0 0 0 0 0 0 058.2475142.1116146.4992135.5304145.8795136.7066141.0466113.833174.38665.128871.886858.2475QC'd by Tocris
Cytotoxic0.833386.219185Complete curve; high efficacy-6.079210.930267.549153.7681-1.10 0 0 0 0 0 0 0 0 0 069.8532158.4753142.7847153.7541141.7507166.925141.693105.2958104.667477.221776.165269.8532QC'd by Tocris
Cytotoxic3.722164.493585Complete curve; high efficacy-5.42924.95490.792112.0642176.5577-1.10 0 0 0 0 0 0 0 0 0 089.6942158.9633166.2699180.3984167.1951174.9654191.2964181.3214193.1909122.0222135.538889.6942QC'd by Tocris
Cytotoxic0.0526123.236885Complete curve; high efficacy-7.27920.60.972433.4065156.6433-1.10 0 0 0 0 0 0 0 0 0 035.7651153.6951126.1364142.4363103.249192.595173.147860.614343.388740.031337.882135.7651QC'd by Tocris
Cytotoxic0.006677.526284Complete curve; high efficacy-8.17920.80.975321.696999.2231-1.10 0 0 0 0 0 0 0 0 0 013.262791.55276.413756.561242.193434.028331.180927.350626.077820.634320.214413.2627QC'd by Tocris
Cytotoxic0.5258123.459984Complete curve; high efficacy-6.27921.39870.968242.1223165.5821-1.10 0 0 0 0 0 0 0 0 0 025.7016164.86160.7689152.0063170.1205168.2257149.303488.213874.069651.798249.790125.7016QC'd by JohnsHopkins
Cytotoxic1.865582.375984Complete curve; high efficacy-5.72922.33320.929161.702144.078-1.10 0 0 0 0 0 0 0 0 0 051.7606136.01140.2451152.6106148.0124143.6336147.0904134.4052111.284254.479484.371251.7606QC'd by Selleck
Cytotoxic2.3485101.924784Complete curve; high efficacy-5.62920.60.955871.9549173.8795-1.10 0 0 0 0 0 0 0 0 0 091.649176.6761171.0851177.7813159.9071159.3009150.4576153.7054126.8633116.427184.815491.649QC'd by SynKinase
Cytotoxic0.018790.923784Complete curve; high efficacy-7.72920.70.995926.7347117.6584-1.10 0 0 0 0 0 0 0 0 0 029.5723109.5774101.759683.749673.379952.652141.5735.435430.241226.675925.387729.5723QC'd by Microsource
Cytotoxic0.0132127.373583Complete curve; high efficacy-7.87920.70.972217.3385144.712-1.10 0 0 0 0 0 0 0 0 0 033.7384132.8301113.247589.341775.717555.400227.741422.107814.440214.011616.778533.7384QC'd by Tocris
Cytotoxic3.722186.014283Complete curve; high efficacy-5.42921.210.972165.5416151.5558-1.10 0 0 0 0 0 0 0 0 0 066.7748154.8648146.5307153.6238147.9405153.7843144.2907154.4262119.8728100.256583.011166.7748QC'd by Tocris
Cytotoxic0.3722105.789883Complete curve; high efficacy-6.42922.84730.98436.148141.9378-1.10 0 0 0 0 0 0 0 0 0 022.8052141.9378142.9518145.1156141.0583137.6217130.508557.913351.266941.388233.000722.8052QC'd by JohnsHopkins
Cytotoxic1.6626102.314483Complete curve; high efficacy-5.779210.924240.9668143.2813-1.10 0 0 0 0 0 0 0 0 0 047.0105152.3961124.7264140.9824142.6059141.9566147.0368112.397281.287385.089138.460247.0105QC'd by Microsource
Cytotoxic0.0118140.01383Complete curve; high efficacy-7.92922.58840.998217.9926158.0057-1.10 0 0 0 0 0 0 0 0 0 014.8749156.5885154.4434130.9445.126815.310417.374218.814419.415621.188621.270814.8749QC'd by Selleck
Cytotoxic0.4686118.608983Complete curve; high efficacy-6.32921.85790.987228.1061146.7151-1.10 0 0 0 0 0 0 0 0 0 027.0205138.0525155.3457144.6536140.3247148.8544132.291370.355346.41333.133522.075327.0205QC'd by Tocris
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-OC1MY5-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.016675.705499Complete curve; high efficacy-7.77921.62590.8287113.3664189.0718-1.10 0 0 0 0 0 0 0 0 0 076.415189.0718184.1323176.4162143.7765121.3848112.8196136.1769124.1622121.4205110.84976.415QC'd by SigmaAldrich
Cytotoxic0.014878.323895Complete curve; high efficacy-7.82921.88510.884990.161168.4848-1.10 0 0 0 0 0 0 0 0 0 067.4943179.706152.1469156.7226115.95190.887181.242794.0684108.643892.5891100.356267.4943QC'd by BIOMOL
Cytotoxic0.0093193.289593Complete curve; high efficacy-8.02920.50.866672.6851265.9745-1.10 0 0 0 0 0 0 0 0 0 0105.1458244.5929174.7663172.838154.9069132.1222117.372990.589987.865585.670530.7772105.1458QC'd by Microsource
Cytotoxic0.0021162.783989Complete curve; high efficacy-8.67922.25260.909541.4972204.2812-1.10 0 0 0 0 0 0 0 0 0 016.0569187.9512112.283154.611932.400643.04248.563547.468974.45340.548125.593516.0569QC'd by Tocris
Cytotoxic0.0037168.183989Complete curve; high efficacy-8.42921.98870.95444.8326213.0165-1.10 0 0 0 0 0 0 0 0 0 016.7704206.3802163.409786.454636.022349.839739.359743.293852.688461.372857.854816.7704QC'd by Waterstone
Cytotoxic0.0469148.810689Complete curve; high efficacy-7.32922.40640.8561.7336210.5442-1.10 0 0 0 0 0 0 0 0 0 08.2046222.3206202.2319203.978192.1974118.262335.92446.047760.9187116.720798.87498.2046QC'd by ChemAxon
Cytotoxic0.0026113.270989Complete curve; high efficacy-8.57923.1320.897742.9988156.2697-1.10 0 0 0 0 0 0 0 0 0 021.2361152.3367113.413840.593638.127740.362443.602334.137943.871364.736864.064821.2361QC'd by Tocris
Cytotoxic0.0017114.495389Complete curve; high efficacy-8.77924.0950.841643.8532158.3484-1.10 0 0 0 0 0 0 0 0 0 014.1898152.803967.85254.519352.359357.345849.82462.059347.505430.836728.465514.1898QC'd by Selleck
Cytotoxic0.002672.734289Complete curve; high efficacy-8.57922.72020.907441.83114.5643-1.10 0 0 0 0 0 0 0 0 0 049.3766112.187583.595146.53530.954733.435532.312943.245244.089344.797856.003549.3766QC'd by Microsource
Cytotoxic0.0743128.224189Complete curve; high efficacy-7.12920.30.807365.0905193.3146-1.10 0 0 0 0 0 0 0 0 0 071.5247186.4209158.6743129.1227120.8146138.5824133.4969104.1228120.2992101.960377.775671.5247QC'd by Tocris
Cytotoxic0.0662125.720489Complete curve; high efficacy-7.17921.82650.971967.5385193.259-1.10 0 0 0 0 0 0 0 0 0 052.5197186.6163181.5655200.1337192.1342128.241283.363287.409864.631570.685465.116152.5197QC'd by SantaCruz Bio
Cytotoxic0.661978.285988Complete curve; high efficacy-6.17921.88510.946996.3016174.5875-1.10 0 0 0 0 0 0 0 0 0 0101.3711171.7651176.8613184.4702181.7039154.2237171.0284143.1726100.579190.9185104.0348101.3711QC'd by BIOMOL
Cytotoxic0.0935125.731288Complete curve; high efficacy-7.02923.990.970262.9518188.683-1.10 0 0 0 0 0 0 0 0 0 071.3789173.2237176.4213202.4283200.5745169.056972.067947.835455.511865.182873.840471.3789QC'd by Selleck
Cytotoxic0.0743119.127488Complete curve; high efficacy-7.12920.70.98858.8412177.9686-1.10 0 0 0 0 0 0 0 0 0 065.4007172.7284171.0856155.1599146.3776116.585999.779291.984365.419864.002856.279365.4007QC'd by Axon Medchem
Cytotoxic0.3317103.910288Complete curve; high efficacy-6.47920.30.843677.4858181.396-1.10 0 0 0 0 0 0 0 0 0 0101.3477161.302177.473153.8803133.2684139.1275144.3925135.8497117.608691.5334104.8313101.3477QC'd by Tocris
Cytotoxic0.1321123.71788Complete curve; high efficacy-6.879210.962367.9127191.6297-1.10 0 0 0 0 0 0 0 0 0 045.8939178.5371199.9241184.0193181.5655149.5884112.02994.762981.731373.616983.205245.8939QC'd by Microsource
Cytotoxic0.0066144.59188Complete curve; high efficacy-8.17922.72020.931843.5813188.1723-1.10 0 0 0 0 0 0 0 0 0 07.9675169.8483200.8523105.256949.605442.518545.303152.145650.632956.794649.51437.9675QC'd by SIGMA
Cytotoxic0.935111.476387Complete curve; high efficacy-6.02921.46410.907288.9886200.4649-1.10 0 0 0 0 0 0 0 0 0 065.9282174.089200.6763211.7975212.4609203.6327185.8171171.8065108.7421105.1811115.181865.9282QC'd by Selleck
Cytotoxic0.0118148.747387Complete curve; high efficacy-7.92921.88510.914741.9403190.6876-1.10 0 0 0 0 0 0 0 0 0 08.0822198.2962171.9006154.032174.692245.681859.094162.628163.424350.903813.29568.0822QC'd by Selleck
Cytotoxic1.662684.625787Complete curve; high efficacy-5.77922.72020.9593106.2986190.9242-1.10 1 0 0 0 0 0 0 0 0 0104.8088197.9176147.6744188.5439182.4788196.4457175.6724199.742148.305107.0547110.4851104.8088QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-KMS_34-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.041888.877985Complete curve; high efficacy-7.37921.210.83931.4966120.3746-1.10 0 0 0 0 0 0 0 0 0 07.7124132.8926100.448796.9022107.952767.422923.232138.254730.074155.763343.34537.7124QC'd by ChemAxon
Cytotoxic0.0148116.450385Complete curve; high efficacy-7.82920.40.883227.623144.0733-1.10 0 0 0 0 0 0 0 0 0 023.9089133.149384.985690.676488.203880.547548.934346.794939.846148.370238.326523.9089QC'd by Tocris
Cytotoxic0.00363.507484Complete curve; high efficacy-8.52921.24750.846222.061585.5689-1.10 0 0 0 0 0 0 0 0 0 04.685578.444856.901238.37827.125924.86230.850833.175427.356122.258211.85044.6855QC'd by AG Scientific
Cytotoxic0.066281.534784Complete curve; high efficacy-7.17920.50.935226.2812107.8158-1.10 0 0 0 0 0 0 0 0 0 041.7013104.6491.691185.710374.992566.250263.828947.143640.11632.645316.398141.7013QC'd by Microsource
Cytotoxic0.005388.857983Complete curve; high efficacy-8.27920.70.918715.3166104.1745-1.10 0 0 0 0 0 0 0 0 0 017.273995.7755.043766.176737.487330.62723.923816.028919.552917.45899.815517.2739QC'd by Toronto Research
Cytotoxic0.209387.781383Complete curve; high efficacy-6.67923.06540.98628.7833116.5646-1.10 0 0 0 0 0 0 0 0 0 028.0348105.4018124.2663111.216120.9286117.829382.793730.938430.822427.522130.01228.0348QC'd by ACC
Cytotoxic0.016684.33283Complete curve; high efficacy-7.77922.72020.984217.1644101.4964-1.10 0 0 0 0 0 0 0 0 0 016.809492.1572111.714893.822544.879723.29116.702114.931216.05218.314117.449816.8094QC'd by ChemAxon
Cytotoxic0.037278.620483Complete curve; high efficacy-7.42922.58840.984618.797997.4182-1.10 0 0 0 0 0 0 0 0 0 012.888592.420695.8169102.935482.036534.503824.164219.157513.771216.322226.468312.8885QC'd by Selleck
Cytotoxic1.04996.497783Complete curve; high efficacy-5.97920.50.957536.2422132.7399-1.10 0 0 0 0 0 0 0 0 0 054.2766130.3979127.8742134.2077109.0067109.1952107.713199.92678.571159.936952.628454.2766QC'd by LINCS
Cytotoxic0.0469113.5983Complete curve; high efficacy-7.32921.92820.977620.8655134.4556-1.10 0 0 0 0 0 0 0 0 0 021.4008136.3735118.7418147.5619108.852467.204221.009224.201124.538819.698820.300321.4008QC'd by Tocris
Cytotoxic0.0059134.11483Complete curve; high efficacy-8.22920.90.958214.3732148.4872-1.10 0 0 0 0 0 0 0 0 0 07.7187135.6994.255592.291235.67427.57326.610323.447918.96313.139211.28037.7187QC'd by Selleck
Cytotoxic0.016682.99983Complete curve; high efficacy-7.77924.44950.914818.7882101.7872-1.10 0 0 0 0 0 0 0 0 0 01.306589.3692109.2888105.280939.259712.56078.63117.245227.937241.290725.02181.3065QC'd by BIOMOL
Cytotoxic0.0026124.131382Complete curve; high efficacy-8.57921.47810.986411.3246135.4559-1.10 0 0 0 0 0 0 0 0 0 014.9487124.278272.55539.097213.763318.160410.303510.566110.76498.90756.618214.9487QC'd by Tocris
Cytotoxic0.0209112.54382Complete curve; high efficacy-7.67921.96730.932614.5764127.1195-1.10 0 0 0 0 0 0 0 0 0 00.7959123.8363116.6866132.122462.186831.22417.327713.62456.960345.1415.10240.7959QC'd by NCGCChem
Cytotoxic0.104980.762282Complete curve; high efficacy-6.97923.990.931416.214996.9771-1.10 0 0 0 0 0 0 0 0 0 02.1195101.382375.2262112.248999.869687.632124.000528.457125.40816.87938.90662.1195QC'd by ChemAxon
Cytotoxic0.234892.655582Complete curve; high efficacy-6.62920.90.986616.7612109.4167-1.10 0 0 0 0 0 0 0 0 0 013.3983112.307799.4639110.160599.618592.250163.412843.116934.989225.203720.221113.3983QC'd by JohnsHopkins
Cytotoxic0.0264105.223682Complete curve; high efficacy-7.57922.78680.988110.1409115.3645-1.10 0 0 0 0 0 0 0 0 0 05.3828108.8197112.7123124.379475.066919.974411.747517.45588.74528.59417.9615.3828QC'd by Selleck
Cytotoxic0.93588.261382Complete curve; high efficacy-6.02921.78850.855620.4336108.6949-1.10 0 0 0 0 0 0 0 0 0 04.852785.5635121.1104117.096194.650799.9913137.032269.811848.833229.794829.96994.8527QC'd by Selleck
Cytotoxic0.0059119.868782Complete curve; high efficacy-8.22920.90.98910.4647130.3334-1.10 0 0 0 0 0 0 0 0 0 09.7544119.720688.055968.561935.492830.376516.190110.80912.106211.21728.0079.7544QC'd by Tocris
Cytotoxic0.4176152.652182Complete curve; high efficacy-6.37920.40.9686-18.9995133.6526-1.10 0 0 0 0 0 0 0 0 0 02.9146127.427102.6532123.629693.093583.859362.24155.771444.320918.43846.1372.9146QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:dengue virus type 2
External ID: CHEMBL4043018
Protocol: N/A
Comment: Journal: ACS Med Chem Lett
Year: 2017
Volume: 8
Issue: 3
First Page: 344
Last Page: 349
DOI: 10.1021/acsmedchemlett.7b00008

Target ChEMBL ID: CHEMBL613966
ChEMBL Target Name: dengue virus type 2
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeActivity Comment
ActivityNot Active
ActivityNot Active
ActivityNot Active
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-keats_L363-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.011864.8887Complete curve; high efficacy-7.92923.990.906542.9911107.8711-1.10 0 0 0 0 0 0 0 0 0 175.9379117.166298.059101.666744.543237.931551.79645.54545.89855.696524.21575.9379QC'd by ChemAxon
Cytotoxic0.001086Complete curve; high efficacy-900.8727.00327.003-1.10 0 0 0 0 0 0 0 0 0 011.714116.109651.782338.477438.14932.576327.00321.712513.65628.24944.831811.714QC'd by Tocris
Cytotoxic0.014887.3385Complete curve; high efficacy-7.82922.72020.839428.2225115.5525-1.10 0 0 0 0 0 0 0 0 0 02.7164112.6565118.5558105.208650.461432.896456.123844.203245.685613.05273.96712.7164QC'd by ChemAxon
Cytotoxic0.074381.047985Complete curve; high efficacy-7.12922.40640.987736.057117.1048-1.10 0 0 0 0 0 0 0 0 0 036.612118.1815112.941121.7674108.916987.133342.59131.000532.05139.154343.592636.612QC'd by Selleck
Cytotoxic0.013295.183485Complete curve; high efficacy-7.87922.58840.978930.3117125.4951-1.10 0 0 0 0 0 0 0 0 0 022.3434119.5176131.0238109.768849.199641.232339.094429.184232.449924.950225.888622.3434QC'd by Tocris
Cytotoxic0.037296.952684Complete curve; high efficacy-7.42923.67720.943926.3959123.3485-1.10 0 0 0 0 0 0 0 0 0 020.4921101.7407120.2132147.5217112.769437.937439.317124.381225.076727.694220.417320.4921QC'd by Selleck
Cytotoxic0.1147102.026284Complete curve; high efficacy-6.94040.40.945728.8277130.8539-1.10 0 0 0 0 0 0 0 0 0 1108.0014122.9006125.5314115.924689.870995.612875.420675.658466.669245.064945.6837108.0014QC'd by Selleck
Cytotoxic0.009390.158484Complete curve; high efficacy-8.02921.71370.962524.1405114.2989-1.10 0 0 0 0 0 0 0 0 0 020.1633106.7519116.404475.80742.460431.644837.517319.116617.345730.109618.866820.1633QC'd by NCGCChem
Cytotoxic0.468669.609184Complete curve; high efficacy-6.32921.69240.827647.7156117.3247-1.10 0 0 0 0 0 0 0 0 0 195.324899.0689105.4815112.5472134.071139.294895.863678.07556.20561.315734.97695.3248QC'd by Microsource
Cytotoxic0.295785.225883Complete curve; high efficacy-6.52924.95490.905530.0023115.2281-1.10 0 0 0 0 0 0 0 0 1 045.1208102.1961108.7224107.4279107.404145.4631114.174621.348922.64833.189677.55645.1208QC'd by NCGCChem
Cytotoxic0.0118107.387883Complete curve; high efficacy-7.92924.44950.994618.1514125.5392-1.10 0 0 0 0 0 0 0 0 0 1103.6539130.2388120.1313117.134124.788321.804212.746820.289419.91221.366715.3748103.6539QC'd by Selleck
Cytotoxic0.033278.333383Complete curve; high efficacy-7.47924.44950.957520.808999.1422-1.10 0 0 0 0 0 0 0 0 0 1105.677694.56286.401118.767388.388324.521523.716318.859423.322922.567716.9857105.6776QC'd by Chemscene
Cytotoxic0.011886.29183Complete curve; high efficacy-7.92920.910.971220.4028106.6938-1.10 0 0 0 0 0 0 0 0 0 013.990798.3598100.650970.772445.884940.959433.218425.044519.165723.31217.822613.9907QC'd by Selleck
Cytotoxic0.234884.542283Complete curve; high efficacy-6.62921.10.954725.2427109.7849-1.10 0 0 0 0 0 0 0 0 0 1114.3833102.02113.1558103.8422121.074381.328372.684251.920531.812126.372328.0582114.3833QC'd by ChemieTek
Cytotoxic0.014886.1283Complete curve; high efficacy-7.82922.18760.972516.3085102.4286-1.10 0 0 0 0 0 0 0 0 0 07.9507102.926198.733390.777842.92222.299723.200730.230611.653910.657913.08247.9507QC'd by Selleck
Cytotoxic0.148277.093883Complete curve; high efficacy-6.82924.95490.955322.412899.5066-1.10 0 0 0 0 0 0 0 0 0 09.87102.096792.544998.652790.3526113.472742.025228.643431.5424.979314.77199.87QC'd by Chemscene
Cytotoxic0.417691.373683Complete curve; high efficacy-6.37921.69240.985829.7282121.1017-1.10 0 1 0 0 0 0 0 0 0 021.3801116.2452129.3034186.5441118.5918113.5565105.088162.785435.762934.74535.353721.3801QC'd by Selleck
Cytotoxic1.04987.361683Complete curve; high efficacy-5.979210.877236.1973123.5589-1.10 0 0 0 0 0 0 0 0 0 054.1491117.4289109.6638131.7472129.0154136.577793.933688.945583.642543.457225.12354.1491QC'd by SynKinase
Cytotoxic0.1482113.990583Complete curve; high efficacy-6.82921.28760.888823.8075137.7981-1.10 0 0 0 0 0 0 0 0 0 08.0453114.2505119.5624176.2421137.6679106.682559.028455.250738.182324.837127.40678.0453QC'd by Tocris
Cytotoxic1.17785.496383Complete curve; high efficacy-5.92923.62720.914939.2135124.7097-1.10 0 0 0 0 0 0 0 0 0 027.6517113.2381135.3021111.0564135.5045142.3677111.5001118.811556.830633.204257.637227.6517QC'd by Microsource
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-keats_OCIMY7-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.0148138.417292Complete curve; high efficacy-7.82920.80.985473.4473211.8645-1.10 0 0 0 0 0 0 0 0 0 076.0615206.4576176.3477160.675143.036102.215687.458676.386675.942381.513271.284576.0615QC'd by Selleck
Cytotoxic0.1865129.709492Complete curve; high efficacy-6.72922.47290.9102104.5908234.3002-1.10 0 0 0 0 0 0 0 0 0 097.9499212.7695199.584247.0735277.3731227.6905162.5507123.8591102.5004104.1059104.398997.9499QC'd by SantaCruz Bio
Cytotoxic0.525872.960991Complete curve; high efficacy-6.27922.72020.9263121.6641194.625-1.10 0 0 0 0 0 0 0 0 0 1182.846196.2276201.2704206.5478177.6678187.1047193.8819153.4274124.7553110.5225133.7805182.846QC'd by SIGMA
Cytotoxic0.0469134.726691Complete curve; high efficacy-7.32922.33320.942779.2711213.9977-1.10 0 0 0 0 0 0 0 0 0 074.524225.8348183.7696233.1661192.207130.243974.8439101.457875.21388.15864.064774.524QC'd by Selleck
Cytotoxic0.001091Complete curve; high efficacy-900.973648.780348.7803-1.10 0 0 0 0 0 0 0 0 0 047.83166.158106.533567.344835.203147.280344.656348.780346.703651.704556.888247.83QC'd by Tocris
Cytotoxic0.001090Complete curve; high efficacy-900.820746.422646.4226-1.10 0 0 0 0 0 0 0 0 0 05.4032205.1041113.398945.042360.965955.970682.491946.422618.259210.66488.46975.4032QC'd by Tocris
Cytotoxic1.481867.805689Complete curve; high efficacy-5.82924.95490.7621141.433209.2386-1.10 0 0 0 0 0 0 0 0 0 0116.0869187.3686222.298199.2101217.5801185.2508221.0682234.3031161.6854158.4572150.9575116.0869QC'd by ChemAxon
Cytotoxic0.001089Complete curve; high efficacy-900.959138.870638.8706-1.10 0 0 0 0 0 0 0 0 0 039.1109165.4745147.989392.122638.870647.652815.964314.55779.16457.80787.070839.1109QC'd by Selleck
Cytotoxic0.001089Complete curve; high efficacy-900.938841.142141.1421-1.10 0 0 0 0 0 0 0 0 0 03.8961184.0933141.73391.783118.669184.427141.142140.416126.249718.52235.72733.8961QC'd by Selleck
Cytotoxic0.001089Complete curve; high efficacy-900.988840.837940.8379-1.11 0 0 0 0 0 0 0 0 0 026.1407121.6554195.8384155.511388.106368.094737.765640.837940.099127.971631.77326.1407QC'd by Selleck
Cytotoxic0.038292.573488Complete curve; high efficacy-7.4180.40.889752.7945145.3679-1.10 0 0 0 0 0 0 0 0 0 051.9291116.2057136.3435103.092491.965479.473982.026983.101367.37361.55557.499951.9291QC'd by ChemPacific
Cytotoxic0.0743134.535488Complete curve; high efficacy-7.12921.210.930757.9113192.4467-1.10 0 0 0 0 0 0 0 0 0 049.7147175.8519207.2976185.8686162.8742143.048663.049199.107467.380557.937949.251549.7147QC'd by ChemAxon
Cytotoxic0.001088Complete curve; high efficacy-900.875833.721233.7212-1.10 0 0 0 0 0 0 0 0 0 04.1324152.461297.589368.749932.264258.815947.257833.72128.80494.81863.54334.1324QC'd by Microsource
Cytotoxic3.722185.223987Complete curve; high efficacy-5.42924.95490.891150.0271235.251-1.11 0 0 0 0 0 0 0 0 0 0154.7033204.9209231.691212.9559243.8102227.9286234.025230.2626264.0915159.589149.6383154.7033QC'd by SIGMA
Cytotoxic1.3207106.100387Complete curve; high efficacy-5.87921.82650.9417105.4088211.509-1.10 0 0 0 0 0 0 0 0 0 0114.0374223.8378192.8578196.2457228.3532212.5214209.5506192.8647146.6919120.128291.3668114.0374QC'd by XcessBio
Cytotoxic0.1482151.498787Complete curve; high efficacy-6.82920.70.9856.0265207.5252-1.10 1 0 0 0 0 0 0 0 0 051.814202.2596122.7624197.3713167.7834153.3308139.098485.59679.140368.517869.503551.814QC'd by Selleck
Cytotoxic0.093570.605687Complete curve; high efficacy-7.02924.50450.961352.9846123.5901-1.10 1 0 0 0 0 0 0 0 0 041.374115.1832175.7294133.236122.1014112.51554.255357.095263.733753.56750.781741.374QC'd by SynKinase
Cytotoxic0.001087Complete curve; high efficacy-900.957630.251130.2511-1.10 0 0 0 0 0 0 0 0 0 07.7137142.2621159.750441.789140.52422.573521.992937.056330.251115.915614.28657.7137QC'd by Selleck
Cytotoxic0.001087Complete curve; high efficacy-900.935330.652530.6525-1.10 0 0 0 0 0 0 0 0 0 010.0983153.490588.457756.636528.973143.343733.830730.652518.384511.756211.590310.0983QC'd by Selleck
Cytotoxic0.2635171.464186Complete curve; high efficacy-6.57924.95490.90355.2524226.7165-1.10 0 0 0 0 0 0 0 0 0 087.6192224.0953196.7275198.1303295.2794221.4309194.687546.556551.514833.151858.588387.6192QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL5550262
Protocol: N/A
Comment: Journal: Bioorg Med Chem
Year: 2024
Volume: 98
First Page: 117561
Last Page: 117561
DOI: 10.1016/j.bmc.2023.117561
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
Inhibition=-9%
Inhibition=5%
Inhibition=-14.9%Outside typical range
Inhibition=14%
Inhibition=26.5%
Inhibition=25.9%
Inhibition=2.9%
Inhibition=25.7%
Inhibition=1.3%
Inhibition=-10.1%Outside typical range
Inhibition=6.6%
Inhibition=23.6%
Inhibition=7%
Inhibition=18.3%
Inhibition=15%
Inhibition=-4.6%
Inhibition=55.3%
Inhibition=19.7%
Inhibition=1.6%
Inhibition=-16.1%Outside typical range
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: huntington-HTT2-p1-FF-overN
Protocol: PROTOCOL TABLES
SEQUENCE No. (1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Reagent; 4 uL; 2,500 Hek293 luciferase reporter cells per wells
2; Time; 24 hour; 37C, 5% CO2
3; Compound; 23 nL; Control inhibitor / compound library
4; Time; 24 hour; 37C, 5% CO2
5; Reagent; 2.5 uL; Firefly Luc reagent; Dual-Glo Luciferase Reporter Assay System (Promega)
6; Time; 10 min; room temperature incubation
7; Detection; Luminescence; FLuc

NOTES (numbers refer to sequence above)
1; High-throughput screening, measuring luminescence from a Hek293 luciferase reporter, was performed in 1,536 well white-walled tissue-culture treated plates. 2,500 cells were plated in 4 muL of Opti-MEM per well using a Multidrop Combi Reagent Dispenser (ThermoFisher).
2; Assay plates were cultured for 24 hours.
3; Control inhibitor (PTC124; final concentration of 50 uM) and compound library (at final concentrations of 460 nM - 57.5 uM) were added to the assay plate using the Kalypsis Pintool Robotic System equipped with 1536 pinheads.
4; Cells were then incubated for 24 hours at 37 degrees C prior to luminescence measurements.
5; In all cases, luminescence was measured using the Dual-Glo Luciferase Reporter Assay System (Promega) following the manufacturer's instructions.
6; Room temperature incubation.
7; Luminescence signal was obtained using the PerkinElmer ViewLux plate reader. Results were normalized to vehicle control (0% activity) and zero RLU (-100% activity).
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentFF-overN-Activity_ScoreFF-overN-Curve_DescriptionFF-overN-Fit_LogAC50FF-overN-Fit_HillSlopeFF-overN-Fit_R2FF-overN-Fit_InfiniteActivityFF-overN-Fit_ZeroActivityFF-overN-Fit_CurveClassFF-overN-Excluded_PointsFF-overN-Max_ResponseFF-overN-Activity at 0.0000389080 uMFF-overN-Activity at 0.0001066275 uMFF-overN-Activity at 0.0001907270 uMFF-overN-Activity at 0.0004536066 uMFF-overN-Activity at 0.0007545096 uMFF-overN-Activity at 0.0009784578 uMFF-overN-Activity at 0.00290 uMFF-overN-Activity at 0.00507 uMFF-overN-Activity at 0.00876 uMFF-overN-Activity at 0.016 uMFF-overN-Activity at 0.026 uMFF-overN-Activity at 0.052 uMFF-overN-Activity at 0.080 uMFF-overN-Activity at 0.235 uMFF-overN-Activity at 0.459 uMFF-overN-Activity at 0.739 uMFF-overN-Activity at 1.169 uMFF-overN-Activity at 2.226 uMFF-overN-Activity at 6.007 uMFF-overN-Activity at 11.47 uMFF-overN-Activity at 19.12 uMFF-overN-Activity at 25.20 uMFF-overN-Activity at 57.49 uMFF-overN-Activity at 115.7 uMFF-overN-Activity at 221.8 uMFF-overN-Activity at 288.0 uMCompound QC
Inactive0-63.57220.99988-4.57340 0 0 10.0919-4.64423.17137.90590.0919QC'd by Sytravon
Inactive0-4.73.57220.95511-10.455640 0 0 010.3819-7.9209-13.2963-7.862910.3819QC'd by Sytravon
Inactive0-5.13.92950.9982-20.5535-1.415440 0 0 0-20.4612-1.7364-0.7629-17.0693-20.4612QC'd by Sytravon
Inactive0-4.510.6282-19.163-140 0 0 0-14.30250.9125-7.5415-3.4541-14.3025QC'd by Sytravon
Inactive0-5.952.25260.9995-16.77353.540 0 0 0-16.73043.5028-6.5545-16.8946-16.7304QC'd by Sytravon
Inactive0-50.60.9765-26.06220.05740 0 0 0-20.0519-0.7858-6.9465-12.3383-20.0519QC'd by Sytravon
Inactive0-4.51.44870.9277-11.1274140 0 0 0-7.60622.4742-0.4153-0.9904-7.6062QC'd by Sytravon
Inactive0-5.350.60.9824-10.06549.540 0 0 0-7.55457.85382.9441-1.9949-7.5545QC'd by Sytravon
Inactive00042.49361.95961.29456.65052.4936QC'd by Sytravon
Inactive0-4.552.53340.6159-11.4423-23.995640 0 0 0-13.2853-18.831-28.7463-22.7697-13.2853QC'd by Sytravon
Inactive0004-4.075600-9.752-4.0756QC'd by Sytravon
Inactive0-4.651.64360.9984-26.37236.540 0 0 0-20.72696.89525.4769-1.6781-20.7269QC'd by Sytravon
Inactive0-4.354.95490.8085-22.18351.540 0 0 0-16.81961.0548-3.75337.1078-16.8196QC'd by Sytravon
Inactive0004-9.2421-7.2234-5.2389-3.1916-9.2421QC'd by Sytravon
Inactive0004-12.9119-16.3463-12.7285-15.6237-12.9119QC'd by Sytravon
Inactive0-6.84.95490.468-15.2266340 0 0 0-8.97070-26.8555-10.0921-8.9707QC'd by Sytravon
Inactive00042.68233.85667.61518.00282.6823QC'd by Sytravon
Inactive0-6.84.95490.4875-11.1688240 0 0 1-1.24310-17.6407-4.4754-1.2431QC'd by Sytravon
Inactive0-4.552.35310.986-25.99323.540 0 0 0-21.24435.12471.6510.2461-21.2443QC'd by Sytravon
Inactive0-5.14.0950.7467-1.9217640 0 0 0-2.01812.90348.923-0.4967-2.0181QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-MM1R-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.0093104.652788Complete curve; high efficacy-8.02921.96730.994643.2871147.9397-1.10 0 0 0 0 0 0 0 0 0 046.9856151.2515136.3124112.156860.347441.289143.600645.536740.858441.487544.24846.9856QC'd by Cayman
Cytotoxic0.052690.729187Complete curve; high efficacy-7.27921.24750.96949.3002140.0293-1.10 0 0 0 0 0 0 0 0 0 036.2116136.8931136.6639140.7519111.565496.338258.16355.06458.665957.368148.852936.2116QC'd by Selleck
Cytotoxic0.1865111.099886Complete curve; high efficacy-6.72921.55790.959758.0636169.1634-1.10 0 0 0 0 0 0 0 0 0 030.8392165.6134164.7399166.9572172.8379153.7472111.421772.293771.432370.561564.820230.8392QC'd by Tocris
Cytotoxic0.104999.253786Complete curve; high efficacy-6.97923.1320.878851.4415150.6952-1.10 0 0 0 0 0 0 0 0 0 04.3763133.6762159.094152.6324154.4225134.385464.985170.629468.541858.555955.58134.3763QC'd by Selleck
Cytotoxic0.331794.992984Complete curve; high efficacy-6.47920.30.952137.641132.6338-1.10 0 0 0 0 0 0 0 0 0 050.4436114.4568123.9845113.833196.15292.162489.666481.881579.922468.155859.613750.4436QC'd by Tocris
Cytotoxic0.742784.904484Complete curve; high efficacy-6.12922.25260.93345.6644130.5688-1.10 0 0 0 0 0 0 0 0 0 036.4643134.3384115.1991125.3701119.0101144.1666143.817297.989150.782553.051854.389936.4643QC'd by Tocris
Cytotoxic0.833375.35484Complete curve; high efficacy-6.07923.990.961446.5835121.9376-1.10 0 0 0 0 0 0 0 0 0 033.0973124.2208119.0164110.2614120.2463126.3612130.9298108.885950.932550.258656.053633.0973QC'd by Selleck
Cytotoxic0.372288.076284Complete curve; high efficacy-6.42924.44950.970337.6549125.7311-1.10 0 0 0 0 0 0 0 0 0 044.0074106.5992127.2247130.6238138.3415127.8948120.698748.218435.913536.364134.92644.0074QC'd by Selleck
Cytotoxic0.0093130.642584Complete curve; high efficacy-8.02920.90.986724.621155.2635-1.10 0 0 0 0 0 0 0 0 0 018.1076143.3641125.709898.568566.033436.988237.469536.872131.027325.006419.273518.1076QC'd by Toronto Research
Cytotoxic0.468684.349983Complete curve; high efficacy-6.32923.06540.892737.763122.1129-1.10 0 0 0 0 0 0 0 0 0 08.9174100.9718133.1095113.0152128.6977133.2765119.584364.278453.378148.528644.758.9174QC'd by SynKinase
Cytotoxic0.331788.677483Complete curve; high efficacy-6.47921.62590.990934.1483122.8257-1.10 0 0 0 0 0 0 0 0 0 032.8455112.8257122.9968126.477124.3559121.535296.460460.397143.403334.092232.873332.8455QC'd by JohnsHopkins
Cytotoxic0.2957104.439583Complete curve; high efficacy-6.52920.60.963633.4657137.9052-1.10 0 0 0 0 0 0 0 0 0 030.41139.5422127.9789115.7906133.779110.19387.959673.595558.104955.361347.914130.41QC'd by JohnsHopkins
Cytotoxic2.348586.675883Complete curve; high efficacy-5.62924.0950.968453.6121140.2879-1.10 0 0 0 0 0 0 0 0 0 051.2528135.5146146.9511127.3268148.5202130.0159143.2286148.4195122.370157.612755.742751.2528QC'd by LINCS
Cytotoxic0.589978.481583Complete curve; high efficacy-6.229210.96239.6422118.1236-1.10 0 0 0 0 0 0 0 0 0 036.8849113.0988105.5924123.1519126.3882114.847893.448478.396461.99652.62141.616136.8849QC'd by NCGCChem
Cytotoxic1.662685.967283Complete curve; high efficacy-5.77922.47290.929540.7279126.6952-1.10 0 0 0 0 0 0 0 0 0 028.4756118.8121112.7597122.0662124.4452131.3159149.7541122.838280.294449.812550.994128.4756QC'd by Microsource
Cytotoxic0.074390.741383Complete curve; high efficacy-7.12921.96730.946425.6492116.3905-1.10 0 0 0 0 0 0 0 0 0 05.9198106.5785111.2723128.5693109.673979.414437.115833.672241.61829.688719.14745.9198QC'd by Selleck
Cytotoxic0.4176196.850483Complete curve; high efficacy-6.37920.30.9606-31.7676165.0828-1.10 0 0 0 0 0 0 0 0 0 02.8348135.921148.6439123.1507111.473178.544671.308564.760262.7228.685414.04622.8348QC'd by Microsource
Cytotoxic0.525895.995583Complete curve; high efficacy-6.27920.40.975335.9633131.9588-1.10 0 0 0 0 0 0 0 0 0 050.6988124.3759129.0401111.2096110.666498.319199.274582.50577.957559.853253.136550.6988QC'd by Microsource
Cytotoxic0.1865153.297482Complete curve; high efficacy-6.72920.40.9838-19.1976134.0998-1.10 0 0 0 0 0 0 0 0 0 01.5971128.3939102.50195.957690.349376.112759.654643.641425.05494.92791.71.5971QC'd by NCGCChem
Cytotoxic0.4686112.636982Complete curve; high efficacy-6.32920.70.96616.772129.4089-1.10 0 0 0 0 0 0 0 0 0 013.877117.2722122.3984135.2437130.0817105.741580.360967.039351.753440.54130.169413.877QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Toxoplasma gondii
External ID: CHEMBL5506105
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Eur J Med Chem
Year: 2023
Volume: 262
First Page: 115885
Last Page: 115885
DOI: 10.1016/j.ejmech.2023.115885

Target ChEMBL ID: CHEMBL612888
ChEMBL Target Name: Toxoplasma gondii
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.009ED50=0.009uM
14.58ED50=14.58uM
2.76ED50=2.76uM
2.81ED50=2.81uM
0.5ED50=0.5uM
0.001ED50=0.001uM
5.88ED50=5.88uM
0.011ED50=0.011uM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-mm1s-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.013278.888888Complete curve; high efficacy-7.87923.51170.995147.2347126.1235-1.10 0 0 0 0 0 0 0 0 0 042.2827127.6613122.708120.202461.112651.288545.516147.740746.357847.533948.054342.2827QC'd by SigmaAldrich
Cytotoxic0.018794.499187Complete curve; high efficacy-7.72921.96730.992343.1973137.6963-1.10 0 0 0 0 0 0 0 0 0 047.5181141.319129.8171127.504186.807649.094247.049942.27740.938537.815144.862147.5181QC'd by ACC
Cytotoxic0.525873.986887Complete curve; high efficacy-6.27921.53860.960875.2185149.2053-1.10 0 0 0 0 0 0 0 0 0 066.1566142.7053154.8249147.903146.0134146.4254144.006104.273988.096990.959471.649566.1566QC'd by JohnsHopkins
Cytotoxic0.0059140.454587Complete curve; high efficacy-8.22921.41630.968736.1127176.5672-1.10 0 0 0 0 0 0 0 0 0 010.8624168.6765147.515496.349154.200241.544537.572842.209341.742240.483343.494610.8624QC'd by Cayman
Cytotoxic0.013279.744487Complete curve; high efficacy-7.87920.60.898641.6151121.3595-1.10 0 0 0 0 0 0 0 0 0 026.1462113.0499103.137682.203181.485258.693853.314553.669254.537937.118656.47926.1462QC'd by SigmaAldrich
Cytotoxic0.166378.942786Complete curve; high efficacy-6.77923.92950.945949.4968128.4395-1.10 0 0 0 0 0 0 0 0 0 039.1638119.9619118.7114121.8873145.134135.660277.501949.371642.704855.488760.915639.1638QC'd by SynKinase
Cytotoxic0.117799.522986Complete curve; high efficacy-6.92920.50.978453.5004153.0233-1.10 0 0 0 0 0 0 0 0 0 054.2364146.2425146.4285127.5196118.6607112.3725102.003786.351770.597462.725470.168354.2364QC'd by Selleck
Cytotoxic0.234879.922286Complete curve; high efficacy-6.62921.46410.979158.9416138.8638-1.10 0 0 0 0 0 0 0 0 0 062.4132143.4278135.9313129.1028144.3799129.2524105.203973.502570.461953.739757.639662.4132QC'd by BIOMOL
Cytotoxic0.0187133.261986Complete curve; high efficacy-7.72920.60.944135.7906169.0525-1.10 0 0 0 0 0 0 0 0 0 027.5582156.1894139.4018135.437491.108661.224166.094967.717153.596142.584230.965227.5582QC'd by Toronto Research
Cytotoxic0.029679.81285Complete curve; high efficacy-7.52923.1320.836730.4945110.3065-1.10 0 0 0 0 0 0 0 0 0 0-0.421991.4427118.502121.280287.417839.0630.378326.00428.811631.88664.9696-0.4219QC'd by ChemAxon
Cytotoxic0.468672.558485Complete curve; high efficacy-6.32921.47810.89858.4082130.9666-1.10 0 0 0 0 0 0 0 0 0 036.5241121.5091138.67123.1995141.6082124.8321119.084385.203570.543862.760678.203936.5241QC'd by SIGMA
Cytotoxic0.574989.317185Complete curve; high efficacy-6.24043.51170.938153.4216142.7387-1.10 0 0 0 0 0 0 0 0 0 042.1397122.2594133.5752138.8262155.9137150.9759155.3277133.833270.150756.140464.45942.1397QC'd by Selleck
Cytotoxic0.104990.112685Complete curve; high efficacy-6.97921.10.9642.4601132.5727-1.10 0 0 0 0 0 0 0 0 0 048.0597134.7202138.2028122.4795111.2704105.46677.884945.23345.497230.823755.272548.0597QC'd by Tocris
Cytotoxic0.041880.357885Complete curve; high efficacy-7.37920.60.851133.6315113.9892-1.10 0 0 0 0 0 0 0 0 0 011.0841101.2736106.771596.716682.13570.480940.105551.505451.453654.137541.943611.0841QC'd by Microsource
Cytotoxic0.661994.77385Complete curve; high efficacy-6.17921.47810.980353.7716148.5446-1.10 0 0 0 0 0 0 0 0 0 055.0629148.0214138.5482154.1536143.4321157.4598136.588499.863477.243358.434452.819555.0629QC'd by Selleck
Cytotoxic0.2093116.503485Complete curve; high efficacy-6.67921.3310.904546.5044163.0078-1.10 0 0 0 0 0 0 0 0 0 013.0869143.6239161.4686168.1578159.9801164.488797.670664.784668.491371.476350.62513.0869QC'd by Selleck
Cytotoxic0.295796.448284Complete curve; high efficacy-6.52921.82650.979336.1131132.5613-1.10 0 0 0 0 0 0 0 0 0 027.7595137.6757133.1247125.0579141.4133118.8792106.669652.975840.619540.756544.348527.7595QC'd by BIOMOL
Cytotoxic0.372296.5784Complete curve; high efficacy-6.42921.47870.980840.3311136.901-1.10 0 0 0 0 0 0 0 0 0 041.4841141.6948138.6029123.988145.2114122.9084114.816475.052646.365545.832838.682941.4841QC'd by BIOMOL
Cytotoxic0.013299.542284Complete curve; high efficacy-7.87920.50.859825.2368124.779-1.10 0 0 0 0 0 0 0 0 0 033.6254113.8403106.930467.885457.737956.717356.006446.273443.48929.15714.453233.6254QC'd by NCGCChem
Cytotoxic2.093175.060284Complete curve; high efficacy-5.67924.95490.948360.3489135.4091-1.10 0 0 0 0 0 0 0 0 0 060.7384119.1757138.3496139.0789136.1425149.2097137.4143127.2154116.932554.542266.866760.7384QC'd by ChemAxon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-KMS-28PE-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Inconclusive2.093152.377810Complete curve; partial efficacy; poor fit-5.67921.210.8868207.717155.33921.40 0 0 0 1 0 0 0 0 0 1147.1164.4833155.0085150.5868148.3401116.6514156.9711173.7174168.6881199.2135202.8962147.1QC'd by Microsource
Inconclusive0.005712.519610Complete curve; partial efficacy; poor fit-8.24044.95490.312131.5823119.06271.40 0 0 0 0 0 0 0 0 0 1127.1473120.0823122.1295115.8993137.6706122.1335127.163123.7971150.7316133.1825125.6113127.1473QC'd by SIGMA
Inconclusive0.00192110Complete curve; partial efficacy; poor fit-8.72921.10.8356134.2114113.21141.40 0 0 0 0 0 0 0 0 0 1119.1302117.2114127.4759130.4637129.9536131.9164134.6866133.4534131.6405137.8111137.2931119.1302QC'd by Pharmeks
Inconclusive0.066221.510Complete curve; partial efficacy; poor fit-7.17921.96730.9617136.1907114.69071.40 0 0 0 0 0 0 0 0 0 0137.9456114.6907115.3457114.9342114.9118125.4369132.2852136.9063134.4597139.5384132.1379137.9456QC'd by Sequoia
Inconclusive0.148221.099810Complete curve; partial efficacy; poor fit-6.82920.80.8442149.6919128.59211.40 0 0 0 0 0 0 0 0 0 0151.9116131.6919128.2754129.76129.967133.7039147.8377137.7359147.2819148.9579147.0679151.9116QC'd by Tocris
Inconclusive0.083330.510Complete curve; partial efficacy; poor fit-7.07920.30.9065152.817122.3171.40 0 0 0 0 0 0 0 0 0 0149.8479126.317131.9239133.2597133.1414138.2988138.8257144.3744142.6826141.1244150.4849149.8479QC'd by APAC
Inconclusive0.0032310Complete curve; partial efficacy; poor fit-8.52920.70.9042116.673193.67311.40 0 0 0 0 0 0 0 0 0 0115.023597.6731106.1567108.9656113.5207111.3295114.3155115.674116.5526117.8964119.9437115.0235QC'd by SigmaAldrich
Inconclusive0.001925.510Complete curve; partial efficacy-8.72921.55790.7725134.9997109.49971.20 0 0 0 0 0 0 0 0 0 0138.6831113.4997125.8748129.6566135.9028133.275139.8144131.171127.5454138.1274135.3784138.6831QC'd by SigmaAldrich
Inactive0-5.02920.80.4643103.7426121.954440 0 0 0 0 0 0 0 0 0 0106.6946111.4544125.2432128.5053127.1929113.4715124.3917121.815114.296116.6521111.8738106.6946QC'd by BIOMOL
Inactive04125.6815122.8795130.2888125.1136125.6652130.3074128.7078129.9384126.7494127.6785129.7132125.6815QC'd by BIOMOL
Inactive04136.2326163.4273142.6615146.3348166.6634150.6103158.3404165.0578162.7658150.3198139.9664136.2326QC'd by BIOMOL
Inactive0-7.37920.80.6066126.3684141.901940 0 0 0 0 0 0 0 0 0 0126.5818144.4019133.558143.8479137.0521128.3337135.1801122.2906134.5644123.4653125.8628126.5818QC'd by BIOMOL
Inactive0-4.92924.95490.7372120.4574134.013840 0 0 0 0 0 0 0 0 0 0120.7168134.5138134.0383138.0285138.2397129.2732130.6596135.9635130.2877134.4747123.0085120.7168QC'd by BIOMOL
Inactive0-6.87923.1320.4017111.9315106.526540 0 0 0 0 0 0 0 0 0 1105.5505105.9315109.5176101.4274110.4744106.5334110.4821115.977107.3312113.281111.1989105.5505QC'd by BIOMOL
Inactive0-4.67924.50450.6481132.5399143.83940 0 0 0 0 0 0 0 0 0 0132.7564143.839141.5609139.3268147.1235144.923140.6337146.4103146.2306145.3224141.4193132.7564QC'd by BIOMOL
Inactive0-4.57920.90.6882159.3525129.352540 0 0 0 0 0 0 0 0 0 0151.1525125.3525127.8444130.5681128.6677140.8596130.7582127.8002131.1106130.9549139.8805151.1525QC'd by BIOMOL
Inactive0-6.97920.40.9481115.525797.048340 0 0 0 0 0 0 0 0 0 0114.535699.525798.7112102.3247103.7206107.7162106.0966108.4061110.7209110.6769114.5412114.5356QC'd by BIOMOL
Inactive0-5.17922.40640.5201113.1718140.123540 0 0 0 0 0 0 0 0 0 0115.0077144.1235142.7954132.4372151.4407117.6804133.3272147.8257140.0962131.6466114.5804115.0077QC'd by BIOMOL
Inactive04129.9994131.8514126.6454132.768130.4791123.0823132.8921130.718134.7376125.1039126.4003129.9994QC'd by BIOMOL
Inactive0-5.97923.51170.87899.8725117.809540 0 0 0 0 0 0 0 0 0 0106.7355120.8095114.2948118.894116.6347119.8485116.4782116.0413102.243498.24195.0287106.7355QC'd by BIOMOL
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CIB1-p1-p2
Protocol: PROTOCOL TABLES
SEQUENCE No. (1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Reagent; 3 uL; Protein or buffer (4/3x)
2; Compound; 46 nL; Control inhibitor / compound library
3; Time; 15 min; Room temperature incubation
4; Reagent; 1 uL; Fluorescent labeled peptide (4x)
5; Time; 1000 rpm; Centrifuge
6; Time; 15 min; Room temperature incubation
7; Detection; Ex 480/ Em 540; ViewLux Fluorescence Read

NOTES (numbers refer to sequence above)
1; Protein Mixture: C1B1-GST (final concentrations of 1 uM). Buffer composition: 5 mM HEPES pH 7.4, 125 mM NaCl, 5 mM CaCl2, 0.01% Tween20.
2; Control Inhibitor: unlabeled peptide (final concentration range 17.4 nM to 572 uM). Compound Library final concentration range 18.3 nM to 114 uM.
3; Room temperature incubation.
4; Fluorescent Labeled Peptide: FITC-aIIb (final concentration of 100 nM). Sequence of alphaIIb peptide: Acetyl-LVLAMWKVGFFKRNRK-FITC (purity is 95.83%).
5; Centrifuge 1000 rpm (164 g) for 15 seconds.
6; Room temperature incubation.
7; ViewLux Fluorescent Polization Read: excitation = 480(20) / emission = 540(25) S and P; FITC Dichroic mirror.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000386857 uMActivity at 0.0001060182 uMActivity at 0.0002019424 uMActivity at 0.0004510146 uMActivity at 0.0009668607 uMActivity at 0.00168 uMActivity at 0.00290 uMActivity at 0.00509 uMActivity at 0.00877 uMActivity at 0.025 uMActivity at 0.041 uMActivity at 0.083 uMActivity at 0.136 uMActivity at 0.247 uMActivity at 0.490 uMActivity at 1.070 uMActivity at 2.238 uMActivity at 4.221 uMActivity at 6.448 uMActivity at 12.37 uMActivity at 30.23 uMActivity at 57.68 uMActivity at 114.0 uMActivity at 227.8 uMActivity at 383.5 uMActivity at 573.0 uMCompound QC
Inactive00043.79243.150.9632.38293.40883.72213.7924QC'd by MedChem Express
Inactive00041.27893.51021.5281.92384.63466.41821.2789QC'd by Selleck
Inactive00040.0037-4.4248-0.615-1.2841-0.0588-4.05140.0037QC'd by Selleck
Inactive0004-3.0131-5.3427-2.388-5.1553-1.5524-1.7506-3.0131QC'd by Selleck
Inactive00043.3730.82350.03162.1071.7002-1.91383.373QC'd by Selleck
Inactive00042.2123-4.94820.01822.4902-0.04663.47292.2123QC'd by Selleck
Inactive0004-6.8722-2.3397-1.6401-4.488-0.7912-2.054-6.8722QC'd by Selleck
Inactive00042.68872.97954.87572.02642.29024.4582.6887QC'd by MedChem Express
Inactive0004-3.8031-1.1794-1.5257-1.59471.0625-2.7807-3.8031QC'd by Selleck
Inactive0004-10.2079-6.2462-2.2383-3.1976-2.6796-7.2482-10.2079QC'd by Selleck
Inactive00043.20441.15581.27971.8267-0.40880.06273.2044QC'd by Analyticon
Inactive0004-8.9309-1.3351-3.9232-1.9433-5.1495-5.1305-8.9309QC'd by Analyticon
Inactive0004-2.583-2.8916-5.1264-4.8462-1.10660.1205-2.583QC'd by Analyticon
Inactive0004-2.75110.2404-3.0231-3.8049-6.48331.0107-2.7511QC'd by Analyticon
Inactive0004-4.5021.02690.00121.26520.39560.7999-4.502QC'd by Analyticon
Inactive00042.29161.59671.72554.12930.66291.2592.2916QC'd by Analyticon
Inactive00043.0438-1.4768-0.49070.27762.287-0.85233.0438QC'd by Analyticon
Inactive0004-4.3119-0.9159-1.5721-0.78780.5085-2.4781-4.3119QC'd by Analyticon
Inactive00041.0585.28035.28657.895410.16324.55741.058QC'd by Analyticon
Inactive00042.9292-2.6967-2.5902-0.50822.84874.3512.9292QC'd by Analyticon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-LP_1-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.010587.390386Complete curve; high efficacy-7.97921.55790.989332.5525119.9428-1.10 0 0 0 0 0 0 0 0 0 032.5973120.122108.670192.358749.68844.854932.131433.603134.763228.3332.048332.5973QC'd by Tocris
Cytotoxic0.008376.084786Complete curve; high efficacy-8.07922.40640.978834.0695110.1542-1.10 0 0 0 0 0 0 0 0 0 024.173108.041107.758381.913639.516542.556837.70132.500733.657937.059831.016624.173QC'd by Toronto Research
Cytotoxic0.018777.542886Complete curve; high efficacy-7.72921.78850.962734.3529111.8957-1.10 0 0 0 0 0 0 0 0 0 033.0008112.3533115.065889.919978.411730.490234.730734.354633.092838.520140.803433.0008QC'd by Selleck
Cytotoxic0.05988.700585Complete curve; high efficacy-7.22920.60.969436.3948125.0953-1.10 0 0 0 0 0 0 0 0 0 028.5989117.1885119.5312102.469690.645885.862360.636451.829952.266249.734541.128528.5989QC'd by Selleck
Cytotoxic0.033277.128185Complete curve; high efficacy-7.47920.70.965531.2029108.331-1.10 0 0 0 0 0 0 0 0 0 022.5571101.2018101.265588.845670.184569.842243.682140.23739.306637.25836.404722.5571QC'd by Selleck
Cytotoxic0.018779.858785Complete curve; high efficacy-7.72923.51170.958432.0611111.9199-1.10 0 0 0 0 0 0 0 0 0 013.2093112.4294107.1384115.125260.413141.924537.316331.47637.27735.928730.843213.2093QC'd by Cayman
Cytotoxic0.093586.449185Complete curve; high efficacy-7.02921.10.944937.248123.6972-1.10 0 0 0 0 0 0 0 0 0 026.2605129.9165117.2503108.9438120.53891.515551.119756.159151.860742.057332.899826.2605QC'd by Tocris
Cytotoxic0.020993.129385Complete curve; high efficacy-7.67921.46410.961833.1188126.2481-1.10 0 0 0 0 0 0 0 0 0 022.4794117.474125.7046121.844767.966156.055641.326142.215733.927132.351729.697222.4794QC'd by Selleck
Cytotoxic0.0332100.48585Complete curve; high efficacy-7.479210.970731.2298131.7149-1.10 0 0 0 0 0 0 0 0 0 025.5067135.567116.3384110.9262105.252653.915347.874942.057435.306632.7930.969525.5067QC'd by SIGMA
Cytotoxic0.029693.442184Complete curve; high efficacy-7.52923.92950.974823.6719117.114-1.10 0 0 0 0 0 0 0 0 0 025.7428100130.2442120.83397.558327.822521.54819.831323.18926.683424.643725.7428QC'd by SigmaAldrich
Cytotoxic0.372276.55184Complete curve; high efficacy-6.42921.210.930841.5458118.0968-1.10 0 0 0 0 0 0 0 0 0 026.8735126.0105102.8329112.503124.3981120.178987.830470.201454.107949.917250.88526.8735QC'd by ChemieTek
Cytotoxic0.132181.241484Complete curve; high efficacy-6.87924.95490.942234.404115.6454-1.10 0 0 0 0 0 0 0 0 0 026.3475111.8181103.4247109.6276115.8533135.698144.775439.68148.652328.651829.112426.3475QC'd by Microsource
Cytotoxic0.148282.701584Complete curve; high efficacy-6.82923.92950.980732.7831115.4845-1.10 0 0 0 0 0 0 0 0 0 029.9601112.1327117.5155121.9023104.2805119.069555.455342.556433.026630.915628.938629.9601QC'd by Selleck
Cytotoxic0.05976.700284Complete curve; high efficacy-7.22921.50950.976329.9655106.6658-1.10 0 0 0 0 0 0 0 0 0 021.9818106.9151109.4753101.075790.329271.880834.561430.807840.756634.092828.492121.9818QC'd by SantaCruz Bio
Cytotoxic0.020988.802383Complete curve; high efficacy-7.67923.51170.951216.2799105.0822-1.10 0 0 0 0 0 0 0 0 0 03.7081100.414107.4471102.660964.97134.98339.840114.997917.73926.496734.02243.7081QC'd by SIGMA
Cytotoxic0.041893.574583Complete curve; high efficacy-7.37922.18760.998417.8156111.39-1.10 0 0 0 0 0 0 0 0 0 017.4361109.284114.2073106.670495.671445.860321.91818.883416.506916.328316.984617.4361QC'd by ACC
Cytotoxic0.083378.232883Complete curve; high efficacy-7.07920.80.905521.999100.2318-1.10 0 0 0 0 0 0 0 0 0 02.109590.1163103.264689.018286.322667.714235.347539.808535.914336.921628.83652.1095QC'd by ChemAxon
Cytotoxic0.074390.137383Complete curve; high efficacy-7.12920.60.939423.0787113.2161-1.10 0 0 0 0 0 0 0 0 0 014.6398104.4157102.1008106.636185.983463.333350.656440.15953.402331.917625.558714.6398QC'd by Axon Medchem
Cytotoxic0.041884.768783Complete curve; high efficacy-7.37921.22210.965421.7645106.5332-1.10 0 0 0 0 0 0 0 0 0 018.8147105.573699.2727109.218868.570462.902925.88328.211225.408922.860621.049818.8147QC'd by Selleck
Cytotoxic0.0469101.067483Complete curve; high efficacy-7.32920.90.956722.9637124.0311-1.10 0 0 0 0 0 0 0 0 0 07.6524111.1073130.7357106.619390.519265.038238.879739.549834.132432.242524.93497.6524QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-MOLP-8-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.2348112.884984Complete curve; high efficacy-6.62920.40.939237.0886149.9734-1.11 0 0 0 0 0 0 0 0 0 047.4866100.2991140.8419123.7999110.5725117.564587.825378.249885.531267.105248.08847.4866QC'd by SantaCruz Bio
Cytotoxic0.0332135.867784Complete curve; high efficacy-7.47920.40.868624.8504160.7181-1.10 0 0 0 0 0 0 0 0 0 09.5856132.6885149.7338116.748673.778973.989769.730568.018654.415855.950840.44799.5856QC'd by SIGMA
Cytotoxic2.0931100.118383Complete curve; high efficacy-5.67920.40.953450.966151.0844-1.10 0 0 0 0 0 0 0 0 0 067.4421149.8224143.8978144.1774136.6925121.0787121.338115.4935112.696598.792974.828167.4421QC'd by Tocris
Cytotoxic0.0132104.008283Complete curve; high efficacy-7.87921.92820.988715.4484119.4565-1.10 0 0 0 0 0 0 0 0 0 04.6572119.4565113.395898.070346.344719.738622.763617.901420.621915.88212.51264.6572QC'd by Selleck
Cytotoxic0.0235123.025483Complete curve; high efficacy-7.62920.40.833719.8641142.8896-1.10 0 0 0 0 0 0 0 0 0 012.2641131.0145115.543690.295153.905271.215162.338757.160461.969514.810235.382712.2641QC'd by Cayman
Cytotoxic0.209385.298783Complete curve; high efficacy-6.67920.70.933425.0186110.3173-1.10 0 0 0 0 0 0 0 0 0 027.0991109.8173117.737596.065379.189496.830975.536451.699233.826328.186136.413327.0991QC'd by NCGCChem
Cytotoxic3.317381.307483Complete curve; high efficacy-5.47922.33320.931557.6371138.9446-1.10 0 0 0 1 0 0 0 0 0 049.2543138.4338143.9848151.4142126.008995.5126125.5596148.3456124.31378.15369.765749.2543QC'd by Selleck
Cytotoxic0.005936.966482Complete curve; partial efficacy-8.22922.33320.9077119.6572156.6236-1.20 0 0 0 0 0 0 0 0 0 0121.5044156.5384152.389136.5428116.1001121.0618114.6459112.3913119.9242122.9008128.5083121.5044QC'd by Tocris
Cytotoxic0.0235114.209482Complete curve; high efficacy-7.62920.50.976314.7696128.979-1.10 0 0 0 0 0 0 0 0 0 010.4187119.189695.722479.624580.242657.691343.007536.236630.095223.109920.65110.4187QC'd by FLUKA
Cytotoxic3.722180.870382Complete curve; high efficacy-5.42924.95490.903234.983115.8532-1.10 0 0 0 0 0 0 0 0 0 031.7555109.588598.898113.8737107.8306136.1674134.0604103.0938120.4749.927837.402931.7555QC'd by Selleck
Cytotoxic0.093590.511982Complete curve; high efficacy-7.02922.40640.907611.9163102.4282-1.10 0 0 0 0 0 0 0 0 0 012.606679.81796.8282103.1563135.242367.22833.455113.67799.624510.775711.22312.6066QC'd by Selleck
Cytotoxic0.166394.761582Complete curve; high efficacy-6.77922.25260.98616.386111.1475-1.10 0 0 0 0 0 0 0 0 0 013.149108.3556124.8245103.3906106.2074102.246958.785121.215318.077319.677216.032513.149QC'd by Selleck
Cytotoxic0.5258104.154382Complete curve; high efficacy-6.279210.941418.3838122.5381-1.10 0 0 0 0 0 0 0 0 0 011.0314104.3828126.1461116.2417132.0669128.168183.354461.552952.656732.958721.753411.0314QC'd by JohnsHopkins
Cytotoxic0.1321103.787382Complete curve; high efficacy-6.87920.90.96614.4792118.2664-1.10 0 0 0 0 0 0 0 0 0 017.9536125.3305107.6763112.1488100.702673.069975.951528.288418.604519.064616.652717.9536QC'd by Axon Medchem
Cytotoxic0.0132114.512182Complete curve; high efficacy-7.87922.04790.990314.6838129.1959-1.10 0 0 0 0 0 0 0 0 0 013.3585136.7296116.4775107.708242.698923.621911.168115.726818.095413.321414.334613.3585QC'd by ChemieTek
Cytotoxic0.1321156.013482Complete curve; high efficacy-6.87920.40.9789-13.9595142.0539-1.10 0 0 0 0 0 0 0 0 0 02.982129.411119.3857103.9503100.891163.90856.490249.420432.44885.10223.55372.982QC'd by Selleck
Cytotoxic3.722184.036682Complete curve; high efficacy-5.42921.98870.889233.1062117.1428-1.10 0 0 0 0 0 0 0 0 0 022.583104.9664128.4651118.0164124.042993.0546124.0918125.7379103.197156.428452.504522.583QC'd by XcessBio
Cytotoxic1.320784.378182Complete curve; high efficacy-5.87924.44950.910828.6573113.0354-1.10 0 0 0 0 0 0 0 0 0 050.695598.1375111.271125.1555106.5195116.7283107.7109122.303149.824127.93655.97250.6955QC'd by Microsource
Cytotoxic0.525893.379882Complete curve; high efficacy-6.27922.33320.98319.1033112.4831-1.10 0 0 0 0 0 0 0 0 0 016.8591105.468124.7832114.5473109.601102.2654109.906561.363223.850621.146220.522416.8591QC'd by Selleck
Cytotoxic0.052698.055282Complete curve; high efficacy-7.27921.50950.986815.7184113.7736-1.10 0 0 0 0 0 0 0 0 0 012.9644114.8405118.277999.487995.383561.412321.163723.874615.920820.047211.588312.9644QC'd by Axon Medchem
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-MM-M1-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.010576.742198Complete curve; high efficacy-7.97920.40.8143106.1488182.891-1.10 0 0 0 0 0 0 0 0 0 097.0213175.2098149.2496135.4049151.407123.166130.2765116.1855114.3842112.5027122.711897.0213QC'd by SigmaAldrich
Cytotoxic0.020959.606490Complete curve; high efficacy-7.67922.33320.874365.0446124.6509-1.10 0 0 0 0 0 0 0 0 0 042.5491114.2054125.0887133.638390.399669.076975.433362.892474.984266.982668.241342.5491QC'd by Selleck
Cytotoxic0.018799.387289Complete curve; high efficacy-7.72920.70.980954.5973153.9845-1.10 0 0 0 0 0 0 0 0 0 052144.7606143.678116.218996.581992.313370.116662.478959.112861.584152.567552QC'd by SynKinase
Cytotoxic0.417668.959788Complete curve; high efficacy-6.37923.51170.895189.8298158.7896-1.11 0 0 0 0 0 0 0 0 0 095.9522121.7497145.5234145.5172164.4127183.3401150.4309108.335677.511895.882489.823695.9522QC'd by Axon Medchem
Cytotoxic0.589969.181988Complete curve; high efficacy-6.22923.990.762995.3406164.5224-1.10 0 0 0 0 0 0 0 0 0 0109.573149.3937173.4718129.8513191.2497150.3213190.3378133.864783.187296.413691.5262109.573QC'd by Selleck
Cytotoxic0.0743107.054887Complete curve; high efficacy-7.12920.80.984554.8206161.8754-1.10 0 0 0 0 0 0 0 0 0 057.9387151.8563163.9611143.7973136.7288112.919683.16276.873368.177453.226952.637857.9387QC'd by Selleck
Cytotoxic0.148283.542787Complete curve; high efficacy-6.82924.44950.95860.4745144.0173-1.10 0 0 0 0 0 0 0 0 0 069.2734130.5346130.6652147.3751155.1668153.941881.695563.29659.260855.616355.513469.2734QC'd by Selleck
Cytotoxic1.177117.97687Complete curve; high efficacy-5.92920.30.8809103.6252221.6012-1.10 0 0 0 0 0 0 0 0 0 0124.3584204.1012213.7323210.6584195.2614187.4914165.4267159.6533180.5857156.7486132.0473124.3584QC'd by Microsource
Cytotoxic0.005986.11287Complete curve; high efficacy-8.22923.92950.940835.788121.9-1.10 0 0 0 0 0 0 0 0 0 016.9728119.2292123.80460.906149.612339.010736.652141.355244.341829.622331.979616.9728QC'd by Selleck
Cytotoxic0.661977.798687Complete curve; high efficacy-6.17921.46410.905587.7533165.5518-1.11 0 0 0 0 0 0 0 0 0 081.2811136.4201144.0668155.7612179.4399178.5787159.509126.3915103.3855100.192987.184981.2811QC'd by Selleck
Cytotoxic0.132189.890486Complete curve; high efficacy-6.87920.80.95149.0129138.9033-1.10 0 0 0 0 0 0 0 0 0 040.8231126.0203148.1813124.8099131.8805103.371579.016473.44667.02155.440553.384540.8231QC'd by Toronto Research
Cytotoxic0.4176102.258786Complete curve; high efficacy-6.37920.90.955864.4239166.6826-1.10 0 0 0 0 0 0 0 0 0 062.0508169.9186163.4857169.1241146.548155.8497143.523295.509585.826689.782263.021662.0508QC'd by JohnsHopkins
Cytotoxic1.481876.048286Complete curve; high efficacy-5.82921.64360.961186.8287162.8769-1.11 0 0 0 0 0 0 0 0 0 082.8262126.6031167.7674148.1546170.4052160.7596163.2256153.9322115.8888102.739187.384382.8262QC'd by Microsource
Cytotoxic0.93570.299185Complete curve; high efficacy-6.02921.10.944964.9721135.2712-1.10 0 0 0 0 0 0 0 0 0 054.1264136.8416133.7919124.0367139.8306136.3935126.542109.431383.56279.460279.257954.1264QC'd by Selleck
Cytotoxic0.1049113.233785Complete curve; high efficacy-6.97921.10.946739.4295152.6631-1.10 0 0 0 0 0 0 0 0 0 032.5405140.1803150.363153.1014157.369294.872271.375973.052248.593136.378239.149432.5405QC'd by Selleck
Cytotoxic0.0166145.913585Complete curve; high efficacy-7.77920.70.982429.6583175.5718-1.10 0 0 0 0 0 0 0 0 0 034.6378162.9357140.528136.147383.994477.337854.505136.927832.978933.61429.924334.6378QC'd by Selleck
Cytotoxic0.742787.807885Complete curve; high efficacy-6.12921.82650.8961.3799149.1877-1.10 0 0 0 0 0 0 0 0 0 043.6517125.4482151.4934151.5693138.7177162.0934165.3929104.484285.588670.237469.183243.6517QC'd by SynKinase
Cytotoxic0.002672.145785Complete curve; high efficacy-8.57921.22210.943724.741896.8875-1.10 0 0 0 0 0 0 0 0 0 016.212489.740360.566940.694133.868835.347627.530728.413321.997521.291722.494316.2124QC'd by Selleck
Cytotoxic0.935100.642185Complete curve; high efficacy-6.02920.70.92361.7833162.4254-1.10 0 0 0 0 0 0 0 0 0 057.3523168.1282144.1115151.7026171.4086158.4019133.5552112.5955103.328285.466988.368357.3523QC'd by Selleck
Cytotoxic2.635188.832385Complete curve; high efficacy-5.57920.80.900992.8317181.664-1.10 0 0 0 0 0 0 0 0 0 098.7032172.664175.775187.4451189.4966178.714170.8024149.3555161.8016111.5356120.77798.7032QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Glycogen synthase kinase-3 beta
External ID: CHEMBL5065589
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL262
ChEMBL Target Name: Glycogen synthase kinase-3 beta
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned

Data Source: EUbOPEN Chemogenomic Library
Standard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
Delta TM=5.443CThermal Shift Assay
Delta TM=-0.3085CThermal Shift Assay
Delta TM=-0.7C
Delta TM=-0.03CThermal Shift Assay
Delta TM=11.17CThermal Shift Assay
Delta TM=-1.553CThermal Shift Assay
Delta TM=-0.29CThermal Shift Assay
Delta TM=-0.3615CThermal Shift Assay
Delta TM=0.0664CThermal Shift Assay
Delta TM=-0.66C
Delta TM=-0.06CThermal Shift Assay
Delta TM=-0.21CThermal Shift Assay
Delta TM=-0.26CThermal Shift Assay
Delta TM=-1.145CThermal Shift Assay
Delta TM=-0.6697CThermal Shift Assay
Delta TM=0CThermal Shift Assay
Delta TM=-0.4876CThermal Shift Assay
Delta TM=2.74CThermal Shift Assay
Delta TM=0.22CThermal Shift Assay
Delta TM=-0.06CThermal Shift Assay
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-OCI_MY1-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.093583.133787Complete curve; high efficacy-7.02920.60.973252.9139136.0477-1.10 0 0 0 0 0 0 0 0 0 054.7559135.1374118.648125.1116118.336796.366979.597475.149571.390359.692254.239654.7559QC'd by Selleck
Cytotoxic0.0332111.725186Complete curve; high efficacy-7.47920.30.926242.1257153.8508-1.10 0 0 0 0 0 0 0 0 0 051.7825144.6362112.8549103.828595.219288.923187.26580.966170.718165.599553.464751.7825QC'd by Cayman
Cytotoxic0.041882.751485Complete curve; high efficacy-7.37920.50.975933.8657116.617-1.10 0 0 0 0 0 0 0 0 0 028.5726108.62298.686993.798783.828667.416856.438356.969748.110946.342837.744328.5726QC'd by SynKinase
Cytotoxic0.029692.090785Complete curve; high efficacy-7.52920.50.938335.476127.5667-1.10 0 0 0 0 0 0 0 0 0 029.5556114.1336120.894588.726181.575576.202554.682455.648457.304545.91137.137429.5556QC'd by SynKinase
Cytotoxic0.186570.386984Complete curve; high efficacy-6.72922.72020.976138.0815108.4684-1.10 0 0 0 0 0 0 0 0 0 047.1917108.8739108.2531101.5408112.4163108.138570.335743.665234.539228.36141.664847.1917QC'd by JohnsHopkins
Cytotoxic0.417671.667384Complete curve; high efficacy-6.37922.40640.947943.4067115.074-1.10 0 0 0 0 0 0 0 0 0 033.3089105.574126.981118.3238117.612103.7019109.683463.443852.586453.630639.122233.3089QC'd by Selleck
Cytotoxic0.1049108.159184Complete curve; high efficacy-6.97920.30.95531.5875139.7466-1.10 0 0 0 0 0 0 0 0 0 043.3364131.0144114.5692101.756397.195681.028979.285179.03469.839955.06552.703143.3364QC'd by SynKinase
Cytotoxic0.0166112.88483Complete curve; high efficacy-7.77922.72020.988916.1533129.0373-1.10 0 0 0 0 0 0 0 0 0 013.2676116.3272134.3166126.014155.794523.838515.933916.952314.530314.265815.832113.2676QC'd by SIGMA
Cytotoxic0.468694.725883Complete curve; high efficacy-6.32920.60.955729.0284123.7542-1.10 0 0 0 0 0 0 0 0 0 035.6827133.5399103.9822117.9539112.0859105.55983.299274.084264.511341.029741.637235.6827QC'd by Selleck
Cytotoxic0.2635100.875583Complete curve; high efficacy-6.57920.90.896925.7615126.637-1.10 0 0 0 0 0 0 0 0 0 04.542104.9981131.3946122.3505135.6872112.0566.048557.839653.797641.533237.99754.542QC'd by ChemAxon
Cytotoxic0.0469103.265883Complete curve; high efficacy-7.32921.47870.994524.4756127.7413-1.10 0 0 0 0 0 0 0 0 0 022.0142133.8948120.7681119.4508105.615665.752534.739831.818124.476924.170924.920822.0142QC'd by Selleck
Cytotoxic0.468692.471283Complete curve; high efficacy-6.32922.33320.97228.9592121.4304-1.10 0 0 0 0 0 0 0 0 0 029.8907112.9759141.5986120.5517113.8929115.8225112.497662.870633.523828.959228.871129.8907QC'd by Selleck
Cytotoxic0.234889.204483Complete curve; high efficacy-6.62921.46410.977529.1453118.3497-1.10 0 0 0 0 0 0 0 0 0 030.577122.3185120.0124103.9641116.9025116.682575.578553.39729.776427.630331.59430.577QC'd by Selleck
Cytotoxic2.635188.363983Complete curve; high efficacy-5.579210.833353.4354141.7993-1.10 0 0 0 0 0 0 0 0 0 069.1826150.707126.8073140.1173122.6532128.5218127.1755136.3873123.344463.498261.630569.1826QC'd by Chemscene
Cytotoxic1.04994.696982Complete curve; high efficacy-5.97921.92820.986426.5166121.2135-1.10 0 0 0 0 0 0 0 0 0 022.4036111.8163115.5011118.7274126.8177125.7155124.411199.239253.489634.159726.65422.4036QC'd by BIOMOL
Cytotoxic0.132181.439182Complete curve; high efficacy-6.879210.970513.202594.6416-1.10 0 0 0 0 0 0 0 0 0 06.269984.6416100.214488.005489.829466.870145.105225.58927.265521.16810.12696.2699QC'd by Selleck
Cytotoxic0.083392.852382Complete curve; high efficacy-7.07920.40.970612.2421105.0944-1.10 0 0 0 0 0 0 0 0 0 015.231897.301484.070587.11564.466159.841648.860238.500140.277931.426921.966115.2318QC'd by Selleck
Cytotoxic0.023580.806982Complete curve; high efficacy-7.62920.60.988914.690995.4978-1.10 0 0 0 0 0 0 0 0 0 011.797688.131284.02266.582754.926541.216133.27229.074823.708316.203515.847511.7976QC'd by Tocris
Cytotoxic0.001259.123982Complete curve; partial efficacy-8.92924.95490.858799.4449158.5687-1.20 0 0 0 0 0 0 0 0 0 0103.2631152.614894.492295.000194.342694.4109100.4664111.3588107.5709103.868592.1541103.2631QC'd by Selleck
Cytotoxic0.417694.690582Complete curve; high efficacy-6.37922.18760.986124.3029118.9934-1.10 0 0 0 0 0 0 0 0 0 021.4583113.0531121.9635115.8336128.0296109.3466109.274655.291834.103826.512620.023521.4583QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-keats_NCIH929-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.148296.190585Complete curve; high efficacy-6.82923.92950.992444.5048140.6953-1.10 0 0 0 0 0 0 0 0 0 037.5464136.9515141.9942144.5132137.0086139.274769.470850.205143.474741.413450.930437.5464QC'd by JohnsHopkins
Cytotoxic0.012983.536684Complete curve; high efficacy-7.89041.47870.997823.8147107.3513-1.10 0 0 0 0 0 0 0 0 0 023.9151110.1823102.343496.995170.752740.620228.6625.881524.655321.871925.213523.9151QC'd by Chemscene
Cytotoxic0.023592.464784Complete curve; high efficacy-7.62921.96730.956723.2254115.6902-1.10 0 0 0 0 0 0 0 0 0 04.0573111.7434116.8232109.391975.447232.990933.705930.026330.264932.170612.76854.0573QC'd by ChemieTek
Cytotoxic0.288175.880584Complete curve; high efficacy-6.54041.82650.968341.6685117.5491-1.10 0 0 0 0 0 0 0 0 0 036.3204119.5479107.4971113.5971126.3084112.3175118.484679.974545.966145.122348.307136.3204QC'd by Selleck
Cytotoxic0.295781.009684Complete curve; high efficacy-6.52923.19250.926140.4734121.483-1.10 0 0 0 0 0 0 0 0 0 011.322115.4342118.2478121.3497132.2979117.0883107.092749.913546.654851.648750.637411.322QC'd by Prestwick Chemical; Inc.
Cytotoxic0.2635116.509584Complete curve; high efficacy-6.57920.60.970641.249157.7585-1.10 0 0 0 0 0 0 0 0 0 040.8193148.2389152.8144145.5181150.8832117.900795.735582.368280.769561.721251.108540.8193QC'd by Toronto Research
Cytotoxic0.052688.20883Complete curve; high efficacy-7.27921.28760.994223.4223111.6302-1.10 0 0 0 0 0 0 0 0 0 017.5003110.0308111.5061103.845494.601259.384438.839430.849224.832526.413122.221717.5003QC'd by LC Labs
Cytotoxic0.052675.902483Complete curve; high efficacy-7.27922.04790.973721.174997.0774-1.10 0 0 0 0 0 0 0 0 0 018.3476101.803486.025499.482590.080350.384429.228830.857823.374816.245614.543118.3476QC'd by Tocris
Cytotoxic0.052679.925683Complete curve; high efficacy-7.27921.37230.966323.9977103.9232-1.10 0 0 0 0 0 0 0 0 0 017.613998.4232100.1087114.286377.500461.650832.015431.605425.732323.840827.908417.6139QC'd by SynKinase
Cytotoxic0.020990.480783Complete curve; high efficacy-7.67920.90.977517.1515107.6322-1.10 0 0 0 0 0 0 0 0 0 06.471996.9766103.361585.574958.317441.067631.175422.007623.02321.414419.28116.4719QC'd by Selleck
Cytotoxic0.005393.642383Complete curve; high efficacy-8.279210.969714.5291108.1714-1.10 0 0 0 0 0 0 0 0 0 08.149699.284981.998249.133631.068631.287422.589621.209613.435211.247510.25858.1496QC'd by SynKinase
Cytotoxic0.014894.690583Complete curve; high efficacy-7.82921.17050.98217.423112.1135-1.10 0 0 0 0 0 0 0 0 0 012.0947103.9614109.053682.852955.000727.887130.356624.600918.123514.68813.793112.0947QC'd by SynKinase
Cytotoxic0.093596.642483Complete curve; high efficacy-7.02921.66040.992224.5734121.2158-1.10 0 0 0 0 0 0 0 0 0 025.6091121.7166119.6038122.5533110.023190.71841.660937.931622.388222.677922.400325.6091QC'd by Selleck
Cytotoxic0.046982.967883Complete curve; high efficacy-7.32924.95490.917922.6763105.644-1.10 0 0 0 0 0 0 0 0 0 02.6388101.9106107.1814103.9277109.288434.581138.965938.548133.351423.30352.61952.6388QC'd by NCI
Cytotoxic0.0296105.787183Complete curve; high efficacy-7.52920.50.883422.0136127.8007-1.10 0 0 0 0 0 0 0 0 0 04.7056117.0952117.3948102.779158.640855.617851.251852.864946.062539.792825.44594.7056QC'd by Selleck
Cytotoxic0.0209126.334483Complete curve; high efficacy-7.67920.80.98917.1119143.4463-1.10 0 0 0 0 0 0 0 0 0 016.0678134.7593122.167111.586876.247354.666237.345223.48931.102310.658718.953916.0678QC'd by Tocris
Cytotoxic0.0074100.270383Complete curve; high efficacy-8.12922.04790.993616.8213117.0916-1.10 0 0 0 0 0 0 0 0 0 023.4575117.6101105.197473.040125.850513.91814.847215.041116.016216.504218.359623.4575QC'd by Selleck
Cytotoxic0.0235108.888982Complete curve; high efficacy-7.62920.70.99411.7255120.6144-1.10 0 0 0 0 0 0 0 0 0 013.4791114.531297.322186.143674.13546.996429.785423.38115.47313.144913.473313.4791QC'd by BIOMOL
Cytotoxic0.0235110.59682Complete curve; high efficacy-7.62921.62660.976412.0566122.6526-1.10 0 0 0 0 0 0 0 0 0 012.2889128.4612120.246294.57586.24920.741516.111913.685812.951413.59113.568112.2889QC'd by FLUKA
Cytotoxic0.041884.248182Complete curve; high efficacy-7.37920.80.942513.632697.8807-1.10 0 0 0 0 0 0 0 0 0 06.907782.5934102.65586.90856441.11432.79328.119227.818519.73737.48046.9077QC'd by Otava
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Tyrosine-protein kinase ABL1
External ID: CHEMBL5060015
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL1862
ChEMBL Target Name: Tyrosine-protein kinase ABL
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned

Data Source: EUbOPEN Chemogenomic Library
Standard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
Delta TM=2.866CThermal Shift Assay
Delta TM=-0.1161CThermal Shift Assay
Delta TM=0.32C
Delta TM=0.12CThermal Shift Assay
Delta TM=1.321CThermal Shift Assay
Delta TM=-0.3289CThermal Shift Assay
Delta TM=0.97CThermal Shift Assay
Delta TM=-0.00477CThermal Shift Assay
Delta TM=0.8545CThermal Shift Assay
Delta TM=0.25C
Delta TM=0.05CThermal Shift Assay
Delta TM=0.01CThermal Shift Assay
Delta TM=0.57CThermal Shift Assay
Delta TM=-0.2514CThermal Shift Assay
Delta TM=-0.09405CThermal Shift Assay
Delta TM=0.1211CThermal Shift Assay
Delta TM=0.2152CThermal Shift Assay
Delta TM=4.95CThermal Shift Assay
Delta TM=0.78CThermal Shift Assay
Delta TM=0.49CThermal Shift Assay
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ovca-p5-p6-adhesion
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Cells; 4 uL; primary human omental fibroblast, black, clear bottom, low base, 1536-well Aurora assay plate.
2; Incubation; 48 hr; 37C.
3; Cells; 3 uL; 1,200 SKOV3ip1-GFP cells.
4; Compounds; 23nL; acoustic dispenser.
5; Incubation; 2 hr; room temperature.
6; Incubation; 16 hr; 37C.
7; Wash; 5 uL; 1x PBS.
8; Fixing; 5 uL; 4% paraformaldehyde (PFA).
9; Incubation; 15 min; room temperature
10; Wash, 5 uL; 1x PBS.
11; Detection; Fluorescence, excitation filter 488 nm, emission filter 509 nm.

NOTES (numbers refer to Sequence numbers above)
1. For the 1,536-well format, 40 primary human omental fibroblasts and 400 mesothelial cells were seeded with 0.02 mug fibronectin and 0.02 mug collagen type I in 4 muL of growth media (2.3 mm2; Supplementary Fig. S1A).
2. Assay plates were incubated for 48 hours at 37 C.
3. After incubation, 1,200 SKOV3ip1-GFP were seeded in 3 muL of serum-free media (growth media minus FBS) on top of primary human omental cells.
4. Compounds or controls were added to each well immediately after the addition of the cancer cells. Compounds were screened in four doses (0.36-46 mumol/L), and the plates contained the positive control (Tomatine) in eight doses (0.035-75 mumol/L) and DMSO (equal volume controls)
5 - 6. The plates were incubated at room temperature for 2 hours and then at 37 degrees C for 16 hours.
7 - 10. Following incubation, the media were aspirated and each well washed with PBS (5 muL) and then fixed with 4% paraformaldehyde (PFA; 5 muL). After 15 minutes, the PFA solution was aspirated, PBS (5 muL) was added.
11. The number of GFP-labeled cells analyzed using a fluorescent cytometer TTP LabTech Acumen eX3 using 488 nm excitation filter and 509 nm emission filter. Data was normalized to the DMSO treated for negative and Tomatine treated wells for positive control.

REFERENCES:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.

Yasgar A, Shinn P, Jadhav A, Auld DS, Michael S, Zheng W, Austin CP, Inglese J and Simeonov A, Compound Management for Quantitative High-Throughput Screening. J. Assoc. Lab. Auto., 2008, 13: 79-89. doi: 10.1016/j.jala.2007.12.004.
Comment: Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.347 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.717 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.13 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Inactive0-4.44.95490.7-26.5489-2.540 0 0 0-18.7908-9.95531.45561.5083-18.7908QC'd by Sytravon
Inactive0-6.34.95490.83720.73351340 0 0 03.878311.00870-1.47213.8783QC'd by Sytravon
Inactive000400-7.076700QC'd by Sytravon
Inactive0-6.34.95490.42262.5-6.053240 0 0 1-1.1886-4.62777.6987-2.282-1.1886QC'd by Sytravon
Inactive0-4.854.0950.9177-14.9072340 0 0 0-14.08935.888400-14.0893QC'd by Sytravon
Inactive0-4.454.95490.95657-5.210640 0 0 04.4674-6.4255-3.9724-5.77644.4674QC'd by Sytravon
Inactive00045.1862-0.56328.26719.24945.1862QC'd by Sytravon
Inactive0-6.34.95490.6755-15.57673.540 0 0 100-21.7306-9.31520QC'd by Sytravon
Inactive0-4.454.95490.6676-12.8912340 0 0 0-9.4927009.4652-9.4927QC'd by Sytravon
Inactive0-6.34.95490.3745-10.57291440 0 0 14.139610.0525-25.89414.78664.1396QC'd by Sytravon
Inactive000402.67112.75333.70280QC'd by Sytravon
Inactive0004-3.6287-7.1208-7.42331.4494-3.6287QC'd by Sytravon
Inactive0-5.354.95490.728610.5-0.471540 0 0 08.0023.2258-4.559613.14728.002QC'd by Sytravon
Inactive0-5.752.33320.9993-13.324715.540 0 0 114.874814.90020-12.770614.8748QC'd by Sytravon
Inactive0-5.44.95490.79279-1.106240 0 0 05.94010.6656-3.005211.92895.9401QC'd by Sytravon
Inactive00042.60190002.6019QC'd by Sytravon
Inactive00043.4483-2.3916-0.30492.69873.4483QC'd by Sytravon
Inactive00040-0.59793.04882.0990QC'd by Sytravon
Inactive00044.38879.71611.432913.49334.3887QC'd by Sytravon
Inactive000400-6.89300QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: OBG420
Protocol: Assay Protocol Summary:

1,000 cells in 4 uL of media were dispensed into white, solid bottom 1536-well plates using a Multidrop Combi (Thermo Scientific). The Assay plates were incubated for 16 hours at 37 C with 5% CO2 in assay plates, followed by the addition of 23 nL of DMSO or drug dissolved in DMSO. Each compound was assayed in five concentrations (0.092, 0.46, 2.3, 11.5, and 57.5 uM), using the automated Wako 1536 Pin Tool workstation and incubated at 37 C with 5% CO2 48 hours. 4 uL of ATPlite, the ATP monitoring reagent, was then added to the each well of the assay plates using the Multidrop Combi reagent dispenser followed by incubation for 15 minutes at room temperature. The resulting luminescence was measured using the ViewLux plate reader.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, cytotoxic compounds are considered active and show up as apparent inhibitors, which are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0002299000 uMActivity at 0.0009353959 uMActivity at 0.00184 uMActivity at 0.00468 uMActivity at 0.00919 uMActivity at 0.016 uMActivity at 0.027 uMActivity at 0.051 uMActivity at 0.092 uMActivity at 0.155 uMActivity at 0.256 uMActivity at 0.462 uMActivity at 0.846 uMActivity at 1.283 uMActivity at 2.310 uMActivity at 4.246 uMActivity at 6.551 uMActivity at 11.58 uMActivity at 25.26 uMActivity at 38.52 uMActivity at 57.54 uMActivity at 116.1 uMActivity at 221.6 uMActivity at 288.3 uMPanel IDPanel Name
Inactive0.089120.43770-7.054.95490.524316-4.437740 0 0 0 013.1195-1.614723.02214.923222.436413.11953PA-1
Inactive0.501219.5120-6.34.50450.98372.5-17.01240 0 0 0 04.6148-17.0933-15.1392.02030.96314.61484SKOV3
Inactive0.089110.17840-7.054.95490.4664-7.67842.540 0 0 0 0-7.22470.9983-11.3986-10.48-0.961-7.22475C33A
Inactive000046.8018-1.79437.92887.71697.15576.80186JEG-3
Inactive0.6315.87540-6.24.95490.65335-0.875440 0 0 0 04.99780.7404-1.97958.09512.36074.99787Es-2
Inactive00004-1.56592.9339-4.8958-4.79511.5969-1.56598Hek293T
Inactive0.08919.9950-7.054.95490.3786-7.4952.540 0 0 0 0-5.41281.1477-11.5205-0.3743-12.9125-5.41289Tov112D
Inactive00004-3.29573.83081.4062-4.436-2.7163-3.295710Tov-21-G
Inactive0.707914.66040-6.154.95490.999411.5-3.160440 0 0 0 11.8313-3.0503-3.035511.111111.20241.831311OV90
Inactive2.511911.03920-5.61.62590.99184.5-6.539240 0 0 0 04.3244-5.7563-6.6993-3.04413.02174.324412CASKI
Inactive000044.00029.26091.730716.16898.27064.00021CAOV3
Inactive0.112.42240-71.64360.8881-1.922410.540 0 0 0 0-4.51867.76070.4819-0.6217-0.7957-4.51862HeLa
Inactive000049.02713.25131.741213.527517.68579.0273PA-1
Inactive0.3162180-6.54.44950.963772540 0 0 0 119.687125.203421.51315.01739.427119.68714SKOV3
Inactive000040.33690.4452-0.91255.72924.440.33695C33A
Inactive0.063110.50-7.24.95490.8451212.540 0 0 0 01.087910.83860.19022.46194.63951.08796JEG-3
Inactive0.50129.55980-6.34.95490.95170-9.559840 0 0 0 0-0.0179-8.4158-10.46650.9667-1.2439-0.01797Es-2
Inactive0.063114.81190-7.24.95490.534-5.8119940 0 0 0 10.28146.5861-12.75991.4268-6.08970.28148Hek293T
Inactive8.91258.5410-5.054.0450.6148-0.54140 0 0 0 07.75193.7595-4.2009-0.57340.66357.75199Tov112D
Inactive000041.0625-0.46660.2533-1.2691-7.13331.062510Tov-21-G
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: NSD2-synergy-p-2C
Protocol: High-throughput drug screening of isogenic RCH-ACV cell lines was performed at the National Center for Advancing Translational Science (NCATS), National Institutes of Health as previously described (1). Briefly, isogenic RCH-ACV NSD2 p.E1099K mutant (9B) and WT cells (2C) were plated at 500 cells/well in a 1536-well plate with a 72-hour incubation with compounds prior to addition of CellTiter-Glo to assess cell viability. NCATS libraries screened include: NPC, MIPE 5.0, Kinase and NPACT. To determine compound activity in the qHTS assay, the concentration-response data for each sample was plotted and modeled by a four-parameter logistic fit yielding IC50 and efficacy (maximal response) values. The area under the curve (AUC) of the dose-response curve ensures both efficacy (magnitude of cell killing) and potency (concentration that elicits cell killing) are accounted for in the analysis of activity.

Reference:
1. Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Mol Pharmacol. 2019, Nov;96(5):629-640.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000062633 uMActivity at 0.0000234000 uMActivity at 0.0000299492 uMActivity at 0.0000680174 uMActivity at 0.0001469594 uMActivity at 0.0003236290 uMActivity at 0.0006759500 uMActivity at 0.00129 uMActivity at 0.00271 uMActivity at 0.00485 uMActivity at 0.00758 uMActivity at 0.016 uMActivity at 0.038 uMActivity at 0.071 uMActivity at 0.177 uMActivity at 0.355 uMActivity at 0.588 uMActivity at 1.399 uMActivity at 1.898 uMActivity at 4.965 uMActivity at 9.229 uMActivity at 17.27 uMActivity at 44.90 uMActivity at 91.89 uMActivity at 155.1 uMActivity at 231.0 uMCompound QC
Inactive00049.3597000002.228909.3597QC'd by Microsource
Inactive0-4.4754.95490.8748-21.4867440 0 0 0 0 0 0 0-17.07226.10422.829307.402506.12865.2151-17.0722QC'd by Vitas
Inactive0-8.2751.17050.66112-6.66740 0 0 0 0 0 0 0-1.0776-6.3892-2.9698-1.73725.8740.35322.4192.3477-1.0776QC'd by Labotest
Inactive0-4.4254.95490.4933-23.5282-340 0 0 0 0 0 0 0-17.94020.3948-8.1012-10.4184-5.55441.8102-4.77655.7051-17.9402QC'd by Vitas
Inactive000407.8331009.349608.39368.85740QC'd by Sequoia
Inactive000402.13462.08732.87872.198101.071700QC'd by SIGMA
Inactive000406.747707.7196.37060000QC'd by Prestwick
Inactive00041.32598.1273007.30856.14859.763401.3259QC'd by Enzo
Inactive0-6.7754.95490.7871-25.4234-14.789241 0 0 0 0 0 0 1-14.8266-40.4001-18.8558-14.3881-11.9076-28.2695-23.675-23.6904-14.8266QC'd by Microsource
Inactive00040003.22385.382307.503400QC'd by Microsource
Inactive0-4.4754.95490.4377-10.0741240 0 0 0 0 0 0 0-7.9784006.8904-2.128300.76149.8865-7.9784QC'd by Labotest
Inactive0004-2.11844.73944.4107-0.61385.167402.3218-1.3941-2.1184QC'd by Microsource
Inactive000400.23422.97255.131802.023500.05890QC'd by Enzo
Inactive0-8.7250.60.79454.5-11.988640 0 0 0 0 0 0 1-9.0185-8.3238-0.45670.90310.07213.33947.72623.0826-9.0185QC'd by Vitas
Inactive0-9.1254.95490.55695-5.355240 0 0 0 0 0 0 1-2.6103-2.7966.99953.42281.61018.09837.01342.0138-2.6103QC'd by Specs
Inactive00040.9896009.6344004.278600.9896QC'd by GVK
Inactive0-5.5254.0950.6337-3.6963340 0 0 0 0 0 0 0-3.46713.29266.721104.917102.2046-3.4969-3.4671QC'd by Prestwick
Inactive00043.12693.073206.53832.82740-3.41288.31143.1269QC'd by Labotest
Inactive0004002.5786.65920003.36630QC'd by Prestwick
Inactive00042.6761008.9375000.40802.6761QC'd by Prestwick Chemical; Inc.
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: NSD2-synergy-p-9B
Protocol: High-throughput drug screening of isogenic RCH-ACV cell lines was performed at the National Center for Advancing Translational Science (NCATS), National Institutes of Health as previously described (1). Briefly, isogenic RCH-ACV NSD2 p.E1099K mutant (9B) and WT cells (2C) were plated at 500 cells/well in a 1536-well plate with a 72-hour incubation with compounds prior to addition of CellTiter-Glo to assess cell viability. NCATS libraries screened include: NPC, MIPE 5.0, Kinase and NPACT. To determine compound activity in the qHTS assay, the concentration-response data for each sample was plotted and modeled by a four-parameter logistic fit yielding IC50 and efficacy (maximal response) values. The area under the curve (AUC) of the dose-response curve ensures both efficacy (magnitude of cell killing) and potency (concentration that elicits cell killing) are accounted for in the analysis of activity.

Reference:
1. Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Mol Pharmacol. 2019, Nov;96(5):629-640.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000062633 uMActivity at 0.0000234000 uMActivity at 0.0000299492 uMActivity at 0.0000680174 uMActivity at 0.0001469594 uMActivity at 0.0003236290 uMActivity at 0.0006759500 uMActivity at 0.00129 uMActivity at 0.00271 uMActivity at 0.00485 uMActivity at 0.00758 uMActivity at 0.016 uMActivity at 0.038 uMActivity at 0.071 uMActivity at 0.177 uMActivity at 0.355 uMActivity at 0.588 uMActivity at 1.399 uMActivity at 1.898 uMActivity at 4.965 uMActivity at 9.229 uMActivity at 17.27 uMActivity at 44.90 uMActivity at 91.89 uMActivity at 155.1 uMActivity at 231.0 uMCompound QC
Inhibitor0.001595.0131100Complete curve; high efficacy-8.82954.95490.995-92.98592.0272-1.10 0 0 0 0 0 0 0 0 0 0-96.2587-1.6791-84.9271-90.9202-90.8631-90.7375-92.2911-92.6732-94.1019-94.0673-96.0913-96.2587QC'd by SIGMA
Inhibitor0.001796.0144100Complete curve; high efficacy-8.76833.24750.9987-95.37860.6358-1.10 0 0 0 0 0 0 0 0 0 0-96.92941.7123-0.1391-34.4453-93.3159-93.9442-94.1795-94.3745-94.7424-94.9325-95.6129-96.9294QC'd by MedChem Express
Inhibitor0.0017101.1335100Complete curve; high efficacy-8.76834.50450.9988-96.45574.6778-1.10 0 0 0 0 0 0 0 0 0 0-98.62542.93835.3252-23.8352-93.6078-94.3407-94.7755-96.5382-96.9802-98.093-97.488-98.6254QC'd by MedChem Express
Inhibitor0.001495.7664100Complete curve; high efficacy-8.86833.06540.9932-91.73124.0352-1.10 0 0 0 0 0 0 0 0 0 0-94.373606.5073-50.3576-85.2142-89.4583-90.3553-90.6328-93.2878-91.6178-92.6738-94.3736QC'd by MedChem Express
Inhibitor0.002792.056799Complete curve; high efficacy-8.5753.990.9971-93.082-1.0254-1.10 0 0 0 0 0 0 0-97.5703-1.153-56.5542-91.9507-92.331-93.0234-92.9105-92.2466-97.5703QC'd by Alfa Aesar
Inhibitor0.002786.152899Complete curve; high efficacy-8.5754.95490.9984-92.0573-5.9045-1.10 0 0 0 0 0 0 0-92.9872-5.0961-62.3948-91.5014-91.2009-92.0539-90.8793-91.9519-92.9872QC'd by Microsource
Inhibitor0.002198.487899Complete curve; high efficacy-8.6754.50450.9983-91.97956.5083-1.10 0 0 0 0 0 0 0-94.04855.8681-73.3835-89.9758-90.798-91.9458-91.2065-93.7497-94.0485QC'd by Bosche
Inhibitor7.0E-482.733499Complete curve; high efficacy-9.1750.60.8847-82.65670.0767-1.10 0 0 0 0 0 0 0-94.3569-37.5208-62.7186-72.7916-74.3825-79.8918-76.6331-78.5528-94.3569QC'd by Selleck
Inhibitor0.003795.081999Complete curve; high efficacy-8.43621.22210.9994-94.52050.5614-1.10 0 0 0 0 0 0-93.7704-1.16310.6157-11.9264-47.6173-82.383-92.7843-93.7704QC'd by Adooq
Inhibitor0.003394.047999Complete curve; high efficacy-8.47953.51170.9958-93.96230.0856-1.10 0 0 0 0 0 0 0 0 0 0-97.87741.2665-23.1756-88.8678-90.2585-91.8229-92.3997-94.1271-95.2991-93.6757-95.8566-97.8774QC'd by MedChem Express
Inhibitor0.0047102.007598Complete curve; high efficacy-8.32952.24810.997-94.17637.8312-1.10 0 0 0 0 0 0 0 0 0 0-98.71735.6987-9.7434-65.3554-90.638-91.2058-92.371-92.7427-94.2549-94.3053-96.979-98.7173QC'd by GVK
Inhibitor0.0047100.42998Complete curve; high efficacy-8.3253.67720.9994-93.22767.2013-1.10 0 0 0 0 0 0 0-94.74358.1328-8.6557-90.5176-92.1158-93.5383-93.4255-92.4974-94.7435QC'd by Prestwick
Inhibitor0.003896.763498Complete curve; high efficacy-8.4253.990.9994-92.02054.743-1.10 0 0 0 0 0 0 0-93.51674.0536-21.1619-91.8053-91.1174-91.9789-90.7784-91.2901-93.5167QC'd by Selleck
Inhibitor0.004590.539798Complete curve; high efficacy-8.34664.50450.9995-92.4565-1.9167-1.10 0 0 0 0 0 0-93.156-4.128-89.5728-91.2217-93.3904-92.524-93.0057-93.156QC'd by Selleck
Inhibitor0.005298.298798Complete curve; high efficacy-8.2884.95490.9993-92.65815.6406-1.10 0 0 0 0 0 0-93.59410-91.9394-91.381-91.3804-93.5391-93.3571-93.5941QC'd by ChemieTek
Inhibitor0.005298.854698Complete curve; high efficacy-8.2880.60.9861-94.11974.7349-1.10 0 0 0 0 0 0-93.9318-33.6729-64.3585-76.1096-84.2151-92.4038-93.1111-93.9318QC'd by MedChem Express
Inhibitor0.00486.042698Complete curve; high efficacy-8.39924.50450.9996-92.288-6.2454-1.10 0 0 0 0 0 0-91.795-7.0299-86.4668-91.4418-93.2202-92.6549-92.4417-91.795QC'd by Selleck
Inhibitor0.004698.020398Complete curve; high efficacy-8.3383.51170.9996-93.16844.8519-1.10 0 0 0 0 0 0-93.7644-11.8828-91.4502-92.2553-94.1095-92.9439-93.2642-93.7644QC'd by SIGMA
Inhibitor0.0042104.449798Complete curve; high efficacy-8.37954.95490.9968-93.920410.5293-1.10 0 0 0 0 0 0 0 0 0 0-96.62598.66757.5142-90.2575-91.0844-91.1114-92.6871-93.2743-95.4523-94.079-95.5345-96.6259QC'd by BioAustralis
Inhibitor0.004294.942198Complete curve; high efficacy-8.37952.84730.9968-94.75910.183-1.10 0 0 0 0 0 0 0 0 0 0-96.93990.6808-16.1375-78.234-91.1234-91.9081-92.3507-95.4781-97.4887-95.7111-95.4747-96.9399QC'd by ActiveBioChem
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: s-sky_synergy-MV-411_DR-CTG72-MIPE_NPC_NPACT_Kinase-p1
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Media; 2uL; white, solid-bottom Corning assay plate.
2; Compounds; 23nL; Echo acoustic dispenser.
3; Cell; 5uL; 500 cells per well.
4: Incubation; 72hr; 37 C, 5% CO2, 95% humidity.
5; Reagent; 3uL; CellTiter-Glo reagent (Promega).
6; Incubation; 10min; room temperature.
7; Detection; Luminescence; ViewLux plate reader (PerkinElmer).

NOTES (numbers refer to Sequence numbers above
1. Quantitative high-throughput screening (qHTS) of small molecule compounds was conducted on drug resistant SYKi MV4-11 cell line. Briefly, 2uL growth media (RPMI 1640 + 1% penicillin/streptomycin + 10% FBS) were added into an assay plate using a Multidrop Combi dispenser (Thermo Fisher Scientific).
2. Twenty-three nanoliter of small molecule compounds were added to each assay plates using the Echo acoustic dispenser (Beckman Coulter).
3. Cells were seeded into the assay plates at a final density of 500 cells in 5uL of media per well using the Multidrop Combi dispenser.
4. Plates were covered with stainless steel gasketed lids and incubated for 72 hours at standard cell culture conditions.
5. Viability was assessed by adding 3uL of CellTiter-Glo detection reagent (Promega).
6. Plates were covered with gasket lids and incubated for 10 minutes at room temperature.
7. Luminescence was measured on a ViewLux plate reader (PerkinElmer).
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000062652 uMActivity at 0.0000234000 uMActivity at 0.0000299754 uMActivity at 0.0000680318 uMActivity at 0.0001469781 uMActivity at 0.0003237363 uMActivity at 0.0006761082 uMActivity at 0.00130 uMActivity at 0.00271 uMActivity at 0.00486 uMActivity at 0.00759 uMActivity at 0.016 uMActivity at 0.038 uMActivity at 0.071 uMActivity at 0.177 uMActivity at 0.356 uMActivity at 0.588 uMActivity at 1.402 uMActivity at 1.903 uMActivity at 4.972 uMActivity at 9.253 uMActivity at 17.29 uMActivity at 44.98 uMActivity at 91.90 uMActivity at 155.1 uMActivity at 231.0 uMCompound QC
Cytotoxic0.00882.203484Complete curve; high efficacy-8.09921.010.966921.0427103.2462-1.10 0 0 0 0 0 013.188495.474859.067235.842331.665221.923822.070613.1884QC'd by Analyticon
Cytotoxic0.025981.057283Complete curve; high efficacy-7.58624.95490.92316.497297.5544-1.10 0 0 0 0 0 02.512597.003593.26858.94736.670723.420912.53742.5125QC'd by MedChem Express
Cytotoxic0.819985.290183Complete curve; high efficacy-6.08621.75290.99432.3577117.6478-1.10 0 0 0 0 0 034.7953115.2038115.6711122.1398.373449.123231.010634.7953QC'd by Glixx
Cytotoxic0.0190.438383Complete curve; high efficacy-7.99921.06410.985619.9781110.4164-1.10 0 0 0 0 0 013.8267101.704171.224135.805628.627925.082819.478713.8267QC'd by Analyticon
Cytotoxic0.0092105.836183Complete curve; high efficacy-8.03624.0950.998416.204122.0401-1.10 0 0 0 0 0 013.8473120.968928.848618.13117.368317.353714.687813.8473QC'd by SIGMA
Cytotoxic0.468384.095583Complete curve; high efficacy-6.32954.44950.96929.5128113.6083-1.10 0 0 0 0 0 0 0 0 0 021.2667108.9911100.6389111.6185114.5273123.8697121.846750.484436.16335.491326.950121.2667QC'd by MedChem Express
Cytotoxic0.104882.764282Complete curve; high efficacy-6.97951.41630.983812.632295.3964-1.10 0 0 0 0 0 0 0 0 0 010.575588.311793.092698.209696.743461.009638.863620.85115.78315.70359.904810.5755QC'd by BIOMOL
Cytotoxic0.177891.15582Complete curve; high efficacy-6.750.60.967113.9433105.0983-1.10 0 0 0 0 0 09.94996.781688.005652.483744.630729.767723.42539.949QC'd by Waterstone
Cytotoxic0.0106101.825682Complete curve; high efficacy-7.9752.72020.992711.1635112.9891-1.10 0 0 0 0 0 0 010.2995105.5432116.579542.386110.210110.828611.463311.646810.2995QC'd by Prestwick
Cytotoxic0.668497.583882Complete curve; high efficacy-6.1752.33320.990218.8259116.4097-1.10 0 0 0 0 0 0 015.8771121.1891108.6953122.087113.851596.846325.162623.985315.8771QC'd by Enzo
Cytotoxic0.042299.181282Complete curve; high efficacy-7.3751.34430.993310.554109.7352-1.10 0 0 0 0 0 0 010.7613114.3989100.783890.706544.474211.202813.845711.361610.7613QC'd by Tocris
Cytotoxic0.007584.106682Complete curve; high efficacy-8.1254.95490.99839.434493.541-1.10 0 0 0 0 0 0 06.535491.798594.110412.665511.09298.63279.997110.07546.5354QC'd by Bosche
Cytotoxic0.421785.920382Complete curve; high efficacy-6.3750.80.962221.4982107.4185-1.10 0 0 0 0 0 0 016.639100.4185107.3168112.829384.599367.881738.354237.879716.639QC'd by Vitas
Cytotoxic0.145895.744482Complete curve; high efficacy-6.83621.55790.976614.7016110.446-1.10 0 0 0 0 0 04.7392104.3625115.347884.378731.790525.599818.03364.7392QC'd by Microsource
Cytotoxic0.0036107.247382Complete curve; high efficacy-8.4444.95490.99898.6172115.8646-1.10 0 0 0 0 0 07.4398110.64829.223610.03329.4928.91416.32217.4398QC'd by Selleck
Cytotoxic0.163680.294782Complete curve; high efficacy-6.78622.04790.976317.79598.0898-1.10 0 0 0 0 0 06.7352100.462595.567485.02829.253227.68320.08926.7352QC'd by Selleck
Cytotoxic0.023197.640682Complete curve; high efficacy-7.63624.95490.999510.3864108.027-1.10 0 0 0 0 0 010.177107.94198.68449.835111.696111.67178.800110.177QC'd by Selleck
Cytotoxic1.587786.327482Complete curve; high efficacy-5.79921.3310.964223.21109.5374-1.10 0 0 0 0 0 029.2744118.455699.7114104.7412100.992385.097633.922129.2744QC'd by MedChem Express
Cytotoxic0.014689.488582Complete curve; high efficacy-7.83621.28760.99529.344198.8326-1.10 0 0 0 0 0 07.000590.702951.556722.53611.87749.85658.1887.0005QC'd by SynKinase
Cytotoxic0.006596.843182Complete curve; high efficacy-8.18624.0950.99488.9496105.7927-1.10 0 0 0 0 0 03.839102.120912.445311.444810.88219.89667.70273.839QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: s-sky_synergy-MV-411_N-CTG72-MIPE_NPC_NPACT_Kinase-p1
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Media; 2uL; white, solid-bottom Corning assay plate.
2; Compounds; 23nL; Echo acoustic dispenser.
3; Cell; 5uL; 500 cells per well.
4: Incubation; 72hr; 37 C, 5% CO2, 95% humidity.
5; Reagent; 3uL; CellTiter-Glo reagent (Promega).
6; Incubation; 10min; room temperature.
7; Detection; Luminescence; ViewLux plate reader (PerkinElmer).

NOTES (numbers refer to Sequence numbers above
1. Quantitative high-throughput screening (qHTS) of small molecule compounds was conducted on naive SYKi MV4-11 cell line. Briefly, 2uL growth media (RPMI 1640 + 1% penicillin/streptomycin + 10% FBS) were added into an assay plate using a Multidrop Combi dispenser (Thermo Fisher Scientific).
2. Twenty-three nanoliter of small molecule compounds were added to each assay plates using the Echo acoustic dispenser (Beckman Coulter).
3. Cells were seeded into the assay plates at a final density of 500 cells in 5uL of media per well using the Multi-drop Combi dispenser.
4. Plates were covered with stainless steel gasketed lids and incubated for 72 hours at standard cell culture conditions.
5. Viability was assessed by adding 3uL of CellTiter-Glo detection reagent (Promega).
6. Plates were covered with gasket lids and incubated for 10 minutes at room temperature.
7. Luminescence was measured on a ViewLux plate reader (PerkinElmer).
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000062652 uMActivity at 0.0000234000 uMActivity at 0.0000299754 uMActivity at 0.0000680318 uMActivity at 0.0001469781 uMActivity at 0.0003237363 uMActivity at 0.0006761082 uMActivity at 0.00130 uMActivity at 0.00271 uMActivity at 0.00486 uMActivity at 0.00759 uMActivity at 0.016 uMActivity at 0.038 uMActivity at 0.071 uMActivity at 0.177 uMActivity at 0.356 uMActivity at 0.588 uMActivity at 1.402 uMActivity at 1.903 uMActivity at 4.972 uMActivity at 9.253 uMActivity at 17.29 uMActivity at 44.98 uMActivity at 91.90 uMActivity at 155.1 uMActivity at 231.0 uMCompound QC
Cytotoxic0.016689.527684Complete curve; high efficacy-7.77952.09370.944225.8586115.3863-1.10 0 0 0 0 0 0 0 0 0 05.6755108.6505117.9375108.116652.745348.993823.989228.850825.686529.035727.31935.6755QC'd by MedChem Express
Cytotoxic0.0281.223183Complete curve; high efficacy-7.69920.80.972316.819798.0429-1.10 0 0 0 0 0 08.45590.219374.545244.291328.140927.05921.55068.455QC'd by Analyticon
Cytotoxic0.032686.593783Complete curve; high efficacy-7.48620.70.95318.8792105.4729-1.10 0 0 0 0 0 08.453296.808473.066745.439734.552529.766627.43068.4532QC'd by MedChem Express
Cytotoxic0.01683.312682Complete curve; high efficacy-7.79644.95490.99689.607592.9201-1.10 0 0 0 0 0 0 09.777389.297696.418711.99539.71678.86779.754210.35039.7773QC'd by LightBiologicals
Cytotoxic0.010694.295182Complete curve; high efficacy-7.9753.1320.995511.6947105.9898-1.10 0 0 0 0 0 0 011.6947100.9198109.394435.824211.756910.793412.383613.314511.6947QC'd by Prestwick
Cytotoxic0.002788.975382Complete curve; high efficacy-8.5754.95490.99928.907497.8826-1.10 0 0 0 0 0 0 06.903497.991442.29369.96869.10388.22179.30529.09336.9034QC'd by Alfa Aesar
Cytotoxic0.008480.513982Complete curve; high efficacy-8.0754.95490.99738.893889.4076-1.10 0 0 0 0 0 0 06.357787.157291.349912.957111.042110.34028.91169.86186.3577QC'd by Bosche
Cytotoxic0.005197.54282Complete curve; high efficacy-8.2944.50450.99928.7153106.2574-1.10 0 0 0 0 0 07.9842105.047213.76299.49049.84647.65467.1497.9842QC'd by Selleck
Cytotoxic0.020694.499882Complete curve; high efficacy-7.68624.0950.998411.2634105.7632-1.10 0 0 0 0 0 010.8677105.387387.541714.414211.97659.14619.209710.8677QC'd by Selleck
Cytotoxic0.461193.529282Complete curve; high efficacy-6.33621.46410.963718.0367111.5659-1.10 0 0 0 0 0 06.0375113.1729110.6758104.027672.57924.333235.37316.0375QC'd by ChemieTek
Cytotoxic0.025983.407982Complete curve; high efficacy-7.58621.17050.994210.379993.7878-1.10 0 0 0 0 0 05.519287.484466.342228.540116.433812.144911.87075.5192QC'd by MedChem Express
Cytotoxic0.020680.277982Complete curve; high efficacy-7.68623.67720.970514.587194.865-1.10 0 0 0 0 0 07.291596.26274.959527.541914.606313.184910.65757.2915QC'd by MedChem Express
Cytotoxic0.025999.996582Complete curve; high efficacy-7.58621.11050.962710.993110.9895-1.10 0 0 0 0 0 03.5224101.819278.672730.344220.104225.11194.47963.5224QC'd by APExBIO
Cytotoxic0.014690.789582Complete curve; high efficacy-7.83621.34370.9969.109499.8989-1.10 0 0 0 0 0 06.212391.419653.831819.277613.66628.56187.43726.2123QC'd by APExBIO
Cytotoxic0.651381.720382Complete curve; high efficacy-6.18621.47870.989621.402103.1224-1.10 0 0 0 0 0 021.0506108.908195.7413101.202878.035734.663424.989321.0506QC'd by Glixx
Cytotoxic0.01384.007482Complete curve; high efficacy-7.88621.41630.994410.069994.0773-1.10 0 0 0 0 0 05.978686.088247.355717.899613.582410.519910.4225.9786QC'd by MedChem Express
Cytotoxic0.08285.068682Complete curve; high efficacy-7.08620.910.991514.09999.1676-1.10 0 0 0 0 0 010.217194.606584.923959.808127.552123.690516.789310.2171QC'd by Glixx
Cytotoxic0.006584.635382Complete curve; high efficacy-8.18624.0950.99828.850193.4854-1.10 0 0 0 0 0 06.501790.372511.997510.293910.1119.52798.25216.5017QC'd by APExBIO
Cytotoxic0.00982.724382Complete curve; high efficacy-8.0441.28760.991710.51293.2363-1.10 0 0 0 0 0 07.734485.514346.479122.47513.19099.748711.73337.7344QC'd by MedChem Express
Cytotoxic4.0E-494.19682Complete curve; high efficacy-9.3752.40640.99887.7324101.9284-1.10 0 0 0 0 0 07.3587100.769474.71979.88399.60588.64768.49037.3587QC'd by SIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: NTMT1-p-MTaseGlo
Protocol: Materials: NTMT1 enzyme, substrate SPKRIA, control peptide RCC1-6 is provided by the Huang laboratory.

MTaseGlo Assay:
PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION
1; Enzyme; 3 uL; Dispense enzyme mixture (final concentrations of 125 nM NTMT1 and 100 uM SAM) into Greiner 1536-well white / solid bottom assay plate (Greiner Bio One, Monroe, NC).
2; Compounds; 23 nL; Compounds and controls were transferred via a Kalypsys Pin Tool (Wako USA) equipped with a 1536-slotted pin array (Wako Automation, Richmond, VA)
3; Incubation; 15 min; Incubate at room temperature
4; Substrate; 1 uL; Dispense 1 uL of substrate at final concentration of 1 uM. Buffer solution was dispensed in control wells. The assay plate was covered with metal lids.
5; Incubation; 30 min; Incubate at room temperature, protected from lights.
6; Reagent; 1 uL; Dispensed 5x MTase-Glo detection reagent (R) into the assay plate. The plate was covered with metal lids.
7; Incubation; 30 min; Incubate the assay plates at room temperature in the dark to allow for SAH to be converted to ADP.
8; Reagent; 5 uL; Dispense 5 uL of 1x MTase-Glo Detection Solution (R) to allow for ADP to be converted to ATP which was then detected with a luciferase reaction.
9; Centrifuge; 15 sec; Centrifuge the assay plate for 15 seconds at 1000 RPM.
10; Incubation; 30 min; Assay plates were incubation at room temperature in the dark.
11; Detection; Luminescence; Plates were read on ViewLux detector (PerkinElmer). Data were normalized to no-enzyme (0% activity) and no-inhibitor (DMSO; 100%) controls, and the resulting percent inhibition data were fitted to a 4-parameter Hill equation using GraphPad Prism.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000420468 uMActivity at 0.0001060182 uMActivity at 0.0001893301 uMActivity at 0.0004489405 uMActivity at 0.0009664426 uMActivity at 0.00171 uMActivity at 0.00292 uMActivity at 0.00536 uMActivity at 0.00931 uMActivity at 0.020 uMActivity at 0.041 uMActivity at 0.085 uMActivity at 0.146 uMActivity at 0.251 uMActivity at 0.501 uMActivity at 1.073 uMActivity at 2.225 uMActivity at 4.221 uMActivity at 6.452 uMActivity at 12.64 uMActivity at 29.84 uMActivity at 57.50 uMActivity at 114.0 uMActivity at 227.6 uMActivity at 379.2 uMActivity at 573.0 uMCompound QC
Inactive0004-8.3336-1.4117-0.6141-1.80790.0446-8.3336QC'd by Sytravon
Inactive0-5.754.95490.364-29.48243.380540 0 0 0 1-1.39543.25350.7839-59.13736.0E-4-1.3954QC'd by Sytravon
Inactive0-6.753.1320.78430.870212.540 0 0 0 04.496310.2975-0.4426-1.35820.16264.4963QC'd by Sytravon
Inactive00042.0548-1.7066-2.8833-2.0050.36932.0548QC'd by Sytravon
Inactive0004-5.64220.4339-3.0268-4.4255-2.8516-5.6422QC'd by Sytravon
Inactive00040.2315-0.9193-0.962513.7196-1.97040.2315QC'd by Sytravon
Inactive0-5.054.95490.5023-0.05257.540 0 0 0 15.3132.711112.72021.5451-0.04385.313QC'd by Sytravon
Inactive00044.3883-3.3207-0.3808-0.1461-2.9714.3883QC'd by Sytravon
Inactive00045.7635-0.6995-1.72946.10241.83175.7635QC'd by Sytravon
Inactive0-4.31.06930.8616-4.25739.540 0 0 0 0-1.881111.14848.55025.98854.608-1.8811QC'd by Sytravon
Inactive0004-1.7273-3.4115-0.1881-2.6331-1.6916-1.7273QC'd by Sytravon
Inactive00044.3895-3.0627-1.10014.78020.86424.3895QC'd by Sytravon
Inactive0-54.95490.664910.50.702140 0 0 0 013.78374.4863-3.58167.22047.367813.7837QC'd by Sytravon
Inactive00046.01793.3436.89312.29364.52246.0179QC'd by Sytravon
Inactive000411.32073.08785.1642.55725.361511.3207QC'd by Sytravon
Inactive00048.73833.26642.73073.24051.84638.7383QC'd by Sytravon
Inactive0-4.052.72020.9497-18.9142-2.292240 0 0 0 0-14.0952-1.0768-4.0059-2.4795-5.6228-14.0952QC'd by Sytravon
Inactive0004-7.7765-2.2569-3.9959-1.34510.1566-7.7765QC'd by Sytravon
Inactive0-44.95490.7054-25.0658-0.540 0 0 0 0-17.5549-2.6051-3.8192-2.69936.0774-17.5549QC'd by Sytravon
Inactive0-5.84.95490.4109-5.3905440 0 0 0 0-2.49043.8042.4492-14.07540.8551-2.4904QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Colon cancer organoid
External ID: CHEMBL5724559
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL5705881
ChEMBL Target Name: Colon cancer organoid
ChEMBL Target Type: 3D CELL CULTURE - Target is a 3D cell culture model such as an organoid, sphereoid or tumoroid that mimics tissues or organs
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: EUbOPEN Chemogenomic Library
Standard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
Cell Viability=146.93%Luminescence
Cell Viability=92.42%Luminescence
Cell Viability=137.32%Object Area
Cell Viability=95.84%Object Area
Cell Viability=30.1%Luminescence
Cell Viability=45.18%Luminescence
Cell Viability=84.35%Object Area
Cell Viability=67.45%Object Area
Cell Viability=3.322%Luminescence
Cell Viability=3.495%Luminescence
Cell Viability=9.147%Object Area
Cell Viability=11.54%Object Area
Cell Viability=79.36%Luminescence
Cell Viability=89.56%Luminescence
Cell Viability=109.07%Object Area
Cell Viability=103.32%Object Area
Cell Viability=2.387%Luminescence
Cell Viability=3.908%Luminescence
Cell Viability=8.346%Object Area
Cell Viability=9.337%Object Area
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Colon cancer organoid
External ID: CHEMBL5724561
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL5705881
ChEMBL Target Name: Colon cancer organoid
ChEMBL Target Type: 3D CELL CULTURE - Target is a 3D cell culture model such as an organoid, sphereoid or tumoroid that mimics tissues or organs
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: EUbOPEN Chemogenomic Library
Standard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
Cell Viability=110.58%Luminescence
Cell Viability=91.32%Luminescence
Cell Viability=96.41%Object Area
Cell Viability=86.99%Object Area
Cell Viability=121.35%Luminescence
Cell Viability=105.02%Luminescence
Cell Viability=98.38%Object Area
Cell Viability=111.73%Object Area
Cell Viability=107.52%Luminescence
Cell Viability=104.61%Luminescence
Cell Viability=121.53%Object Area
Cell Viability=94.42%Object Area
Cell Viability=89.19%Luminescence
Cell Viability=98.57%Luminescence
Cell Viability=86.74%Object Area
Cell Viability=117.35%Object Area
Cell Viability=123.06%Luminescence
Cell Viability=81.11%Luminescence
Cell Viability=103.62%Object Area
Cell Viability=93.88%Object Area
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Colon cancer organoid
External ID: CHEMBL5724560
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL5705881
ChEMBL Target Name: Colon cancer organoid
ChEMBL Target Type: 3D CELL CULTURE - Target is a 3D cell culture model such as an organoid, sphereoid or tumoroid that mimics tissues or organs
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: EUbOPEN Chemogenomic Library
Standard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
Cell Viability=133.3%Luminescence
Cell Viability=129.12%Luminescence
Cell Viability=96.49%Object Area
Cell Viability=84.49%Object Area
Cell Viability=88.97%Luminescence
Cell Viability=82.19%Luminescence
Cell Viability=63.58%Object Area
Cell Viability=57.5%Object Area
Cell Viability=15.16%Luminescence
Cell Viability=27.56%Luminescence
Cell Viability=31.67%Object Area
Cell Viability=31.58%Object Area
Cell Viability=80.49%Luminescence
Cell Viability=55.99%Luminescence
Cell Viability=115.36%Object Area
Cell Viability=103.89%Object Area
Cell Viability=14.26%Luminescence
Cell Viability=12.85%Luminescence
Cell Viability=15.33%Object Area
Cell Viability=14.47%Object Area
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Hepatocyte spheroids
External ID: CHEMBL5724565
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL5705882
ChEMBL Target Name: Hepatocyte spheroids
ChEMBL Target Type: 3D CELL CULTURE - Target is a 3D cell culture model such as an organoid, sphereoid or tumoroid that mimics tissues or organs
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: EUbOPEN Chemogenomic Library
Standard TypeStandard RelationStandard ValueActivity Comment
Proliferation=0.2575
Proliferation=0.05104
Proliferation=0.2702
Proliferation=0.005874Significantly Altered Human Hepatocyte Proliferation
Proliferation=0.9
Proliferation=0Significantly Altered Human Hepatocyte Proliferation
Proliferation=0.003154Significantly Altered Human Hepatocyte Proliferation
Proliferation=0.02591
Proliferation=0.1212
Proliferation=0.002627Significantly Altered Human Hepatocyte Proliferation
Proliferation=0.2187
Proliferation=0.05128
Proliferation=0.3569
Proliferation=0.874
Proliferation=0.03665
Proliferation=0.04298
Proliferation=0.02286
Proliferation=0.1604
Proliferation=0.882
Proliferation=0.7724
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:U2OS
External ID: CHEMBL5724697
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL615023
ChEMBL Target Name: U2OS
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: EUbOPEN Chemogenomic Library
Standard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
ER-phagy suppression=176.07%Very Strong Suppressor
ER-phagy suppression=134.35%Very Strong Suppressor
ER-phagy suppression=114.59%Very Strong Suppressor
ER-phagy suppression=104.14%Very Strong Suppressor
ER-phagy suppression=11.37%
ER-phagy suppression=-2.822%
ER-phagy suppression=-4.115%
ER-phagy suppression=-4.142%
ER-phagy suppression=35.01%
ER-phagy suppression=19.49%
ER-phagy suppression=15.62%
ER-phagy suppression=9.495%
ER-phagy suppression=-13.45%
ER-phagy suppression=-24.79%
ER-phagy suppression=-11.7%
ER-phagy suppression=-13.18%
ER-phagy suppression=-2.095%
ER-phagy suppression=14.41%
ER-phagy suppression=8.467%
ER-phagy suppression=13.31%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:IUPHAR-DB 靶标:Bruton tyrosine kinase (Tec family) [Homo sapiens]
External ID: 1948_Human
Protocol: The International Union of Basic and Clinical Pharmacology/British Pharmacological Society (IUPHAR/BPS) Guide to PHARMACOLOGY Database (GtoPdb) uses expert subcommittees to collate peer-reviewed information from the published literature regarding individual protein targets, and describes the pharmacology, genetics, function and anatomy of each target. Its pages provide a richly curated overview of the pharmacology of receptors, ion channels, enzymes and other target types, which can be found by following the external link to the GtoPdb website.

Comment: The data collected focuses on ligands at human receptors. Data are provided at rat or mouse orthologues where there are significant species differences, or where data are not yet available at the human target.

Information on individual experimental protocols can be found in the primary references listed for each ligand.

Affinity data are expressed as pKi [-log(Ki)], pKd [-log(Kd)], pIC50 [-log(IC50)], pEC50 [-log(EC50)], pKB [-log(KB)], pA2 or as a micromolar concentration range. In most cases the original concentration can be found in the primary reference.
pKd_minpKd_maxpIC50_minpIC50_maxpEC50_minpEC50_maxTypeActionReference (PubMed ID)
9.39.3InhibitorInhibition
7.67.6InhibitorIrreversible inhibition28352114
77InhibitorInhibition
8.89.3InhibitorInhibition26641137,17154430
8.78.7InhibitorInhibition21113169
9.59.5InhibitorInhibition22228807
8.28.2InhibitorInhibition25701252
99InhibitorInhibition22621397
8.48.4InhibitorInhibition24915291
4.84.8InhibitorInhibition10092645
8.58.5InhibitorInhibition24900538
8.78.7InhibitorInhibition26006010
7.87.8InhibitorInhibition25593320
6.46.4InhibitorInhibition22394077
InhibitorInhibition
1010InhibitorInhibition
8.48.4InhibitorInhibition
9.89.8InhibitorInhibition
8.48.4InhibitorInhibition24915291
8.78.7InhibitorInhibition21958547
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Replicase polyprotein 1ab
External ID: CHEMBL4495582
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4523582
ChEMBL Target Name: Replicase polyprotein 1ab
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned

Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
Inhibition=13.77%
Inhibition=2.35%
Inhibition=21.17%
Inhibition=18.36%
Inhibition=5.381%
Inhibition=18.17%
Inhibition=10.15%
Inhibition=29.56%
Inhibition=18.27%
Inhibition=11.42%
Inhibition=15.4%
Inhibition=7.437%
Inhibition=-3.216%
Inhibition=18%
Inhibition=1.021%
Inhibition=16.4%
Inhibition=2.544%
Inhibition=19.11%
Inhibition=26.15%
Inhibition=5.133%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CYP3A7681
Protocol: Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). Compounds dissolved in DMSO, and positive control (ketoconazole) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000073560 uMActivity at 0.0000367800 uMActivity at 0.0000735600 uMActivity at 0.0001677464 uMActivity at 0.0003678000 uMActivity at 0.0007363003 uMActivity at 0.00153 uMActivity at 0.00368 uMActivity at 0.00723 uMActivity at 0.00914 uMActivity at 0.018 uMActivity at 0.039 uMActivity at 0.092 uMActivity at 0.191 uMActivity at 0.460 uMActivity at 0.910 uMActivity at 1.182 uMActivity at 2.302 uMActivity at 4.834 uMActivity at 11.49 uMActivity at 23.94 uMActivity at 57.45 uMActivity at 115.4 uMActivity at 193.5 uMActivity at 288.3 uMCompound QC
Inhibitor1.0964121.524587Complete curve; high efficacy-5.960.60.996-99.00122.5235-1.10 0 0 0 0 0 0 0-91.416421.20118.089711.55633.2362-23.6097-54.3722-70.1237-91.4164QC'd by GVK
Inactive00041.30296.4095.7452-8.127411.434512.7995.91137.13891.3029QC'd by Vitas
Inhibitor0.05596.749490Complete curve; high efficacy-7.260.60.9836-74.157422.592-1.10 0 0 0 0 0 0 0-78.849512.345912.9899-11.4013-37.5586-53.042-61.5426-65.313-78.8495QC'd by Bosche
Inactive0004-9.339-4.094-2.86744.5071-4.4459-5.3433-2.46713.5091-9.339QC'd by BIOMOL
Inactive0-6.614.95490.77852.5-6.094140 0 0 0 0 0 0 1-8.7946-5.07-2.6335-5.97-10.49513.49112.05881.9174-8.7946QC'd by SIGMA
Inhibitor34.671339.82710Single point of activity-4.462.30310.825-41.327-1.5-30 0 0 0 0 0 0 0-31.93923.6009-5.26172.22954.1407-8.6455-6.9529-4.2362-31.9392QC'd by Microsource
Inactive040 0 0 0 0 0 0 0-13.898620.649216.42211.68939.501116.6467-2.6177-2.1673-13.8986QC'd by Vitas
Inhibitor15.487178.566741Partial curve; partial efficacy-4.810.80.995-76.6721.8947-2.20 0 0 0 0 0 0 0-58.08492.73420.67454.0214-0.609-3.975-12.9528-31.6593-58.0849QC'd by Sequoia
Inactive000426.644512.4429-0.644219.37847.33520.35134.22857.434426.6445QC'd by Microsource
Inactive0-5.92134.95490.79423.5-5.645240 0 0 0 0 0 1-9.4213-2.1113-8.4544-4.6822-8.22654.16062.7472-9.4213QC'd by Tocris
Inactive0004-2.8012-11.1342-2.1920-10.8176-0.6934-3.3166-1.4979-2.8012QC'd by SIGMA
Inactive0-5.764.95490.510428.8996-2.44840 1 0 0 0 0 0 1-2.30523.7377-36.8683-4.4543-19.5675-9.380122.243229.0984-2.305QC'd by Vitas
Inhibitor12.301887.401142Partial curve; high efficacy-4.910.60.9549-73.550113.8509-2.10 0 0 0 0 0 0 0-54.873522.14538.368412.13289.0141-1.3852-8.6537-22.9862-54.8735QC'd by Microsource
Inhibitor27.540450.239310Single point of activity-4.561.75290.9401-50.16480.0744-30 0 0 0 0 0 0 0-39.142.8036-3.03351.3596-6.01625.1159-1.7887-9.2175-39.14QC'd by Microsource
Inactive0-5.310.60.8041-16.01361740 0 0 0 0 0 0 0-11.67817.682513.435821.75976.519717.4375-0.6278-0.9036-11.678QC'd by Enzo
Inhibitor15.487177.547110Partial curve; partial efficacy; poor fit-4.811.1110.829-67.10610.4411-2.40 0 0 0 0 0 0 0-53.05410.743524.16552.70531.738225.7669-4.8999-19.2859-53.0541QC'd by Bosche
Inactive0-6.361.46410.8922-22.47584.540 0 0 0 0 0 0 0-25.49972.54256.30397.767-1.9911-6.3102-26.2299-15.2464-25.4997QC'd by Microsource
Inactive0-4.511.96730.4991426.540 0 0 0 0 0 0 016.846225.531732.670220.285228.569325.635926.981725.029716.8462QC'd by GVK
Inhibitor0.870947.278824Complete curve; partial efficacy-6.064.95490.9676-45.67661.6021-1.20 0 0 0 0 0 0 1-20.51278.27430.9756-1.5573-1.30970.8922-49.683-41.1152-20.5127QC'd by Enzo
Inactive0-6.064.95490.4399-0.676240 0 0 0 0 0 0 1-0.0131.95381.5464-4.31350.312-2.768216.93540.8252-0.013QC'd by Sequoia
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsp2-p
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Control / Compound; 20 nL; Echo 655 acoustic dispenser, Greiner 1536-well solid bottom black plate.
2; Enzyme; 4 uL; BioRAPTR FRD liquid dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature.
4; Reagent; 4 uL; 2.5 uM Peptide 2 substrate.
5; Incubation; 1 hr; room temperature.
6; Detection; Fluorescence; WiewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Briefly, 20 nL DMSO, positive control ZnAc (20nM final concentration), and test compounds were transferred into a 1,536-well solid bottom black plate (789176-F, Greiner One) via Echo 655 acoustic dispenser (Beckman Coulter). For primary screens, compounds were tested at 7 concentrations, 1:3 dilution points ranging from 25 uM to 34 nM. Follow-up confirmatory screens were carried out at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
2. Four uL nsP2pro enzyme mix (150 nM final concentration) in 10 mM Tris-HCl pH 8.0 with 0.01% Tween 20 assay buffer was dispensed into the plate using a BioRAPTR FRD liquid dispenser (Beckman Coulter).
3. The plate was incubated at room temperature (protected from light) for 15 min
4. Four microliter of peptide 2 substrate (2.5 uM final concentration) in assay buffer was added to the plate.
5. After 1 hour, plates were immediately read on a ViewLux high-throughput CCD imager (Exposure = 10 sec, Gain = High, Speed = Slow, Binning = 2X). The above assay was also incorporated in the NCATS HTS facility41, which allowed for robotic liquid and compound dispensing, microplate handling, and fluorescence reading..

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000040000 uMActivity at 0.0000163452 uMActivity at 0.0000320000 uMActivity at 0.0000806082 uMActivity at 0.0001439601 uMActivity at 0.0003895389 uMActivity at 0.0007288991 uMActivity at 0.00154 uMActivity at 0.00290 uMActivity at 0.00454 uMActivity at 0.00833 uMActivity at 0.021 uMActivity at 0.041 uMActivity at 0.095 uMActivity at 0.199 uMActivity at 0.321 uMActivity at 0.689 uMActivity at 1.028 uMActivity at 2.684 uMActivity at 5.101 uMActivity at 10.05 uMActivity at 24.85 uMActivity at 39.21 uMActivity at 78.39 uMActivity at 125.0 uMCompound QC
Inactive000458.411643.591625.884333.42079.110921.639545.688610.891128.395531.312738.991441.655858.4116QC'd by Sytravon
Inactive0004-12.6805-10.7548-9.5107-10.6418-15.9997-12.6805QC'd by Sytravon
Inactive0004-7.1462-9.2235-11.8601-6.118-12.2196-7.1462QC'd by Sytravon
Inactive0-4.754.95490.6661-22.0013-240 0 0 0 0-18.751-10.987-0.99352.3561.2583-18.751QC'd by Sytravon
Inactive0004-11.1249-10.2692-11.5229-11.032-13.325-11.1249QC'd by Sytravon
Inactive0-4.81.88510.5555-23.9168-5.408840 0 0 0 0-18.264-13.0121-2.8407-6.6548-7.1687-18.264QC'd by Sytravon
Inactive0-6.354.95490.9083-3.1815-14.928340 0 0 0 1-10.2909-13.1276-17.0236-1.4012-4.6174-10.2909QC'd by Sytravon
Inactive0-5.950.40.9812-20.7272-0.994240 0 0 0 0-16.0227-4.9952-8.1266-9.7286-14.3153-16.0227QC'd by Sytravon
Inactive0-6.54.95490.6409-9.2158-16.601140 0 0 0 1-12.7654-16.3342-16.1896-6.0131-13.084-12.7654QC'd by Sytravon
Inactive00041.9752.61033.4198-3.47481.76241.975QC'd by Sytravon
Inactive0004-8.2223-0.1456-4.3339-1.582-3.6253-8.2223QC'd by Sytravon
Inactive0-7.254.95490.602-10.0715240 0 0 0 0-12.60110.2325-14.2262-4.5441-8.7364-12.6011QC'd by Sytravon
Inactive0-4.754.50450.9809-24.6554-10.844240 0 0 0 0-22.2129-9.8702-10.3098-11.7375-10.6121-22.2129QC'd by Sytravon
Inactive0-4.754.95490.8409-13.5514240 0 0 0 0-11.2928-1.92764.61061.33364.0275-11.2928QC'd by Sytravon
Inactive0-5.20.50.9077-28.8252-9.445240 0 0 0 0-23.1876-10.7877-12.0613-16.7104-16.3414-23.1876QC'd by Sytravon
Inactive0004-18.3436-16.2788-21.7212-19.8613-16.6894-18.3436QC'd by Sytravon
Inactive0004-5.4025-9.518-0.16940.2848-4.8162-5.4025QC'd by Sytravon
Inactive0004-23.1229-14.0834-13.5556-16.7644-18.8145-23.1229QC'd by Sytravon
Inactive0-4.953.29750.9426-35.5663-15.226240 0 0 0 0-34.2687-12.6885-18.3414-14.0693-16.4909-34.2687QC'd by Sytravon
Inactive0-4.754.95490.7952-15.6253-4.893240 0 0 0 0-13.8544-4.3645-8.5252-3.661-3.9903-13.8544QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Aurora kinase A
External ID: CHEMBL5067447
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4722
ChEMBL Target Name: Serine/threonine-protein kinase Aurora-A
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned

Data Source: EUbOPEN Chemogenomic Library
Standard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
Delta TM=0.05675CThermal Shift Assay
Delta TM=0.06056CThermal Shift Assay
Delta TM=-0.26C
Delta TM=0.05CThermal Shift Assay
Delta TM=0.2158CThermal Shift Assay
Delta TM=0.1132CThermal Shift Assay
Delta TM=-0.21CThermal Shift Assay
Delta TM=0.07973CThermal Shift Assay
Delta TM=0.3724CThermal Shift Assay
Delta TM=-0.3C
Delta TM=-0.04CThermal Shift Assay
Delta TM=-0.08CThermal Shift Assay
Delta TM=-0.49CThermal Shift Assay
Delta TM=0.08515CThermal Shift Assay
Delta TM=0.01057CThermal Shift Assay
Delta TM=0CThermal Shift Assay
Delta TM=0.1944CThermal Shift Assay
Delta TM=2.51CThermal Shift Assay
Delta TM=-0.01CThermal Shift Assay
Delta TM=-0.24CThermal Shift Assay
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-keats_PE2-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.046989.907785Complete curve; high efficacy-7.32920.90.984634.8594124.7671-1.10 0 0 0 0 0 0 0 0 0 038.7443116.6148123.331115.2192.887373.482954.77243.446743.503138.090226.377138.7443QC'd by Selleck
Cytotoxic0.033290.122784Complete curve; high efficacy-7.47922.53340.987627.2436117.3663-1.10 0 0 0 0 0 0 0 0 0 029.451110.6569116.5957125.888391.665243.291222.668227.450327.29630.860728.195929.451QC'd by BIOMOL
Cytotoxic0.148264.205284Complete curve; high efficacy-6.82921.34430.938335.677799.8829-1.10 0 0 0 0 0 0 0 0 0 018.76692.8829102.3239101.104696.674386.689358.744943.920147.14646.611735.32418.766QC'd by SynKinase
Cytotoxic0.0264104.286983Complete curve; high efficacy-7.57922.25260.99219.9841124.271-1.10 0 0 0 0 0 0 0 0 0 017.5117129.8899116.807122.529184.303325.788520.417822.548120.312219.526425.140817.5117QC'd by SIGMA
Cytotoxic0.002626.63983Complete curve; partial efficacy-8.57921.98870.8564111.547138.1859-1.20 0 0 0 0 0 0 0 0 0 0108.481135.6859126.6133115.6739109.1315116.6885116.992110.3541110.2737107.2368115.0049108.481QC'd by ACC
Cytotoxic0.234880.969683Complete curve; high efficacy-6.62921.78850.985232.18113.1497-1.10 0 0 0 0 0 0 0 0 0 033.7541104.2396122.5796115.8743108.3231105.995778.906447.543330.781731.351534.678933.7541QC'd by Selleck
Cytotoxic0.001083Complete curve; high efficacy-900.996313.160913.1609-1.10 0 0 0 0 0 0 0 0 0 04.6553125.3758112.277641.10713.604813.349813.160911.332710.04888.48916.5714.6553QC'd by Selleck
Cytotoxic0.001083Complete curve; high efficacy-900.980614.952314.9523-1.10 0 0 0 0 0 0 0 0 0 01.9606113.65391.115925.163217.069519.800114.849213.662614.95238.48115.04721.9606QC'd by Selleck
Cytotoxic0.0118107.886383Complete curve; high efficacy-7.92921.92820.963819.892127.7783-1.10 0 0 0 0 0 0 0 0 0 04.9614125.3701124.7044100.389341.410632.872532.207326.744225.714217.83226.2324.9614QC'd by AG Scientific
Cytotoxic0.372294.850183Complete curve; high efficacy-6.42920.60.991126.0632120.9133-1.10 0 0 0 0 0 0 0 0 0 025.7075114.6134119.7084115.335105.949297.07279.836767.710351.942944.634340.413225.7075QC'd by Microsource
Cytotoxic0.295783.559583Complete curve; high efficacy-6.52921.71370.971332.2123115.7718-1.10 0 0 0 0 0 0 0 0 0 025.1892117.5987113.5632114.8624123.457597.634794.853650.285831.661742.440335.287425.1892QC'd by Prestwick Chemical; Inc.
Cytotoxic0.1049110.062782Complete curve; high efficacy-6.97924.95490.991314.2288124.2915-1.10 0 0 0 0 0 0 0 0 0 08.833111.9056125.2889132.6917124.9518117.939518.40515.002917.132516.988113.28148.833QC'd by Selleck
Cytotoxic0.0935106.276382Complete curve; high efficacy-7.02921.86170.980719.6881125.9644-1.10 0 0 0 0 0 0 0 0 0 05.9721122.2096130.9365117.8896131.133285.381841.721227.424723.665124.350621.41385.9721QC'd by Selleck
Cytotoxic0.007477.603582Complete curve; high efficacy-8.12921.37230.98598.398186.0016-1.10 0 0 0 0 0 0 0 0 0 03.488279.614278.646744.786424.413415.536412.334910.79449.02098.12136.19523.4882QC'd by Cayman
Cytotoxic2.956689.179382Complete curve; high efficacy-5.52920.80.905529.8253119.0047-1.10 0 0 0 0 0 0 0 0 0 037.0236127.0025110.5416116.0121109.5326121.7776119.809695.625984.706849.342866.243537.0236QC'd by NCGCChem
Cytotoxic0.4686129.158882Complete curve; high efficacy-6.32920.90.980318.9796148.1384-1.10 0 0 0 0 0 0 0 0 0 019.266162.4576139.7546143.1217130.0758136.3624104.834182.859444.90727.383831.407519.266QC'd by JohnsHopkins
Cytotoxic1.17797.381882Complete curve; high efficacy-5.92920.70.885929.6487127.0306-1.10 0 0 0 0 0 0 0 0 0 044.9605136.9675105.3073113.3963109.5793122.1768119.755691.219358.526161.437937.598344.9605QC'd by Microsource
Cytotoxic0.1177103.349682Complete curve; high efficacy-6.92922.47290.994617.3097120.6593-1.10 0 0 0 0 0 0 0 0 0 012.8645123.9931123.868120.9824111.7642104.531439.781121.665622.488516.391316.374112.8645QC'd by Selleck
Cytotoxic1.4818102.788882Complete curve; high efficacy-5.82921.010.991128.4021131.191-1.10 0 0 0 0 0 0 0 0 0 030.4075130.6744126.7233128.4612133.7271130.3488120.9413104.380868.914157.480835.84230.4075QC'd by Tocris
Cytotoxic3.722179.686782Complete curve; high efficacy-5.42923.990.97640.7926120.4793-1.10 0 0 0 0 0 0 0 0 0 031.948114.7205115.9019124.3465123.1905115.4231126.7717120.1747119.832659.309849.124231.948QC'd by Axon Medchem